AU2020267230A1 - Compounds and methods for reducing tau expression - Google Patents

Abstract

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Tau mRNA in a cell or animal, and in certain instances reducing the amount of Tau protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include loss of memory, loss of motor function, and increase in the number and/or volume of neurofibrillary inclusions. Such neurodegenerative diseases include tauopathies, Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, and Dravet's Syndrome.

Description

COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION

Sequence Listing The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled BIOL0285WOSEQ_ST25, created on September 7, 2017, which is 176 KB in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

Field Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Tau mRNA in a cell or animal, and in certain instances reducing the amount of Tau protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include loss of memory, loss of motor function, and increase in the number and/or volume of neurofibrillary inclusions. Such neurodegenerative diseases include tauopathies, Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, and Dravet's Syndrome.

Background The primary function of Tau is to bind to and stabilize microtubules, which are important structural components of the cytoskeleton involved in mitosis, cytokinesis, and vesicular transport. Tau is found in multiple tissues, but is particularly abundant in axons of neurons. In humans, there are six isoforms of Tau that are generated by alternative splicing of exons 2, 3, and 10. Splicing of exons 2 and 3 at the N-terminus of

the protein leads to inclusion of zero, one, or two 29 amino acid acidic domains and is termed ON, IN, or 2N Tau respectively. The influence of these domains on Tau function is not fully clear, though may play a role in interactions with the plasma membrane. Inclusion of exon 10 at the C-terminus leads to inclusion of the microtubule binding domain encoded by exon 10. Since there are 3 microtubule binding domains elsewhere in Tau, this Tau isoform (with exon 10 included) is termed 4R Tau, where 'R' refers to the number of repeats of microtubule binding domains. Tau without exon 10 is termed 3R Tau. Since more microtubule binding domains (4R compared with 3R) increases the binding to microtubules, 4R Tau presumably significantly increases microtubule binding and assembly. The ratio of 3R/4R Tau is developmentally regulated, with fetal tissues expressing exclusively 3R Tau and adult human tissues expressing approximately equal levels of 3R/4R Tau. Deviations from the normal ratio of 3R/4R Tau are characteristic of neurodegenerative FTD Tauopathies. It is not known how changing the 3R/4R Tau ratio at a later stage in the adult animal will affect

Tau pathogenesis. Serine-threonine directed phosphorylation regulates the microtubule binding ability of Tau.

Hyperphosphorylation promotes detachment of Tau from microtubules. Other post translational modifications of Tau have been described; however the significance of these is unclear. Phosphorylation of Tau is also developmentally regulated with higher phosphorylation in fetal tissues and much lower phosphorylation in the adult. One characteristic of neurodegenerative disorders is aberrantly increased Tau phosphorylation. The microtubule network is involved in many important processes within the cell including structural integrity needed for maintaining morphology of cells and operating transport machinery. Since binding of Tau to microtubules stabilizes microtubules, Tau is likely to be a key mediator of some of these processes and disruption of normal Tau in neurodegenerative diseases may disrupt some of these key cellular processes. One ofthe early indicators that Tau may be important in neurodegenerative syndromes was the recognition that Tau is a key component of neurofibrillary inclusions in Alzheimer's disease. In fact, neurofibrillary inclusions are aggregates of hyperphosphorylated Tau protein. Along with amyloid beta containing plaques, neurofibrillary inclusions are a hallmark of Alzheimer's disease and correlate significantly with cognitive impairment. 95% of Tau accumulations in AD are found in neuronal processes and is termed neuritic dystrophy. The process(es) whereby this microtubule associated protein becomes disengaged from microtubules and forms accumulations of proteins and how this relates to neuronal toxicity is not well understood. Neuronal Tau inclusions are a pathological characteristic of not only Alzheimer's disease, but also a subset of Frontotemporal dementia (FTD), PSP, and CBD. The link between Tau and neurodegeneration was solidified by the discovery that mutations in the Tau gene cause a subset of FTD. These genetic data have also highlighted the importance of the 3R:4R ratio of Tau. Many of the Tau mutations that cause FTD lead to a change in Tau splicing which leads to preferential inclusion of exon 10, and thus to increased 4R Tau. The overall Tau levels are normal. Whether the Tau isoform change or the amino acid change or both cause neurodegeneration remains unknown. Recent data suggest that PSP may also be associated with an increased 4R:3R Tau ratio. To help understand the influence of Tau ratios on neurodegeneration, a mouse model based on one of

the splicing Tau mutations (N279K) has been generated using a minigene that includes the Tau promoter and the flanking intronic sequences of exon 10. As in humans, these mice demonstrate increased levels of 4R Tau

compared with transgenics expressing WT Tau and develop behavioral and motor abnormalities as well as accumulations of aggregated Tau in the brain and spinal cord. Tau protein has been associated with multiple diseases of the brain including Alzheimer's disease, FTD, PSP, CBD, dementia pugilistica, parkinsonism linked to chromosome, Lytico-Bodig disease, tangle

predominant dementia, ganglioglioma, gangliocytoma, meningioangiomatosis, subacute sclerosing panencephalitis, lead encephalopathy, tuberous sclerosis, Hallervorden-Spatz disease, Pick's disease, argyrophilic grain disease, corticobasal degeneration or frontotemporal lobar degeneration and others. Tau associated disorders such as AD are the most common cause of dementia in the elderly. AD affects an estimated 15 million people worldwide and 40% of the population above 85 years of age. AD is characterized by two pathological hallmarks: Tau neurofibrillary inclusions (NFT) and amyloid-p (AP) plaques. There is currently a lack of acceptable options for treating such neurodegenerative diseases. It is therefore an object herein to provide methods for the treatment of such diseases.

Summary of the Invention Provided herein are compounds and methods for reducing the amount or activity of Tau mRNA, and in certain embodiments reducing the amount of Tau protein in a cell or animal. In certain embodiments, the animal has a neurodegenerative disease. In certain embodiments, the animal has a tauopathy, Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, or Dravet's Syndrome. In certain embodiments, compounds useful for reducing expression of Tau mRNA are oligomeric compounds. In certain embodiments, Compound No. 814907 is useful for reducing expression of Tau mRNA and/or Tau protein. Also provided are methods useful for preventing or ameliorating at least one symptom of a neurodegenerative disease. In certain embodiments, such symptoms are loss of memory, loss of motor function, and increase in the number and/or volume of neurofibrillary inclusions. In certain embodiments, prevention or amelioration results in maintining or improving memory, maintaining or improving motor function, and/or maintenance or reduction in the number and/or volume of neurofibrillary inclusions. In certain embodiments, such prevention or amelioration of symptoms is the decrease in the rate of progression or delay in onest of such symptoms.

Detailed Description of the Invention It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive, Herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, the use of "or" means "and/or" unless stated otherwise. Furthermore, the use of the term "including" as well as other forms, such as "includes" and

"included", is not limiting. Also, terms such as "element" or "component" encompass both elements and components comprising one unit and elements and components that comprise more than one subunit, unless specifically stated otherwise. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, and treatises, are hereby expressly incorporated-by-reference for the portions of the document discussed herein, as well as in their entirety.

Definitions Unless specific definitions are provided, the nomenclature used in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Where permitted, all patents, applications, published applications and other publications and other data referred to throughout in the disclosure are incorporated by reference herein in their entirety. Unless otherwise indicated, the following terms have the following meanings: DEFINITIONS As used herein, "2'-deoxynucleoside" means a nucleoside comprising 2'-H(H) furanosyl sugar moiety, as found in naturally occurring deoxyribonucleic acids (DNA). In certain embodiments, a 2' deoxynucleoside may comprise a modified nucleobase or may comprise an RNA nucleobase (uracil). As used herein, "2'-substituted nucleoside" means a nucleoside comprising a 2'-substituted sugar moiety. As used herein, "2'-substituted" in reference to a sugar moiety means a sugar moiety comprising at least one 2'-substituent group other than H or OH. As used herein, "administering" means providing a pharmaceutical agent to an animal. As used herein, "animal" means a human or non-human animal. As used herein, "antisense activity" means any detectable and/or measurable change attributable to the hybridization of an antisense compound to its target nucleic acid. In certain embodiments, antisense activity is a decrease in the amount or expression of a target nucleic acid or protein encoded by such target nucleic acid compared to target nucleic acid levels or target protein levels in the absence of the antisense compound. As used herein, "antisense compound" means an oligomeric compound or oligomeric duplex capable of achieving at least one antisense activity. As used herein, "ameliorate" in reference to a treatment means improvement in at least one symptom relative to the same symptom in the absence of the treatment. In certain embodiments, amelioration is the reduction in the severity or frequency of a symptom or the delayed onset or slowing of progression in the severity or frequency of a symptom. In certain embodiments, the symptom is loss of memory, loss of motor function, or increase in the number and/or volume ofneurofibrillary inclusions. In certain embodiments, amelioration of these symptoms results in maintining or improving memory, maintaining or improving motor function, and/or maintenance or reduction in the number and/or volume of neurofibrillary inclusions. As used herein, "at least one symptom of a neurodegenerative disease" includes loss of memory, loss of motor function, or increase in the number and/or volume of neurofibrillary inclusions. As used herein, "bicyclic nucleoside" or "BNA" means a nucleoside comprising a bicyclic sugar moiety. As used herein, "bicyclic sugar" or "bicyclic sugar moiety" means a modified sugar moiety comprising two rings, wherein the second ring is formed via a bridge connecting two ofthe atoms in the first ring thereby forming a bicyclic structure. In certain embodiments, the first ring of the bicyclic sugar moiety is a furanosyl moiety. In certain embodiments, the bicyclic sugar moiety does not comprise a furanosyl moiety. As used herein, "chirally enriched population" means a plurality of molecules of identical molecular formula, wherein the number or percentage of molecules within the population that contain a particular stereochemical configuration at a particular chiral center is greater than the number or percentage of molecules expected to contain the same particular stereochemical configuration at the same particular chiral center within the population if the particular chiral center were stereorandom. Chirally enriched populations of molecules having multiple chiral centers within each molecule may contain one or more sterorandom chiral centers. In certain embodiments, the molecules are modified oligonucleotides. In certain embodiments, the molecules are compounds comprising modified oligonucleotides. As used herein, "cleavable moiety" means a bond or group of atoms that is cleaved under physiological conditions, for example, inside a cell, an animal, or a human. As used herein, "complementary" in reference to an oligonucleotide means that at least 70% of the nucleobases of the oligonucleotide or one or more regions thereof and the nucleobases of another nucleic acid or one or more regions thereof are capable of hydrogen bonding with one another when the nucleobase sequence of the oligonucleotide and the other nucleic acid are aligned in opposing directions. Complementary nucleobases means nucleobases that are capable of forming hydrogen bonds with one another. Complementary nucleobase pairs include adenine (A) and thymine (T), adenine (A) and uracil (U), cytosine (C) and guanine (G), 5-methylcytosine (mC) and guanine (G). Complementary oligonucleotides and/or nucleic acids need not have nucleobase complementarity at each nucleoside. Rather, some mismatches are tolerated. As used herein, "fully complementary" or "100% complementary" in reference to oligonucleotides means that oligonucleotides are complementary to another oligonucleotide or nucleic acid at each nucleoside of the oligonucleotide. As used herein, "conjugate group" means a group of atoms that is directly or indirectly attached to an oligonucleotide. Conjugate groups include a conjugate moiety and a conjugate linker that attaches the conjugate moiety to the oligonucleotide. As used herein, "conjugate linker" means a group of atoms comprising at least one bond that connects a conjugate moiety to an oligonucleotide. As used herein, "conjugate moiety" means a group of atoms that is attached to an oligonucleotide via a conjugate linker. As used herein, "contiguous" in the context of an oligonucleotide refers to nucleosides, nucleobases, sugar moieties, or internucleoside linkages that are immediately adjacent to each other. For example, contiguous nucleobases" means nucleobases that are immediately adjacent to each other in a sequence. As used herein, "gapmer" means a modified oligonucleotide comprising an internal region having a plurality of nucleosides that support RNase H cleavage positioned between external regions having one or more nucleosides, wherein the nucleosides comprising the internal region are chemically distinct from the nucleoside or nucleosides comprising the external regions. The internal region may be referred to as the "gap" and the external regions may be referred to as the "wings." Unless otherwise indicated, "gapmer" refers to a sugar motif Unless otherwise indicated, the sugar moieties of the nucleosides of the gap of a gapmer are unmodified 2'-deoxyfuranosyl. Thus, the term "MOE gapmer" indicates a gapmer having a sugar motif of 2'-MOE nucleosides in both wings and a gap of 2'-deoxynucleosides. Unless otherwise indicated, a MOE gapmer may comprise one or more modified internucleoside linkages and/or modified nucleobases and such modifications do not necessarily follow the gapmer pattern of the sugar modifications. As used herein, "hybridization" means the pairing or annealing of complementary oligonucleotides and/or nucleic acids. While not limited to a particular mechanism, the most common mechanism of hybridization involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases. As used herein, the term "internucleoside linkage" is the covalent linkage between adjacent nucleosides in an oligonucleotide. As used herein "modified internucleoside linkage" means any intemucleoside linkage other than a phosphodiester internucleoside linkage. "Phosphorothioate linkage" is a modified internucleoside linkage in which one of the non-bridging oxygen atoms of a phosphodiester internucleoside linkage is replaced with a sulfur atom. As used herein, "linker-nucleoside" means a nucleoside that links, either directly or indirectly, an oligonucleotide to a conjugate moiety. Linker-nucleosides are located within the conjugate linker of an oligomeric compound. Linker-nucleosides are not considered part of the oligonucleotide portion of an oligomeric compound even if they are contiguous with the oligonucleotide. As used herein, "non-bicyclic modified sugar moiety" means a modified sugar moiety that comprises a modification, such as a substitutent, that does not forma bridge between two atoms of the sugar to form a second ring. As used herein, "mismatch" or "non-complementary" means a nucleobase of a first oligonucleotide that is not complementary with the corresponding nucleobase of a second oligonucleotide or target nucleic acid when the first and second oligomeric compound are aligned,

As used herein, "MOE" means methoxyethyl. "2'-MOE" means a -OCH2CH 2OCH 3 group at the 2' position of a furanosyl ring. As used herein, "motif' means the pattern of unmodified and/or modified sugar moieties, nucleobases, and/or intemucleoside linkages, in an oligonucleotide. As used herein, "mRNA" means an RNA transcript that encodes a protein and includes pre-mRNA and mature mRNA unless otherwise specified. As used herein, "nucleobase" means an unmodified nucleobase or a modified nucleobase. As used herein an "unmodified nucleobase" is adenine (A), thymine (T), cytosine (C), uracil (U), and guanine (G).

As used herein, a "modified nucleobase" is a group of atoms other than unmodified A, T, C, U, or G capable of pairing with at least one unmodified nucleobase. A "5-methylcytosine" is a modified nucleobase. A universal base is a modified nucleobase that can pair with any one ofthe five unmodified nucleobases. As used herein, "nucleobase sequence" means the order of contiguous nucleobases in a nucleic acid or oligonucleotide independent of any sugar or intemucleoside linkage modification. As used herein, "nucleoside" means a compound comprising a nucleobase and a sugar moiety. The nucleobase and sugar moiety are each, independently, unmodified or modified. As used herein, "modified nucleoside" means a nucleoside comprising a modified nucleobase and/or a modified sugar moiety. Modified nucleosides include abasic nucleosides, which lack a nucleobase. "Linked nucleosides" are nucleosides that are connected in a contiuous sequence (i.e., no additional nucleosides are presented between those that are linked). As used herein, "oligomeric compound" means an oligonucleotide and optionally one or more additional features, such as a conjugate group or terminal group. An oligomeric compound may be paired with a second oligomeric compound that is complementary to the first oligomeric compound or may be unpaired. A "singled-stranded oligomeric compound" is an unpaired oligomeric compound. The term "oligomeric duplex" means a duplex formed by two oligomeric compounds having complementary

nucleobase sequences. Each oligomeric compound of an oligomeric duplex may be refered to as a "duplexed oligomeric compound." As used herein, "oligonucleotide" means a strand of linked nucleosides connected via internucleoside linkages, wherein each nucleoside and internucleoside linkage may be modified or unmodified. Unless otherwise indicated, oligonucleotides consist of 8-50 linked nucleosides. As used herein, "modified oligonucleotide" means an oligonucleotide, wherein at least one nucleoside or internucleoside linkage is modified. As used herein, "unmodified oligonucleotide" means an oligonucleotide that does not comprise any nucleoside modifications or intemucleoside modifications. As used herein, "phannaceutically acceptable carrier or diluent" means any substance suitable for use

in administering to an animal. Certain such carriers enable pharmaceutical compositions to be formulated as, for example, tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspension and lozenges for the

oral ingestion by a subject. In certain embodiments, a pharmaceutically acceptable carrier or diluent is sterile water; sterile saline; or sterile buffer solution. As used herein "pharmaceutically acceptable salts" means physiologically and pharmaceutically acceptable salts of compounds, such as oligomeric compounds, i.e., salts that retain the desired biological

activity of the parent compound and do not impart undesired toxicological effects thereto. As used herein "pharmaceutical composition" means a mixture of substances suitable for administering to a subject. For example, a pharmaceutical composition may comprise an antisense compound and a sterile aqueous solution. In certain embodiments, a pharmaceutical composition shows activity in free uptake assay in certain cell lines. As used herein, "phosphorus moiety" means a group of atoms comprising a phosphorus atom. In certain embodiments, a phosphorus moiety comprises a mono-, di-, or tri-phosphate, or phosphorothioate. As used herein "prodrug" means a therapeutic agent in a form outside the body that is converted to a different form within an animal or cells thereof Typically conversion of a prodrug within the animal is facilitated by the action of an enzymes (e.g., endogenous or viral enzyme) or chemicals present in cells or tissues and/or by physiologic conditions. As used herein, "reducing or inhibiting the amount or activity" refers to a reduction or blockade of the transcriptional expression or activity relative to the transcriptional expression or activity in an untreated or control sample and does not necessarily indicate a total elimination of transcriptional expression or activity. As used herein, "RNAi compound" means an antisense compound that acts, at least in part, through RISC or Ago2 to modulate a target nucleic acid and/or protein encoded by a target nucleic acid. RNAi compounds include, but are not limited to double-stranded siRNA, single-stranded RNA (ssRNA), and microRNA, including microRNA mimics. In certain embodiments, an RNAi compound modulates the amount, activity, and/or splicing of a target nucleic acid. The term RNAi compound excludes antisense compounds that act through RNase H. As used herein, "Self-complementary" in reference to an oligonucleotide means an oligonucleotide that at least partially hybridizes to itself As used herein, "standard cell assay" means the assay described in Example 1 and reasonable variations thereof. As used herein, "stereorandom chiral center" in the context of a population of molecules of identical molecular formula means a chiral center having a random stereochemical configuration. For example, in a population of molecules comprising a stereorandom chiral center, the number of molecules having the (S) configuration of the stereorandom chiral center may be but is not necessarily the same as the number of molecules having the (R) configuration of the stereorandom chiral center. The stereochemical configuration of a chiral center is considered random when it is the result of a synthetic method that is not designed to control the stereochemical configuration. In certain embodiments, a stereorandom chiral center is a stereorandom phosphorothioate intemucleoside linkage. As used herein, "sugar moiety" means an unmodified sugar moiety or a modified sugar moiety. As used herein, "unmodified sugar moiety" means a 2'-OH(H) furanosyl moiety, as found in RNA (an "unmodified RNA sugar moiety"), or a 2'-H(H) moiety, as found in DNA (an "unmodified DNA sugar moiety"). Unmodified sugar moieties have one hydrogen at each of the ', 3', and 4' positions, an oxygen at the 3' position, and two hydrogens at the 5' position. As used herein, "modified sugar moiety" or "modified sugar" means a modified furanosyl sugar moiety or a sugar surrogate. As used herein, modified furanosyl sugar moiety means a furanosyl sugar comprising a non-hydrogen substituent in place of at least one hydrogen of an unmodified sugar moiety. In certain embodiments, a modified furanosyl sugar moiety is a 2' substituted sugar moiety. Such modified furanosyl sugar moieties include bicyclic sugars and non-bicyclic sugars. As used herein, "sugar surrogate" means a modified sugar moiety having other than a furanosyl moiety that can link a nucleobase to another group, such as an intemucleoside linkage, conjugate group, or terminal group in an oligonucleotide. Modified nucleosides comprising sugar surrogates can be incorporated into one or more positions within an oligonucleotide and such oligonucleotides are capable of hybridizing to complementary oligomeric compounds or nucleic acids. As used herein, "target nucleic acid" and "target RNA" mean a nucleic acid that an antisense compound is designed to affect. As used herein, "target region" means a portion of a target nucleic acid to which an oligomeric compound is designed to hybridize. As used herein, "terminal group" means a chemical group or group of atoms that is covalently linked to a terminus of an oligonucleotide. As used herein, "therapeutically effective amount" means an amount of a pharmaceutical agent that provides a therapeutic benefit to an animal. For exampoe, a therapeutically effective amount improves a symptom of a disease. The present disclosure provides the following non-limiting numbered embodiments:

Embodiment 1: A modified oligonucleotide according to the following formula:

NH 2

NH 2 HO N'NH 2

HO 0 OO -

' O O) NH 2 0 0 HS-P=O N 0 O o 0 O N HS-P=O NH N

O-P-0 N 0 N0O O -- 0 o HO-P=O N NH 0 OO HS-P0 NH 0 "1 NH 2 N N NH 2 N O HS-P-O 0-t HSP O o 0 0 NH 2 0 HS-PO NH HS-P=O N sN N'O N N 0 0 0 0 HS-P=O NH2 0

HS-P=O HS-P=O N

HS N OHNHO O 0 0- NH 2 O N O NH2 HS O) 0 O HS-O O0 ' 010 0 HSNO NON HS-O S-P0 HS-O 0 SP

O O~

(SEQ ID NO: 8).

Consistent with the definititions and disclosure herein, compounds of Embodiment 1may be made by deliberately controlling stereochemistry of any, all or none of the linkages.

Embodiment 2:An oligomeric compound comprising amodified oligonucleotide according to the following formula: mCes mCeo Ges Tes Tes Tds Tds mCds Tds Tds Ads mCds mCds AesmCeo mCes mCesTe; wherein, A =an adenine, mC =a 5-methylcytosine, G =a guanine, T=a thymine, e = a 2'-MOE nucleoside, d = a 2'-deoxynucleoside, s = a phosphorothioate intemucleoside linkage, and o = a phosphodiester intemucleoside linkage.

Embodiment 3: The oligomeric compound of embodiment 2 comprising a conjugate group.

Embodiment 4: An oligomeric duplex comprising an oligomeric compound of embodiment 2 or embodiment 3.

Embodiment 5: An antisense compound comprising or consisting of a modified oligonucleotide according to embodiment 1, an oligomeric compound according to embodiment 2 or embodiment 3, or an oligomeric duplex according to embodiment 4.

Embodiment 6: A pharmaceutical composition comprising a modified oligonucleotide according to embodiment 1, an oligomeric compound according to embodiment 2 or embodiment 3, or an oligomeric duplex according to embodiment 4 or a salt thereof and a pharmaceutically acceptable carrier or diluent.

Embodiment 7: The composition of embodiment 6, wherein the salt is sodium.

Embodiment 8: A method comprising administering to an animal a pharmaceutical composition

according to embodiment 6 or embodiment 7.

Embodiment 9: A method of treating a disease associated with Tau comprising administering to an individual having or at risk for developing a disease associated with Tau a therapeutically effective amount of a pharmaceutical composition according to embodiment 6 or embodiment 7; and thereby treating the disease

associated with Tau.

Embodiment 10: The method of embodiment 9, wherein the disease associated with Tau is a neurodegenerative disease.

Embodiment 11: The method of embodiment 10, wherein the neurodegenerative disease is any of a tauopathy, Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, or Dravet's Syndrome.

Embodiment 12: The method of embodiment 10 or embodiment 11, wherein at least one symptom of the neurodegenerative disease is ameliorated.

Embodiment 13: The method of embodiment 12, wherein the symptom is any of loss of memory, loss of motor function, and increase in the number and/or volume of neurofibrillary inclusions.

Embodiment 14: A modified oligonucleotide according to the following formula:

NH 2

NH 2 HO N'NH 2

HO 0 OO -

' O O) NH 2 0 0 HS-P=O N 0 O N O N HS-P=O NH N

O-P-0 N 0 N0O O -- 0 o HO-P=O N NH 0 OO HS- P0 NH 0 "1 NH 2 N N NH 2 N O HS-P-O 0-t HSP O o 0 0 NH 2 0 HS-PO NH HS-P=O N sN N'O N N 0 0 0 0 HS-P=O NH2 0

HS-P=O HS-P=O N

N O 2 2NH HS N OHNHO H O> 0 HS-PO HS-NNO N

0 0

O o 0NH 2 HS- O HS-PO HS-P 0 NH I /N O N( O N N

0 0

O HS-P0HS-P0O ON

(SEQ ID NO: 8)

or a salt thereof

Embodiment 15. The modified oligonucleotide of embodiment 14, which is a sodium salt of the formula.

Embodiment 16. A compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is a gapmer consisting of a 5' wing segment, a central gap segment, and a 3' wing segment, wherein: the 5' wing segment consists of five 2'-MOE nucleosides, the central gap segment consists of eight 2'-deoxynucleosides, and the 3' wing segment consists of five 2'-MOE nucleosides; wherein the modified oligonucleotide has the nucleobase sequence 5'-CCGTTTTCTTACCACCCT 3' (SEQ ID NO: 8), wherein each cytosine is a 5-methylcytosine; and wherein the intemucleoside linkages of the modified oligonucleotide are, from 5' to 3', sossssssssssssoss, wherein each s is a phosphorothioate linkage and each o is a phosphodiester linkage.

Embodiment 17. A modified oligonucleotide, wherein the modified oligonucleotide is a gapmer consisting of a 5' wing segment, a central gap segment, and a 3' wing segment, wherein: the 5' wing segment consists of five 2'-MOE nucleosides, the central gap segment consists of eight 2'-deoxynucleosides, and the 3' wing segment consists of five 2'-MOE nucleosides; wherein the modified oligonucleotide has the nucleobase sequence 5'-CCGTTTTCTTACCACCCT-3' (SEQ ID NO: 8), wherein each cytosine is a 5-methylcytosine; and wherein the internucleoside linkages of the modified oligonucleotide are, from 5' to 3', sossssssssssssoss, wherein each s is a phosphorothioate linkage and each o is a phosphodiester linkage.

Embodiment 18. A chirally enriched population of modified oligonucleotides of any of embodiments 14, 15 or 17 wherein the population is enriched for modified oligonucleotides comprising at least one particular phorphorothioate intemucleoside linkage having a particular stereochemical configuration.

Embodiment 19. The chirally enriched population of embodiment 18, wherein the population is enriched for modified oligonucleotides comprising at least one particular phorphorothioate intemucleoside linkage having the (Sp) configuration.

Embodiment 20. The chirally enriched population of embodiment 18, wherein the population is enriched for modified oligonucleotides comprising at least one particular phorphorothioate intemucleoside linkage having the (Rp) configuration.

Embodiment 21. The chirally enriched population of embodiment 18, wherein the population is enriched for modified oligonucleotides having a particular, independently selected stereochemical configuration at each phosphorothioate internucleoside linkage

Embodiment 22. The chirally enriched population of embodiment 21, wherein the population is enriched for modified oligonucleotides having the (Sp) configuration at each phosphorothioate intemucleoside linkage.

Embodiment 23. The chirally enriched population of embodiment 21, wherein the population is enriched for modified oligonucleotides having the (Rp) configuration at each phosphorothioate intemucleoside linkage.

Embodiment 24. The chirally enriched population of embodiment 21, wherein the population is enriched for modified oligonucleotides having the (Rp) configuration at one particular phosphorothioate internucleoside linkage and the (Sp) configuration at each of the remaining phosphorothioate internucleoside linkages.

Embodiment 25. The chirally enriched population of embodiment 18 or embodiment 21 wherein the population is enriched for modified oligonucleotides having at least 3 contiguous phosphorothioate internucleoside linkages in the Rp, Sp, and Sp configurations, in the 5' to 3' direction.

Embodiment 26. A chirally enriched population of modified oligonucleotides of any of embodiment 1-17, wherein all of the phosphorothioate internucleoside linkages of the modified oligonucleotide are stereorandom.

Embodiment 27. A pharmaceutical composition comprising the modified oligonucleotide of any of embodiments 14, 15, or 17 and a pharmaceutically acceptable diluent or carrier.

Embodiment 28, A pharmaceutical composition comprising the population of modified oligonucleotides of any of embodiments 18-26 and a pharmaceutically acceptable diluent or carrier.

Embodiment 29. The pharmaceutical composition of embodiment 27 or embodiment 28, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS) or artificial CSF (aCSF).

Embodiment 30. The pharmaceutical composition of embodiment 27 or embodiment 28, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and phosphate-buffered saline (PBS) or artificial CSF (aCSF).

I. Certain Oligonucleotides In certain embodiments, provided herein are oligonucleotides, which consist of linked nucleosides. Oligonucleotides may be unmodified oligonucleotides (RNA or DNA) or may be modified oligonucleotides. Modified oligonucleotides comprise at least one modification relative to unmodified RNA or DNA. That is, modified oligonucleotides comprise at least one modified nucleoside (comprising a modified sugar moiety and/or a modified nucleobase) and/or at least one modified intemucleoside linkage. A. Certain Modified Nucleosides Modified nucleosides comprise a modified sugar moiety or a modified nucleobase or both a modifed sugar moiety and a modified nucleobase. 1. Certain Sugar Moieties In certain embodiments, modified sugar moieties are non-bicyclic modified sugar moieties. In certain embodiments, modified sugar moieties are bicyclic or tricyclic sugar moieties. In certain embodiments, modified sugar moieties are sugar surrogates. Such sugar surrogates may comprise one or more substitutions corresponding to those of other types of modified sugar moieties. In certain embodiments, modified sugar moieties are non-bicyclic modified sugar moieties comprising a furanosyl ring with one or more substituent groups none of which bridges two atoms of the furanosyl ring to form a bicyclic structure. Such non bridging substituents may be at any position of the furanosyl, including but not limited to substituents at the 2', 4', and/or 5' positions. In certain embodiments one or more non-bridging substituent of non-bicyclic modified sugar moieties is branched. Examples of 2' substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to: 2'-F, 2' OCH3 ("OMe" or "O-methyl"), and 2'-O(CH2) 20CH3 ("MOE"). In certain embodiments, 2'-substituent groups are selected from among: halo, allyl, amino, azido, SH, CN, OCN, CF3 , OCF3 ,0-C-C10 alkoxy, 0 C 1-Co substituted alkoxy, 0-C 1-C 1 0alkyl, 0-C1 -C 1 0 substituted alkyl, S-alkyl, N(Rm)-alkyl, 0-alkenyl, S alkenyl, N(Rm)-alkenyl, 0-alkynyl, S-alkynyl, N(Rm)-alkynyl, 0-alkylenyl-O-alkyl, alkynyl, alkaryl, aralkyl, 0-alkaryl, 0-aralkyl, O(CH 2 ) 2 SCH3, O(CH 2)2ON(Rm)(Rn) or OCH 2C(=0)-N(Rm)(R), where each Rm and R. is, independently, H, an amino protecting group, or substituted or unsubstituted C1 -C 10 alkyl, and the 2' substituent groups described in Cook et al., U.S. 6,531,584; Cook et al., U.S. 5,859,221; and Cook et al., U.S. 6,005,087. Certain embodiments of these 2'-substituent groups can be further substituted with one or more substituent groups independently selected from among: hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO 2), thiol, thioalkoxy, thioalkyl, halogen, alkyl, aryl, alkenyl and alkynyl. Examples of 4'-substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to alkoxy (e.g., methoxy), alkyl, and those described in Manoharan et al., WO 2015/106128. Examples of 5'-substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to: 5'-methyl (R or S), 5' vinyl, and 5'-methoxy. In certain embodiments, non-bicyclic modified sugar moieties comprise more than one non-bridging sugar substituent, for example, 2'-F-5'-methyl sugar moieties and the modified sugar moieties and modified nucleosides described in Migawa et al., WO 2008/101157 and Rajeev et al., US2013/0203836.). In certain embodiments, a 2'-substituted non-bicyclic modified nucleoside comprises a sugar moiety comprising a non-bridging 2'-substituent group selected from: F, NH 2 , N 3, OCF 3, OCH3

O(CH 2 ) 3 NH 2 , CH2CH=CH 2, OCH 2CH=CH ,2 OCH2CH2OCH3, O(CH 2)2 SCH3 , O(CH2)2ON(Rm)(R), O(CH 2)2 0(CH2)2N(CH 3)2, and N-substituted acetamide (OCH 2C(=O)-N(Rm)(R)), where each Rm and R. is, independently, H, an amino protecting group, or substituted or unsubstituted C1 -C1 0 alkyl. In certain embodiments, a 2'-substituted nucleoside non-bicyclic modified nucleoside comprises a sugar moiety comprising a non-bridging 2'-substituent group selected from: F, OCF 3 , OCH 3 ,

OCH2 CH2 OCH3, O(CH 2) 2SCH 3, O(CH 2 ) 2 0N(CH 3 ) 2 , O(CH2 )2 0(CH 2)2N(CH 3 )2 , and OCH 2C(=O)-N(H)CH 3

("NMA").

In certain embodiments, a 2'-substituted non-bicyclic modified nucleoside comprises a sugar moiety comprising a non-bridging 2'-substituent group selected from: F, OCH 3, and OCH2 CHOCH 2 3

. Certain modifed sugar moieties comprise a substituent that bridges two atoms of the furanosyl ring to form a second ring, resulting in a bicyclic sugar moiety. In certain such embodiments, the bicyclic sugar moiety comprises a bridge between the 4'and the 2'furanose ring atoms. Examples of such 4'to 2' bridging sugar substituents include but are not limited to: 4'-CH 2-2', 4'-(CH 2)2-2', 4'-(CH 2) 3-2', 4'-CH 2-0-2' ("LNA"), 4'-CH 2-S-2', 4'-(CH 2) 2-O-2'("ENA"), 4'-CH(CH 3 )--2'(referred to as "constrained ethyl" or "cEt"), 4'-CH2 O-CH 2 -2', 4'-CH 2-N(R)-2', 4'-CH(CH 20CH 3)-0-2'("constrained MOE" or "cMOE") and analogs thereof (see, e.g., Seth et al., U.S. 7,399,845, Bhat et al., U.S. 7,569,686, Swayze et al., U.S. 7,741,457, and Swayze et al., U.S. 8,022,193), 4'-C(CH3)(CH 3 )--2' and analogs thereof (see, e.g., Seth et al., U.S. 8,278,283), 4' CH 2-N(OCH3)-2'and analogs thereof (see, e.g., Prakash et al., U.S. 8,278,425), 4'-CH2-- N(CH3 )-2' (see, e.g., Allerson et al., U.S. 7,696,345 and Allerson et al., U.S. 8,124,745), 4'-CH 2 -C(H)(CH 3)-2' (see, e.g., Zhou, et al., J. Org. Chem.,2009, 74, 118-134), 4'-CH2 -C(=CH 2)-2'and analogs thereof (see e.g., Seth et al., U.S. 8,278,426), 4'-C(RaRb)-N(R)--2', 4'-C(RaR)0-N(R)-2', 4'-CH 2 -O-N(R)-2', and 4'-CH 2 -N(R)-O-2', wherein each R, Ra, and Rb is, independently, H, a protecting group, or CI-C 12 alkyl (see, e.g. Imanishi et al., U.S. 7,427,672). In certain embodiments, such 4' to 2' bridges independently comprise from I to 4 linked groups independently selected from: -[C(Ra)(Rb)].-, -[C(Ra)(Rb)].-O-, -C(Ra)=C(Rb)-, -C(Ra)=N-, -C(=NRa)-, C(=0)-, -C(=S)-, -O-, -Si(Ra)r, -S(=O)x-, and -N(Ra)-; wherein: x is 0, 1, or 2;

n is 1, 2, 3, or 4; each Ra and R is, independently, H, a protecting group, hydroxyl, CC1 2 alkyl, substituted CC1 2

alkyl, C2 -C 1 2 alkenyl, substituted C2 -C 1 2 alkenyl, C2 -C 1 2 alkynyl, substituted C2 -C 1 2 alkynyl, C 5-C 20 aryl, substituted C5 -C 2 0 aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl,

C 5-C 7 alicyclic radical, substituted C5-C. alicyclic radical, halogen, OJi, NJJ2 , SJ1 , N 3, COOJi, acyl (C(=O) H), substituted acyl, CN, sulfonyl (S(=0) 2 -JI), or sulfoxyl (S(=0)-Ji); and each J, andJ 2 is, independently, H,CC1 2 alkyl, substitutedCC1 2 alkyl, C2 -C 1 2 alkenyl, substituted

C 2 -C 1 alkenyl, C 2 -C 1 2 alkynyl, substituted C2 -C alkynyl, C5 -C 2o aryl, substituted C5 -C 20 aryl, acyl (C(=O) H), substituted acyl, a heterocycle radical, a substituted heterocycle radical,CC 1 2 aminoalkyl, substituted

C 1-C 1 2 aminoalkyl, or a protecting group. Additional bicyclic sugar moieties are known in the art, see, for example: Freier et al., Nucleic Acids Research, 1997, 25(22), 4429-4443, Albaek et al., J Org. Chem., 2006, 71, 7731-7740, Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et al., Tetrahedron, 1998, 54, 3607-3630; Kumar et al., Bioorg. Med Chem. Lett., 1998, 8, 2219-2222; Singh et al., J Org. Chem., 1998, 63, 10035-10039; Srivastava et al., J.Am.

Chem. Soc., 20017, 129, 8362-8379;Wengel et a., U.S. 7,053,207; Imanishi et al., U.S. 6,268,490; Imanishi et al. U.S. 6,770,748; Imanishi et al., U.S. RE44,779; Wengel et al., U.S. 6,794,499; Wengel et al., U.S. 6,670,461; Wengel et al., U.S. 7,034,133; Wengel et al., U.S. 8,080,644; Wengel et al., U.S. 8,034,909; Wengel et al., U.S. 8,153,365; Wengel et al., U.S. 7,572,582; and Ramasamy et al., U.S. 6,525,191;; Torsten et al., WO 2004/106356;Wengel et al., WO 1999/014226; Seth et al., WO 2007/134181; Seth et al., U.S. 7,547,684; Seth et al., U.S. 7,666,854; Seth et al., U.S. 8,088,746; Seth et al., U.S. 7,750,131; Seth et al., U.S. 8,030,467; Seth et al., U.S. 8,268,980; Seth et al., U.S. 8,546,556; Seth et al., U.S. 8,530,640; Migawa et al., U.S. 9,012,421; Seth et al., U.S. 8,501,805; and U.S. Patent Publication Nos. Allerson et al., US2008/0039618 and Migawa et al., US2015/0191727. In certain embodiments, bicyclic sugar moieties and nucleosides incorporating such bicyclic sugar moieties are further defined by isomeric configuration. For example, an LNA nucleoside (described herein) may be in the a-L configuration or in the -D configuration.

O Bx S Bx

LNA (p-D-configuration) a-L-LNA (a-L-configuration) bridge = 4-CH 2 -0-2' bridge = 4'-CH 2 -0-2'

a-L-methyleneoxy (4'-CH 2 -O-2') or a-L-LNA bicyclic nucleosides have been incorporated into oligonucleotides that showed antisense activity (Frieden et al., Nucleic Acids Research, 2003, 21, 6365 6372). Herein, general descriptions of bicyclic nucleosides include both isomeric configurations. When the positions of specific bicyclic nucleosides (e.g., LNA or cEt) are identified in exemplified embodiments herein, they are in the p-D configuration, unless otherwise specified. In certain embodiments, modified sugar moieties comprise one or more non-bridging sugar substituent and one or more bridging sugar substituent (e.g., 5'-substituted and 4'-2' bridged sugars). In certain embodiments, modified sugar moieties are sugar surrogates. In certain such embodiments, the oxygen atom of the sugar moiety is replaced, e.g., with a sulfur, carbon or nitrogen atom. In certain such embodiments, such modified sugar moieties also comprise bridging and/or non-bridging substituents as described herein. For example, certain sugar surrogates comprise a 4'-sulfur atom and a substitution at the 2' position (see, e.g., Bhat et al., U.S. 7,875,733 and Bhat et al., U.S. 7,939,677) and/or the 5' position. In certain embodiments, sugar surrogates comprise rings having other than 5 atoms. For example, in certain embodiments, a sugar surrogate comprises a six-membered tetrahydropyran ("THP"). Such tetrahydropyrans may be further modified or substituted. Nucleosides comprising such modified tetrahydropyrans include but are not limited to hexitol nucleic acid ("HNA"), anitol nucleic acid ("ANA"), manitol nucleic acid ("MNA") (see, e.g, Leumann, CJ. Bioorg. & Med. Chem. 2002, 10, 841-854), fluoro HNA:

O 0

Bx

F-HNA

("F-HNA", see e.g. Swayze et al., U.S. 8,088,904; Swayze et al., U.S. 8,440,803; Swayze et al., U.S. 8,796,437; and Swayze et al., U.S. 9,005,906; F-HNA can also be referred to as a F-THP or3-fluoro tetrahydropyran), and nucleosides comprising additional modified THP compounds having the formula:

T3-0 0

q6 Bx 0 q / R1 R2 5 T4

wherein, independently, for each of said modified THP nucleoside: Bx is a nucleobase moiety; T3 and T4 are each, independently, an internucleoside linking group linking the modified THP nucleoside to the remainder of an oligonucleotide or one of T3 and T4 is an intemucleoside linking group

linking the modified THP nucleoside to the remainder of an oligonucleotide and the other of T3 and T4 is H, a hydroxyl protecting group, a linked conjugate group, or a 5' or3-terminal group; qi, q2, q3, q4, q5, q6 and q are each, independently, H, Ci-C6 alkyl, substituted C 1-C 6 alkyl, C2-C alkenyl, substituted C2 -C 6 alkenyl, C2-C 6 alkynyl, or substituted C2-C6 alkynyl; and each of R1 and R2 is independently selected from among: hydrogen, halogen, substituted or unsubstituted alkoxy, NJiJ2, SJI, N 3, OC(=X)Ji, OC(=X)NJiJ 2, NJ 3C(=X)NJJ 2, and CN, wherein X is 0, S or NJi, and each Ji, J2, and J3 is, independently, H or C1-C6 alkyl. In certain embodiments, modified THP nucleosides are provided wherein qi, q2, q3, q4, q5, q6 and q7 are each H. In certain embodiments, at least one of qi, q2, q3, q4, q5, q6and q7 is other than H. In certain embodiments, at least one ofqi, q2, q3, q4, q5, q6 and q is methyl. In certain embodiments, modified THP nucleosides are provided wherein one of R 1 and R2 is F. In certain embodiments, R 1 is F and R2 is H, in certain embodiments, R 1 is methoxy and R2 is H, and in certain embodiments, R1 is methoxyethoxy and R2 is H. In certain embodiments, sugar surrogates comprise rings having more than 5 atoms and more than one heteroatom. For example, nucleosides comprising morpholino sugar moieties and their use in

oligonucleotides have been reported (see, e.g., Braasch et al., Biochemistry, 2002, 41, 4503-4510 and

Summerton et al., U.S. 5,698,685; Summerton et al., U.S. 5,166,315; Summerton et al., U.S. 5,185,444; and Summerton et al., U.S. 5,034,506). As used here, the term "morpholino" means a sugar surrogate having the following structure:

0 A0Bx

N

In certain embodiments, morpholinos may be modified, for example by adding or altering various substituent groups from the above morpholino structure. Such sugar surrogates are refered to herein as "modifed morpholinos." In certain embodiments, sugar surrogates comprise acyclic moieites. Examples of nucleosides and oligonucleotides comprising such acyclic sugar surrogates include but are not limited to: peptide nucleic acid ("PNA"), acyclic butyl nucleic acid (see, e.g., Kumar et al., Org. Biomol. Chem., 2013, 11, 5853-5865), and nucleosides and oligonucleotides described in Manoharan et al., W02011/133876. Many other bicyclic and tricyclic sugar and sugar surrogate ring systems are known in the art that can

be used in modified nucleosides). 2. Certain Modified Nucleobases In certain embodiments, modified oligonucleotides comprise one or more nucleoside comprising an unmodified nucleobase. In certain embodiments, modified oligonucleotides comprise one or more nucleoside comprising a modified nucleobase. In certain embodiments, modified oligonucleotides comprise one or more nucleoside that does not comprise a nucleobase, referred to as an abasic nucleoside. In certain embodiments, modified nucleobases are selected from: 5-substituted pyrimidines, 6 azapyrimidines, alkyl or alkynyl substituted pyrimidines, alkyl substituted purines, and N-2, N-6 and 0-6 substituted purines. In certain embodiments, modified nucleobases are selected from: 2-aminopropyladenine, 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-N-methylguanine, 6-N-methyladenine,

2-propyladenine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl (-C=C-CH 3) uracil, 5 propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymine, 5-ribosyluracil (pseudouracil), 4-thiouracil, 8 halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, 8-aza and other 8-substituted purines, 5-halo, particularly 5 bromo, 5-trifluoromethyl, 5-halouracil, and 5-halocytosine, 7-methylguanine, 7-methyladenine, 2-F-adenine, 2-aminoadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, 3-deazaadenine, 6-N-benzoyladenine, 2 N-isobutyrylguanine, 4-N-benzoylcytosine, 4-N-benzoyluracil, 5-methyl 4-N-benzoylcytosine, 5-methyl 4-N benzoyluracil, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases. Further modified nucleobases include tricyclic pyrimidines, such as 1,3-diazaphenoxazine-2-one, 1,3 diazaphenothiazine-2-one and 9-(2-aminoethoxy)-1,3-diazaphenoxazine-2-one (G-clamp). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in Merigan et al., U.S. 3,687,808, those disclosed in 7he Concise Encyclopedia OfPolymer ScienceAnd Engineering, Kroschwitz, J.I., Ed., John Wiley & Sons, 1990, 858 859; Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613; Sanghvi, Y.S., Chapter 15, Antisense Research andApplications,Crooke, S.T. and Lebleu, B., Eds., CRC Press, 1993, 273-288; and those disclosed in Chapters 6 and 15,Antisense Drug Technology, Crooke S.T., Ed., CRC Press, 2008, 163 166 and 442-443. Publications that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include without limitation, Manohara et al., US2003/0158403; Manoharan et al., US2003/0175906; Dinh et al., U.S. 4,845,205; Spielvogel et al., U.S. 5,130,302; Rogers et al., U.S. 5,134,066; Bischofberger et al., U.S. 5,175,273; Urdea et al., U.S. 5,367,066; Benner et al., U.S. 5,432,272; Matteucci et al., U.S. 5,434,257; Gmeiner et al., U.S. 5,457,187; Cook et al., U.S. 5,459,255; Froehler et al., U.S. 5,484,908; Matteucci et al., U.S. 5,502,177; Hawkins et al., U.S. 5,525,711; Haralambidis et al., U.S. 5,552,540; Cook et al., U.S. 5,587,469; Froehler et al., U.S. 5,594,121; Switzer et al., U.S. 5,596,091; Cook et al., U.S. 5,614,617; Froehler et al., U.S. 5,645,985; Cook et al., U.S. 5,681,941; Cook et al., U.S. 5,811,534; Cook et al., U.S. 5,750,692; Cook et al., U.S. 5,948,903; Cook et al., U.S. 5,587,470; Cook et al., U.S. 5,457,191; Matteucci et al., U.S. 5,763,588; Froehler et al., U.S. 5,830,653; Cook et al., U.S. 5,808,027; Cook et al., 6,166,199; and Matteucci et al., U.S. 6,005,096. 3. Certain Modified Internucleoside Linka2es In certain embodiments, nucleosides of modified oligonucleotides may be linked together using any intemucleoside linkage. The two main classes of internucleoside linking groups are defined by the presence or absence of a phosphorus atom. Representative phosphorus-containing internucleoside linkages include but are not limited to phosphates, which contain a phosphodiester bond ("P=O") (also referred to as unmodified or naturally occurring linkages), phosphotriesters, methylphosphonates, phosphoramidates, and phosphorothioates ("P=S"), and phosphorodithioates ("HS-P=S"). Representative non-phosphorus containing intemucleoside linking groups include but are not limited to methylenemethylimino (-CH 2 N(CH 3)-O-CH 2-), thiodiester, thionocarbamate (-O-C(=O)(NH)-S-); siloxane (-O-SiH 2-O-); and N,N' dimethylhydrazine (-CH 2 -N(CH 3 )-N(CH 3 )-). Modified intemucleoside linkages, compared to naturally occurring phosphate linkages, can be used to alter, typically increase, nuclease resistance of the oligonucleotide. Methods of preparation of phosphorous-containing and non-phosphorous-containing intermucleoside linkages are well known to those skilled in the art.

Representative internucleoside linkages having a chiral center include but are not limited to alkylphosphonates and phosphorothioates. Modified oligonucleotides comprising intemucleoside linkages having a chiral center can be prepared as populations of modified oligonucleotides comprising stereorandom internucleoside linkages, or as populations of modified oligonucleotides comprising phosphorothioate linkages in particular stereochemical configurations. In certain embodiments, populations of modified oligonucleotides comprise phosphorothioate internucleoside linkages wherein all of the phosphorothioate internucleoside linkages are stereorandom. Such modified oligonucleotides can be generated using synthetic methods that result in random selection of the stereochemical configuration of each phosphorothioate linkage. Nonetheless, as is well understood by those of skill in the art, each individual phosphorothioate of each individual oligonucleotide molecule has a defined stereoconfiguration. In certain embodiments, populations of modified oligonucleotides are enriched for modified oligonucleotides comprising one or more particular phosphorothioate intemucleoside linkages in a particular, independently selected stereochemical configuration. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 65% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 70% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 80% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 90% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 99% of the molecules in the population. Such chirally enriched populations of modified oligonucleotides can be generated using synthetic methods known in the art, e.g., methods described in Oka et al., JACS 125, 8307 (2003), Wan et al. Nuc. Acid. Res. 42, 13456 (2014), and WO 2017/015555. In certain embodiments, a population of modified oligonucleotides is enriched for modified oligonucleotides having at least one indicated phosphorothioate in the (Sp) configuration. In certain embodiments, a population of modified oligonucleotides is enriched for modified oligonucleotides having at least one phosphorothioate in the (Rp) configuration. In certain embodiments, modified oligonucleotides comprising (Rp) and/or (Sp) phosphorothioates comprise one or more of the following formulas, respectively, wherein "B" indicates a nucleobase: B O B o o - T O=P-SH O=P-'SH o o B B 0 0

(RP) (SP) Unless otherwise indicated, chiral intemucleoside linkages of modified oligonucleotides described herein can be stereorandom or in a particular stereochemical configuration.

Neutral internucleoside linkages include, without limitation, phosphotriesters, methylphosphonates, MMI (3'-CH2-N(CH 3 )-0-5'), amide-3 (3'-CH 2-C(=O)-N(H)-5'), amide-4 (3'-CH2-N(H)-C(=O)-5'), formacetal (3'-O-CH2 -0-5'), methoxypropyl, and thioformacetal (3'-S-CH 2-0-5'). Further neutral internucleoside linkages include nonionic linkages comprising siloxane (dialkylsiloxane), carboxylate ester, carboxamide, sulfide, sulfonate ester and amides (See for example: CarbohydrateModifications in Antisense Research; Y.S. Sanghvi and P.D. Cook, Eds., ACS Symposium Series 580; Chapters 3 and 4, 40-65). Further neutral internucleoside linkages include nonionic linkages comprising mixed N, 0, S and CH2 component parts. B. Certain Motifs In certain embodiments, modified oligonucleotides comprise one or more modified nucleosides comprising a modified sugar moiety. In certain embodiments, modified oligonucleotides comprise one or more modified nucleosides comprising a modified nucleobase. In certain embodiments, modified oligonucleotides comprise one or more modified intemucleoside linkage. In such embodiments, the modified, unmodified, and differently modified sugar moieties, nucleobases, and/or internucleoside linkages of a modified oligonucleotide define a pattern or motif. In certain embodiments, the patterns of sugar moieties, nucleobases, and intemucleoside linkages are each independent of one another. Thus, a modified oligonucleotide may be described by its sugar motif, nucleobase motif and/or internucleoside linkage motif (as used herein, nucleobase motif describes the modifications to the nucleobases independent of the sequence of nucleobases). 1. Certain Su2ar Motifs In certain embodiments, oligonucleotides comprise one or more type of modified sugar and/or unmodified sugar moiety arranged along the oligonucleotide or region thereof in a defined pattern or sugar motif. In certain instances, such sugar motifs include but are not limited to any of the sugar modifications discussed herein. In certain embodiments, modified oligonucleotides comprise or consist of a region having a gapmer motif, which is defined by two external regions or "wings" and a central or internal region or "gap." The three regions of a gapmer motif (the 5'-wing, the gap, and the 3'-wing) form a contiguous sequence of nucleosides wherein at least some ofthe sugar moieties of the nucleosides of each ofthe wings differ from at

least some of the sugar moieties of the nucleosides of the gap. Specifically, at least the sugar moieties of the nucleosides of each wing that are closest to the gap (the 3'-most nucleoside of the 5'-wing and the 5'-most nucleoside of the 3'-wing) differ from the sugar moiety of the neighboring gap nucleosides, thus defining the boundary between the wings and the gap (i.e., the wing/gap junction). In certain embodiments, the sugar moieties within the gap are the same as one another. In certain embodiments, the gap includes one or more nucleoside having a sugar moiety that differs from the sugar moiety of one or more other nucleosides of the gap. In certain embodiments, the sugar motifs of the two wings are the same as one another (symmetric gapmer). In certain embodiments, the sugar motif of the 5'-wing differs from the sugar motif of the 3-wing (asymmetric gapmer). In certain embodiments, the wings of a gapmer comprise 1-5 nucleosides. In certain embodiments, each nucleoside of each wing of a gapmer is a modified nucleoside. In certain embodiments, the gap of a gapmer comprises 7-12 nucleosides. In certain embodiments, each nucleoside of the gap of a gapmer is an unmodified 2'-deoxy nucleoside. In certain embodiments, the gapmer is a deoxy gapmer. In embodiments, the nucleosides on the gap side of each wing/gap junction are unmodified 2'-deoxy nucleosides and the nucleosides on the wing sides of each wing/gap junction are modified nucleosides. In certain embodiments, each nucleoside of the gap is an unmodified 2'-deoxy nucleoside. In certain embodiments, each nucleoside of each wing of a gapmer is a modified nucleoside. In certain embodiments, modified oligonucleotides comprise or consist of a region having a fully modified sugar motif. In such embodiments, each nucleoside of the fully modified region of the modified oligonucleotide comprises a modified sugar moiety. In certain embodiments, each nucleoside of the entire modified oligonucleotide comprises a modified sugar moiety. In certain embodiments, modified oligonucleotides comprise or consist of a region having a fully modified sugar motif, wherein each nucleoside within the fully modified region comprises the same modified sugar moiety, referred to herein as a uniformly modified sugar motif. In certain embodiments, a fully modified oligonucleotide is a uniformly modified oligonucleotide. In certain embodiments, each nucleoside of a uniformly modified comprises the same 2'-modification. Herein, the lengths (number of nucleosides) of the three regions of a gapmer may be provided using the notation [# of nucleosides in the 5'-wing] - [# of nucleosides in the gap] - [# of nucleosides in the 3' wing]. Thus, a 5-8-5 gapmer consists of 5 linked nucleosides in each wing and 8 linked nucleosides in the gap. Where such nomenclature is followed by a specific modification, that modification is the modification in the wings and the gap nucleosides comprise unmodified deoxynucleosides sugars. Thus, a 5-8-5 MOE gapmer consists of 5 linked MOE modified nucleosides in the 5'-wing, 8 linked deoxynucleosides in the gap, and 5 linked MOE nucleosides in the 3'-wing. In certain embodiments, modified oligonucleotides are 5-8-5

MOE gapmers. 2. Certain Nucleobase Motifs In certain embodiments, oligonucleotides comprise modified and/or unmodified nucleobases arranged along the oligonucleotide or region thereof in a defined pattern or motif In certain embodiments, each nucleobase is modified. In certain embodiments, none of the nucleobases are modified. In certain embodiments, each purine or each pyrimidine is modified. In certain embodiments, each adenine is modified. In certain embodiments, each guanine is modified. In certain embodiments, each thymine is modified. In certain embodiments, each uracil is modified. In certain embodiments, each cytosine is modified. In certain embodiments, some or all of the cytosine nucleobases in a modified oligonucleotide are 5-methylcytosines. In certain embodiments, all of the cytosine nucleobases are 5-methylcytosines and all of the other nucleobases of the modified oligonucleotide are unmodified nucleobases. In certain embodiments, modified oligonucleotides comprise a block of modified nucleobases. In certain such embodiments, the block is at the 3'-end of the oligonucleotide. In certain embodiments the block is within 3 nucleosides of the 3'-end of the oligonucleotide. In certain embodiments, the block is at the 5' end of the oligonucleotide. In certain embodiments the block is within 3 nucleosides of the 5'-end of the oligonucleotide. In certain embodiments, oligonucleotides having a gapmer motif comprise a nucleoside comprising a modified nucleobase. In certain such embodiments, one nucleoside comprising a modified nucleobase is in the central gap of an oligonucleotide having a gapmer motif In certain such embodiments, the sugar moiety of said nucleoside is a 2'-deoxyribosyl moiety. In certain embodiments, the modified nucleobase is selected from: a 2-thiopyrimidine and a 5-propynepyrimidine. 3. Certain Internucleoside Linkage Motifs In certain embodiments, oligonucleotides comprise modified and/or unmodified intemucleoside linkages arranged along the oligonucleotide or region thereof in a defined pattern or motif. In certain embodiments, each internucleoside linking group is a phosphodiester internucleoside linkage (P=O). In certain embodiments, each internucleoside linking group of a modified oligonucleotide is a phosphorothioate internucleoside linkage (P=S). In certain embodiments, each intemucleoside linkage of a modified oligonucleotide is independently selected from a phosphorothioate intemucleoside linkage and phosphodiester intemucleoside linkage. In certain embodiments, each phosphorothioate intemucleoside linkage is independently selected from a stereorandom phosphorothioate, a (Sp) phosphorothioate, and a (Rp) phosphorothioate. In certain embodiments, the sugar motif of a modified oligonucleotide is a gapmer and the internucleoside linkages within the gap are all modified. In certain such embodiments, some or all of the internucleoside linkages in the wings are unmodified phosphate linkages. In certain embodiments, the terminal intemucleoside linkages are modified. In certain embodiments, the sugar motif of a modified oligonucleotide is a gapmer, and the intemucleoside linkage motif comprises at least one phosphodiester internucleoside linkage in at least one wing, wherein the at least one phosphodiester linkage is not a terminal internucleoside linkage, and the remaining internucleoside linkages are phosphorothioate internucleoside linkages. In certain such embodiments, all of the phosphorothioate linkages are stereorandom. In certain embodiments, all of the phosphorothioate linkages in the wings are (Sp) phosphorothioates, and the gap comprises at least one Sp, Sp, Rp motif In certain embodiments, populations of modified oligonucleotides are enriched for modified oligonucleotides comprising such intemucleoside linkage motifs.

C. Certain Lengths It is possible to increase or decrease the length of an oligonuclotide without eliminating activity. For example, in Woolf et al. (Proc. Natl. Acad. Sci. USA 89:7305-7309, 1992), a series of oligonucleotides 13-25 nucleobases in length were tested for their ability to induce cleavage of a target RNA in an oocyte injection model. Oligonucleotides 25 nucleobases in length with 8 or 11 mismatch bases near the ends of the oligonucleotides were able to direct specific cleavage of the target mRNA, albeit to a lesser extent than the oligonucleotides that contained no mismatches. Similarly, target specific cleavage was achieved using 13 nucleobase oligonucleotides, including those with 1 or 3 mismatches, In certain embodiments, oligonucleotides (including modified oligonucleotides) can have any of a variety of ranges of lengths. In certain embodiments, oligonucleotides consist of X to Y linked nucleosides, where X represents the fewest number of nucleosides in the range and Y represents the largest number nucleosides in the range. In certain such embodiments, X and Y are each independently selected from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 45, 46, 47, 48, 49, and 50; provided that XY. For example, in certain embodiments, oligonucleotides consist of 12 to 13, 12 to 14, 12 to 15, 12 to 16, 12 to 17, 12 to 18, 12 to 19, 12 to 20, 12 to 21, 12 to 22, 12 to 23, 12 to 24, 12 to 25, 12 to 26, 12 to 27, 12 to 28, 12 to 29, 12 to 30, 13 to 14, 13 to 15, 13 to 16, 13 to 17, 13 to 18, 13 to 19, 13 to 20, 13 to 21, 13 to 22, 13 to 23, 13 to 24, 13 to 25, 13 to 26, 13 to 27, 13 to 28, 13 to 29, 13 to 30, 14 to 15, 14 to 16, 14 to 17, 14 to 18, 14 to 19, 14 to 20, 14 to 21, 14 to 22, 14 to 23, 14 to 24, 14 to 25, 14 to 26, 14 to 27, 14 to 28, 14 to 29, 14 to 30, 15 to 16, 15 to 17, 15 to 18, 15 to 19, 15 to 20, 15 to 21, 15 to 22, 15 to 23, 15 to 24, 15 to 25, 15 to 26, 15 to 27, 15 to 28, 15 to 29, 15 to 30, 16 to 17, 16 to 18, 16 to 19, 16 to 20, 16 to 21, 16 to 22, 16 to 23, 16 to 24, 16 to 25, 16 to 26, 16 to 27, 16 to 28, 16 to 29, 16 to 30, 17 to 18, 17 to 19, 17 to 20, 17 to 21, 17 to 22, 17 to 23, 17 to 24, 17 to 25, 17 to 26, 17 to 27, 17 to 28, 17 to 29, 17 to 30, 18 to 19, 18 to 20, 18 to 21, 18 to 22, 18 to 23, 18 to 24, 18 to 25, 18 to 26, 18 to 27, 18 to 28, 18 to 29, 18 to 30, 19 to 20, 19 to 21, 19 to 22, 19 to 23, 19 to 24, 19 to 25, 19 to 26, 19 to o 29to28, 19 to 29, 19 to 30, 20 to 21, 20 to 22, 20 to 23, 20 to 24, 20 to 25, 20 to 26, 20 to 27, 20 to 28, 20 to 29, 20 to 30, 21 to 22, 21 to 23, 21 to 24, 21 to 25, 21 to 26, 21 to 27, 21 to 28, 21 to 29, 21 to 30, 22 to 23, 22 to 24, 22 to 25, 22 to 26, 22 to 27, 22 to 28, 22 to 29, 22 to 30, 23 to 24, 23 to 25, 23 to 26, 23 to 27, 23 to 28, 23 to 29, 23 to 30, 24 to 25, 24 to 26, 24 to 27, 24 to 28, 24 to 29, 24 to 30, 25 to 26, 25 to 27, 25 to 28, 25 to 29, 25 to 30, 26 to 27, 26 to 28, 26 to 29, 26 to 30, 27 to 28, 27 to 29, 27 to 30, 28 to 29, 28 to 30, or 29 to 30 linked nucleosides D. Certain Modified Oligonucleotides In certain embodiments, the above modifications (sugar, nucleobase, intemucleoside linkage) are incorporated into a modified oligonucleotide. In certain embodiments, modified oligonucleotides are characterized by their modification motifs and overall lengths. In certain embodiments, such parameters are each independent of one another. Thus, unless otherwise indicated, each intemucleoside linkage of an oligonucleotide having a gapmer sugar motif may be modified or unmodified and may or may not follow the gapmer modification pattern of the sugar modifications. For example, the intermucleoside linkages within the wing regions of a sugar gapmer may be the same or different from one another and may be the same or different from the internucleoside linkages of the gap region of the sugar motif. Likewise, such sugar gapmer oligonucleotides may comprise one or more modified nucleobase independent of the gapmer pattern of the sugar modifications. Unless otherwise indicated, all modifications are independent of nucleobase sequence.

E. Certain populations of modified oligonucleotides Populations of modified oligonucleotides in which all of the modified oligonucleotides of the population have the same molecular formula can be stereorandom populations or chirally enriched populations. All of

the chiral centers of all of the modified oligonucleotides are stereorandom in a stereorandom population. In a chirally enriched population, at least one particular chiral center is not stereorandom in the modified oligonucleotides of the population. In certain embodiments, the modified oligonucleotides of a chirally enriched population are enriched for P-D ribosyl sugar moieties, and all of the phosphorothioate internucleoside linkages are stereorandom. In certain embodiments, the modified oligonucltoides of a chirally enriched population are enriched for both p-D ribosyl sugar moieties and at least one, particular phosphorothioate intemucleoside linkage in a particular sterochemical configuration. F. Nucleobase Sequence

In certain embodiments, oligonucleotides (unmodified or modified oligonucleotides) are further described by their nucleobase sequence. In certain embodiments oligonucleotides have a nucleobase sequence that is complementary to a second oligonucleotide or an identified reference nucleic acid, such as a target nucleic acid. In certain such embodiments, a region of an oligonucleotide has a nucleobase sequence that is complementary to a second oligonucleotide or an identified reference nucleic acid, such as a target nucleic acid. In certain embodiments, the nucleobase sequence of a region or entire length of an oligonucleotide is at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least

95%, or 100% complementary to the second oligonucleotide or nucleic acid, such as a target nucleic acid. II. Certain Oligomeric Compounds In certain embodiments, the invention provides oligomeric compounds, which consist of an oligonucleotide (modified or unmodified) and optionally one or more conjugate groups and/or terminal

groups. Conjugate groups consist of one or more conjugate moiety and a conjugate linker which links the conjugate moiety to the oligonucleotide. Conjugate groups may be attached to either or both ends of an oligonucleotide and/or at any internal position. In certain embodiments, conjugate groups are attached to the 2-position of a nucleoside of a modified oligonucleotide. In certain embodiments, conjugate groups that are attached to either or both ends of an oligonucleotide are terminal groups. In certain such embodiments, conjugate groups or terminal groups are attached at the 3' and/or 5'-end of oligonucleotides. In certain such embodiments, conjugate groups (or terminal groups) are attached at the 3'-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 3'-end of oligonucleotides. In certain embodiments, conjugate groups (or terminal groups) are attached at the 5'-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 5'-end of oligonucleotides. Examples of terminal groups include but are not limited to conjugate groups, capping groups, phosphate moieties, protecting groups, modified or unmodified nucleosides, and two or more nucleosides that are independently modified or unmodified. A. Certain Conajugate Groups In certain embodiments, oligonucleotides are covalently attached to one or more conjugate groups. In certain embodiments, conjugate groups modify one or more properties of the attached oligonucleotide, including but not limited to pharmacodynamics, phannacokinetics, stability, binding, absorption, tissue distribution, cellular distribution, cellular uptake, charge and clearance. In certain embodiments, conjugate groups impart a new property on the attached oligonucleotide, e.g., fluorophores or reporter groups that enable detection of the oligonucleotide. Certain conjugate groups and conjugate moieties have been described previously, for example: cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med Chem. Lett., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N Y Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Left., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533 538), an aliphatic chain, e.g., do-decan-diol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49 54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-0-hexadecyl-rac-glycero-3 H-phosphonate (Manoharan et al., TetrahedronLett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides

& Nucleotides, 1995, 14, 969-973), or adamantane acetic acid a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J Pharmacol. Exp. Ther., 1996, 277, 923-937), a tocopherol group (Nishina et al., Molecular Therapy Nucleic Acids, 2015, 4, e220; and Nishina et al., Molecular Therapy, 2008, 16, 734-740), or a GalNAc cluster (e.g., W02014/179620). 1. Coniuage Moieties Conjugate moieties include, without limitation, intercalators, reporter molecules, polyamines,

polyamides, peptides, carbohydrates, vitamin moieties, polyethylene glycols, thioethers, polyethers, cholesterols, thiocholesterols, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins, fluorophores, and dyes. In certain embodiments, a conjugate moiety comprises an active drug substance, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fen-bufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, fingolimod, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indo-methicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. 2. Coniugage Linkers Conjugate moieties are attached to oligonucleotides through conjugate linkers. In certain oligomeric compounds, the conjugate linker is a single chemical bond (i.e., the conjugate moiety is attached directly to an oligonucleotide through a single bond). In certain embodiments, the conjugate linker comprises a chain structure, such as a hydrocarbyl chain, or an oligomer of repeating units such as ethylene glycol, nucleosides, or amino acid units. In certain embodiments, a conjugate linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino. In certain such embodiments, the conjugate linker comprises groups selected from alkyl, amino, oxo, amide and ether groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and amide groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and ether groups. In certain embodiments, the conjugate linker comprises at least one phosphorus moiety. In certain embodiments, the conjugate linker comprises at least one phosphate group. In certain embodiments, the conjugate linker includes at least one neutral linking group. In certain embodiments, conjugate linkers, including the conjugate linkers described above, are bifunctional linking moieties, e.g., those known in the art to be useful for attaching conjugate groups to parent compounds, such as the oligonucleotides provided herein. In general, a bifunctional linking moiety comprises at least two functional groups. One of the functional groups is selected to bind to a particular site on a parent compound and the other is selected to bind to a conjugate group. Examples of functional groups used in a bifunctional linking moiety include but are not limited to electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups. In certain embodiments, bifunctional linking moieties comprise one or more groups selected from amino, hydroxyl, carboxylic acid, thiol, alkyl, alkenyl, and alkynyl. Examples of conjugate linkers include but are not limited to pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and 6-aminohexanoic acid (AHEX or AHA). Other conjugate linkers include but are not limited to substituted or unsubstituted C1

Cio alkyl, substituted or unsubstituted C2 -C1 0 alkenyl or substituted or unsubstituted C2 -Cio alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl. In certain embodiments, conjugate linkers comprise 1-10 linker-nucleosides. In certain

embodiments, conjugate linkers comprise 2-5 linker-nucleosides. In certain embodiments, conjugate linkers comprise exactly 3 linker-nucleosides. In certain embodiments, conjugate linkers comprise the TCA motif In certain embodiments, such linker-nucleosides are modified nucleosides. In certain embodiments such linker-nucleosides comprise a modified sugar moiety. In certain embodiments, linker-nucleosides are unmodified. In certain embodiments, linker-nucleosides comprise an optionally protected heterocyclic base selected from a purine, substituted purine, pyrimidine or substituted pyrimidine. In certain embodiments, a cleavable moiety is a nucleoside selected from uracil, thymine, cytosine, 4-N-benzoylcytosine, 5 methylcytosine, 4-N-benzoyl-5-methylcytosine, adenine, 6-N-benzoyladenine, guanine and 2-N isobutyrylguanine. It is typically desirable for linker-nucleosides to be cleaved from the oligomeric compound after it reaches a target tissue. Accordingly, linker-nucleosides are typically linked to one another and to the remainder of the oligomeric compound through cleavable bonds. In certain embodimements, such cleavable bonds are phosphodiester bonds. Herein, linker-nucleosides are not considered to be part of the oligonucleotide. Accordingly, in embodiments in which an oligomeric compound comprises an oligonucleotide consisting of a specified number or range of linked nucleosides and/or a specified percent complementarity to a reference nucleic acid and the oligomeric compound also comprises a conjugate group comprising a conjugate linker comprising linker-nucleosides, those linker-nucleosides are not counted toward the length of the oligonucleotide and are not used in determining the percent complementarity of the oligonucleotide for the reference nucleic acid. For example, an oligomeric compound may comprise (1) a modified oligonucleotide consisting of 8-30 nucleosides and (2) a conjugate group comprising 1-10 linker-nucleosides that are contiguous with the nucleosides of the modified oligonucleotide. The total number of contiguous linked nucleosides in such an oligomeric compound is more than 30. Alternatively, an oligomeric compound may comprise a modified oligonucleotide consisting of 8-30 nucleosides and no conjugate group. The total number of contiguous linked nucleosides in such an oligomeric compound is no more than 30. Unless otherwise indicated conjugate linkers comprise no more than 10 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 5 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 3 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 2 linker nucleosides. In certain embodiments, conjugate linkers comprise no more than1 linker-nucleoside. In certain embodiments, it is desirable for a conjugate group to be cleaved from the oligonucleotide.

For example, in certain circumstances oligomeric compounds comprising a particular conjugate moiety are better taken up by a particular cell type, but once the oligomeric compound has been taken up, it is desirable

that the conjugate group be cleaved to release the unconjugated or parent oligonucleotide. Thus, certain conjugate linkers may comprise one or more cleavable moieties. In certain embodiments, a cleavable moiety is a cleavable bond. In certain embodiments, a cleavable moiety is a group of atoms comprising at least one cleavable bond. In certain embodiments, a cleavable moiety comprises a group of atoms having one, two, three, four, or more than four cleavable bonds. In certain embodiments, a cleavable moiety is selectively cleaved inside a cell or subeellular compartment, such as a lysosome. In certain embodiments, a cleavable moiety is selectively cleaved by endogenous enzymes, such as nucleases. In certain embodiments, a cleavable bond is selected from among: an amide, an ester, an ether, one or both esters of a phosphodiester, a phosphate ester, a carbamate, or a disulfide. In certain embodiments, a cleavable bond is one or both of the esters of a phosphodiester. In certain embodiments, a cleavable moiety comprises a phosphate or phosphodiester. In certain embodiments, the cleavable moiety is a phosphate linkage between an oligonucleotide and a conjugate moiety or conjugate group. In certain embodiments, a cleavable moiety comprises or consists of one or more linker-nucleosides. In certain such embodiments, the one or more linker-nucleosides are linked to one another and/or to the remainder of the oligomeric compound through cleavable bonds. In certain embodiments, such cleavable bonds are unmodified phosphodiester bonds. In certain embodiments, a cleavable moiety is 2'-deoxy nucleoside that is attached to either the 3' or5-terminal nucleoside of an oligonucleotide by a phosphate internucleoside linkage and covalently attached to the remainder of the conjugate linker or conjugate moiety by a phosphate or phosphorothioate linkage. In certain such embodiments, the cleavable moiety is 2' deoxyadenosine.

B. Certain Terminal Groups In certain embodiments, oligomeric compounds comprise one or more terminal groups. In certain such embodiments, oligomeric compounds comprise a stabilized 5'-phophate. Stabilized 5'-phosphates include, but are not limited to 5'-phosphanates, including, but not limited to 5'-vinylphosphonates. In certain embodiments, terminal groups comprise one or more abasic nucleosides and/or inverted nucleosides. In certain embodiments, terminal groups comprise one or more 2'-linked nucleosides. In certain such embodiments, the 2'-linked nucleoside is an abasic nucleoside. III. Oligomeric Duplexes In certain embodiments, oligomeric compounds described herein comprise an oligonucleotide, having a nucleobase sequence complementary to that of a target nucleic acid. In certain embodiments, an oligomeric compound is paired with a second oligomeric compound to form an oligomeric duplex. Such oligomeric duplexes comprise a first oligomeric compound having a region complementary to a target nucleic

acid and a second oligomeric compound having a region complementary to the first oligomeric compound. In certain embodiments, the first oligomeric compound of an oligomeric duplex comprises or consists of (1) a modified or unmodified oligonucleotide and optionally a conjugate group and (2) a second modified or unmodified oligonucleotide and optionally a conjugate group. Either or both oligomeric compounds of an oligomeric duplex may comprise a conjugate group. The oligonucleotides of each oligomeric compound of an oligomeric duplex may include non-complementary overhanging nucleosides. IV. Antisense Activity In certain embodiments, oligomeric compounds and oligomeric duplexes are capable of hybridizing to a target nucleic acid, resulting in at least one antisense activity; such oligomeric compounds and oligomeric duplexes are antisense compounds. In certain embodiments, antisense compounds have antisense activity when they reduce or inhibit the amount or activity of a target nucleic acid by 25% or more in the standard cell assay. In certain embodiments, antisense compounds selectively affect one or more target nucleic acid. Such antisense compounds comprise a nucleobase sequence that hybridizes to one or more target nucleic acid, resulting in one or more desired antisense activity and does not byridize to one or more non-target nucleic acid or does not hybridize to one or more non-target nucleic acid in such a way that results in significant undesired antisense activity. In certain antisense activities, hybridization of an antisense compound to a target nucleic acid results in recruitment of a protein that cleaves the target nucleic acid. For example, certain antisense compounds result in RNase H mediated cleavage of the target nucleic acid. RNase H is a cellular endonuclease that cleaves the RNA strand of an RNA:DNA duplex. The DNA in such an RNA:DNA duplex need not be unmodified DNA. In certain embodiments, described herein are antisense compounds that are sufficiently "DNA-like" to elicit RNase H activity. In certain embodiments, one or more non-DNA-like nucleoside in the gap of a gapmer is tolerated. In certain antisense activities, an antisense compound or a portion of an antisense compound is loaded into an RNA-induced silencing complex (RISC), ultimately resulting in cleavage of the target nucleic acid. For example, certain antisense compounds result in cleavage of the target nucleic acid by Argonaute.Antisense compounds that are loaded into RISC are RNAi compounds. RNAi compounds may be double-stranded (siRNA) or single-stranded (ssRNA). In certain embodiments, hybridization of an antisense compound to a target nucleic acid does not result in recruitment of a protein that cleaves that target nucleic acid. In certain embodiments, hybridization ofthe antisense compound to the target nucleic acid results in alteration of splicing of the target nucleic acid. In certain embodiments, hybridization of an antisense compound to a target nucleic acid results in inhibition of a binding interaction between the target nucleic acid and a protein or other nucleic acid. In certain embodiments, hybridization of an antisense compound to a target nucleic acid results in alteration of translation of the target nucleic acid. Antisense activities may be observed directly or indirectly. In certain embodiments, observation or detection of an antisense activity involves observation or detection of a change in an amount of a target nucleic acid or protein encoded by such target nucleic acid, a change in the ratio of splice variants of a nucleic acid or protein, and/or a phenotypic change in a cell or animal. V. Certain Tar2et Nucleic Acids In certain embodiments, oligomeric compounds comprise or consist of an oligonucleotide comprising a region that is complementary to a target nucleic acid. In certain embodiments, the target nucleic acid is an endogenous RNA molecule. In certain embodiments, the target nucleic acid encodes a protein. In certain such embodiments, the target nucleic acid is selected from: a mature mRNA and a pre-mRNA, including intronic, exonic and untranslated regions. In certain embodiments, the target RNA is a mature mRNA. In certain embodiments, the target nucleic acid is a pre-mRNA. In certain such embodiments, the target region is entirely within an intron. In certain embodiments, the target region spans an intron/exon junction. In certain embodiments, the target region is at least 50% within an intron. A. Complementarity/Mismatches to the Target Nucleic Acid It is possible to incroduce mismatch bases without eliminating activity. For example, Gautschi et al (J. Natl. Cancer Inst. 93:463-471, March 2001) demonstrated the ability of an oligonucleotide having 100% complementarity to the bcl-2 mRNA and having 3 mismatches to the bcl-xL mRNA to reduce the expression of both bcl-2 and bcl-xL in vitro and in vivo. Furthermore, this oligonucleotide demonstrated potent anti tumor activity in vivo. Maher and Dolnick (Nuc. Acid. Res. 16:3341-3358, 1988) tested a series of tandem 14 nucleobase oligonucleotides, and a 28 and 42 nucleobase oligonucleotides comprised of the sequence of two or three of the tandem oligonucleotides, respectively, for their ability to arrest translation of human DHFR in a rabbit reticulocyte assay. Each ofthe three 14 nucleobase oligonucleotides alone was able to inhibit translation, albeit at a more modest level than the 28 or 42 nucleobase oligonucleotides. In certain embodiments, oligomeric compounds comprise oligonucletoides that are complementary to the target nucleic acid over the entire length of the oligonucleotide. In certain embodiments, oligonucleotides are 99%,95%, 90%,85%, or 80% complementary to the target nucleic acid. In certain embodiments, oligonucleotides are at least 80% complementary to the target nucleic acid over the entire length of the oligonucleotide and comprise a region that is 100% or fully complementary to a target nucleic acid. In certain embodiments, the region of full complementarity is from 6 to 20, 10 to 18, or 18 to 20 nucleobases in length. In certain embodiments, oligonucleotides comprise one or more mismatched nucleobases relative to the target nucleic acid. In certain embodiments, antisense activity against the target is reduced by such mismatch, but activity against a non-target is reduced by a greater amount. Thus, in certain embodiments selectivity of the oligomeric compound comprising an oligonucleotide is improved. In certain embodiments, the mismatch is specifically positioned within an oligonucleotide having a gapmer motif. In certain embodiments, the mismatch is at position 1, 2, 3, 4, 5, 6, 7, or 8 from the 5'-end of the gap region. In certain embodiments, the mismatch is at position 9, 8, 7, 6, 5, 4, 3, 2, 1 from the 3'-end of the gap region. In certain embodiments, the mismatch is at position 1, 2, 3, or 4 from the 5'-end of the wing region. In certain embodiments, the mismatch is at position 4, 3, 2, or 1 from the 3'-end of the wing region. B. Tau In certain embodiments, oligomeric compounds comprise or consist of an oligonucleotide comprising a region that is complementary to a target nucleic acid, wherein the target nucleic acid is Tau. In certain embodiments, Tau nucleic acid has the sequence set forth in SEQ ID NO: 1 (GENBANK Accession No. NT_010783.14 truncated from nucleotides 2624000 to 2761000). In certain embodiments, contacting a cell with an oligomeric compound complementary to SEQ ID NO: 1 reduces the amount of Tau mRNA, and in certain embodiments reduces the amount of Tau protein. In certain embodiments, contacting a cell in an animal with an oligomeric compound complementary to SEQ ID NO: 1 ameliroates one or more symptoms of a neurodegenerative disease. In certain embodiments, the symptom is loss of memory, loss of motor function, or increase in the number and/or volume of neurofibrillary inclusions. In certain embodiments, contacting a cell in an animal with an oligonucleotide complementary to SEQ ID NO: 1 results in maintining or improving memory, maintaining or improving motor function, and/or maintenance or reduction in the number and/or volume of neurofibrillary inclusions. C. Certain Target Nucleic Acids in Certain Tissues In certain embodiments, oligomeric compounds comprise or consist of an oligonucleotide comprising a region that is complementary to a target nucleic acid, wherein the target nucleic acid is expressed in the central nervous system (CNS). VI.Certain Pharmaceutical Compositions In certain embodiments, described herein are pharmaceutical compositions comprising one or more oligomeric compounds or a salt thereof In certain embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable diluent or carrier. In certain embodiments, a pharmaceutical composition comprises a sterile saline solution and one or more oligomeric compound. In certain embodiments, a pharmaceutical composition consists of a sterile saline solution and one or more oligomeric compound. In certain embodiments, the sterile saline is pharmaceutical grade saline. In certain embodiments, a pharmaceutical composition comprises one or more oligomeric compound and sterile water. In certain embodiments, a pharmaceutical composition consists of one oligomeric compound and sterile water. In certain embodiments, the sterile water is pharmaceutical grade water. In certain embodiments, a pharmaceutical composition comprises one or more oligomeric compound and phosphate-buffered saline (PBS). In certain embodiments, a pharmaceutical composition consists of one or moreoligomeric compound and sterile PBS. In certain embodiments, the sterile PBS is pharmaceutical grade PBS. In certain embodiments, pharmaceutical compositions comprise one or more oligomeric compound and one or more excipients. In certain embodiments, excipients are selected from water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose and polyvinylpyrrolidone,

In certain embodiments, oligomeric compounds may be admixed with pharmaceutically acceptable active and/or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions depend on a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered. In certain embodiments, pharmaceutical compositions comprising an oligomeric compound encompass any pharmaceutically acceptable salts of the oligomeric compound, esters of the oligomeric compound, or salts of such esters. In certain embodiments, pharmaceutical compositions comprising oligomeric compounds comprising one or more oligonucleotide, upon administration to an animal, including a human, are capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of oligomeric compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts. In certain embodiments, prodrugs comprise one or more conjugate group attached to an oligonucleotide, wherein the conjugate group is cleaved by endogenous nucleases within the body. Lipid moieties have been used in nucleic acid therapies in a variety of methods. In certain such methods, the nucleic acid, such as an oligomeric compound, is introduced into preformed liposomes or lipoplexes made of mixtures of cationic lipids and neutral lipids. In certain methods, DNA complexes with mono- or poly-cationic lipids are formed without the presence of a neutral lipid. In certain embodiments, a lipid moiety is selected to increase distribution of a pharmaceutical agent to a particular cell or tissue. In certain embodiments, a lipid moiety is selected to increase distribution of a pharmaceutical agent to fat tissue. In certain embodiments, a lipid moiety is selected to increase distribution of a pharmaceutical agent to muscle tissue. In certain embodiments, pharmaceutical compositions comprise a delivery system. Examples of delivery systems include, but are not limited to, liposomes and emulsions. Certain delivery systems are useful for preparing certain pharmaceutical compositions including those comprising hydrophobic compounds. In certain embodiments, certain organic solvents such as dimethylsulfoxide are used. In certain embodiments, pharmaceutical compositions comprise one or more tissue-specific delivery molecules designed to deliver the one or more pharmaceutical agents of the present invention to specific tissues or cell types. For example, in certain embodiments, pharmaceutical compositions include liposomes coated with a tissue-specific antibody. In certain embodiments, pharmaceutical compositions comprise a co-solvent system. Certain of such co-solvent systems comprise, for example, benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. In certain embodiments, such co-solvent systems are used for hydrophobic compounds. A non-limiting example of such a co-solvent system is the VPD co-solvent system, which is a solution of absolute ethanol comprising 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 8OTMand 65% w/v polyethylene glycol 300. The proportions of such co-solvent systems may be varied considerably without significantly altering their solubility and toxicity characteristics. Furthermore, the identity of co-solvent components may be varied: for example, other surfactants may be used instead of Polysorbate 8OTM;the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose. In certain embodiments, pharmaceutical compositions are prepared for oral administration. In certain embodiments, pharmaceutical compositions are prepared for buccal administration. In certain embodiments, a pharmaceutical composition is prepared for administration by injection (e.g., intravenous, subcutaneous, intramuscular, intrathecal, intracerebroventricular, etc.). In certain of such embodiments, a pharmaceutical composition comprises a carrier and is formulated in aqueous solution, such as water or physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. In certain embodiments, other ingredients are included (e.g., ingredients that aid in solubility or serve as preservatives). In certain embodiments, injectable suspensions are prepared using appropriate liquid carriers, suspending agents and the like. Certain pharmaceutical compositions for injection are presented in unit dosage form, e.g., in ampoules or in multi-dose containers. Certain pharmaceutical compositions for injection are suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Certain solvents suitable for use in pharmaceutical compositions for injection include, but are not limited to, lipophilic solvents and fatty oils, such as sesame oil, synthetic fatty acid esters, such as ethyl oleate ortriglycerides, and liposomes. Aqueous injection suspensions may contain.

VII. Certain Compounds In certain embodiments, Compound No. 814907 is characterized as a 5-8-5 MOE gapmer, having a

sequence of (from 5' to 3') CCGTTTTCTTACCACCCT (incorporated herein as SEQ ID NO: 8), wherein each of nucleosides 1-5 and 14-18 are 2'-MOE nucleosides and each of nucleosides 6-13 are 2' deoxynucleosides, wherein the intemucleoside linkages between nucleoside 2 and nucleoside 3 and nucleoside 15 to nucleoside 16 are phosphodiester internucleoside linkages and the remainder of the internucleoside linkages are phosphorothioate intemucleoside linkages, and wherein each cytosine is a 5 methylcytosine. In certain embodiments, Compound No. 814907 is characterized by the following chemical notation: mCes mCeo Ges Tes Tes Tds Tds mCds Tds Tds Ads mCds mCds Aes mCeo mCes mCes Te; wherein, A = an adenine, mC = a 5-methylcytosine, G = a guanine, T = a thymine, e = a 2'-MOE nucleoside, d = a 2'-deoxynucleoside, s = a phosphorothioate intemucleoside linkage, and

o = a phosphodiester intemucleoside linkage.

In certain embodiments, Compound No. 814907 is characterized by the following chemical structure:

NH 2

HO NO ON 0N

O NH 2 0 HS-P=0 N O 0 O NH 2 O NO HS-P=O NHN O HO-P=O O

0 0o u O o O N HO-P0 ,N NH 9 O O HS-P=O NH 0 NH 2 N N NH 2 0 N O HS-P=O ON O) 0 0O NH2 0 HS-P=O HS-P=0 N O

N N 0 O HS-P=O NH NO NH 2 0 O H-P2O N HS-P O NN O

O N Or N N O OU o NH 2

O HS-O 0SHS-PH N ONH2 HS-O H S- O N HS-P-0 NH 0 I NN--O 00

0 0 NH 2 IHS-P=0 NH S-01 ~ 6 N N 0 0 00~ HS-P=0 HS-=

(SEQ ID NO: 8).

Strucutre 1. Compound No. 814907

VIII. Certain Benchmarks In certain embodiments, Compound No. 623782 (characterized hereinbelow in Example 1), first described in WO 2015/010135, is a benchmark. Compound No. 623782 was a top performer among the compounds described in WO 2015/010135 in terms of potency, efficacy, and tolerability. Compound No. 623782 is provided as a benchmark to demonstrate the superior efficacy and tolerability of Compound No. 814907 (characterized hereinbelow in Example 1) as compared to Compound No. 623782 in comparative studies described hereinbelow in Example 1 and Example 2.

As demonstrated in Example 1, Compound No. 814907 achieved an ED5 o of 25 g in Tau transgenic mice treated with 30 g, 100 pg, 500 pg, whereas Compound No. 623782 achieved an ED 5 oof 94 g in Tau transgenic mice treated with 10 pg, 30 pg, 100 pg, 300 pg, 700 pg. Thus, Compound No. 814907 is more efficacious than Compound No. 623782. As demonstrated in Example 2, administration of Compound No. 814907 to wild-type mice resulted in no Purkinje cell loss, whereas administration of Compound No. 623782 resulted in Purkinje cell loss in calbindin stained cerebellum sections in 3 of 11 animals. Therefore, Compound No. 814907 is more tolerable than Compound No. 623782.

Nonlimiting disclosure and incorporation by reference Each of the literature and patent publications listed herein is incorporated by reference in its entirety. While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds described herein and are not intended to limit the same. Each of the references, accession numbers, and the like recited in the present application is incorporated herein by reference in its entirety. Although the sequence listing accompanying this filing identifies each sequence as either "RNA" or "DNA" as required, in reality, those sequences may be modified with any combination of chemical modifications. One of skill in the art will readily appreciate that such designation as "RNA" or "DNA" to describe modified oligonucleotides is, in certain instances, arbitrary. For example, an oligonucleotide comprising a nucleoside comprising a 2'-OH sugar moiety and a thymine base could be described as a DNA having a modified sugar (2'-OH in place of'one 2'-H of DNA) or as an RNA having a modified base (thymine (methylated uracil) in place of a uracil of RNA). Accordingly, nucleic acid sequences provided herein, including, but not limited to those in the sequence listing, are intended to encompass nucleic acids containing any combination of natural or modified RNA and/or DNA, including, but not limited to such nucleic acids having modified nucleobases. By way of further example and without limitation, an oligomeric compound having the nucleobase sequence "ATCGATCG" encompasses any oligomeric compounds having such nucleobase sequence, whether modified or unmodified, including, but not limited to, such compounds comprising RNA bases, such as those having sequence "AUCGAUCG" and those having some DNA bases

and some RNA bases such as "AUCGATCG" and oligomeric compounds having other modified nucleobases, such as "ATmCGAUCG," wherein 'C indicates a cytosine base comprising a methyl group at the 5-position. Certain compounds described herein (e.g., modified oligonucleotides) have one or more asymmetric

center and thus give rise to enantiomers, diastereomers, and other stereoisomeric configurations that may be defined, in terms of absolute stereochemistry, as (R) or (S), as a or Q such as for sugar anomers, or as (D) or (L), such as for amino acids, etc. Compounds provided herein that are drawn or described as having certain stereoisomeric configurations include only the indicated compounds. Compounds provided herein that are drawn or described with undefined stereochemistry include all such possible isomers, including their stereorandom and optically pure forms, unless specified otherwise. Likewise, tautomeric forms of the compounds herein are also included unless otherwise indicated. Unless otherwise indicated, oligomeric compounds and modified oligonucleotides described herein are intended to include corresponding salt forms. The compounds described herein include variations in which one or more atoms are replaced with a non-radioactive isotope or radioactive isotope of the indicated element. For example, compounds herein that comprise hydrogen atoms encompass all possible deuterium substitutions for each of the 'H hydrogen atoms. Isotopic substitutions encompassed by the compounds herein include but are not limited to: 2Hor 3H in place 5 of H, 13C or 4C in place of "C, N in place of1 4 N, " or 180 in place of 160, and33S, 4 SS, or 36S in place of "S. In certain embodiments, non-radioactive isotopic substitutions may impart new properties on the oligomeric compound that are beneficial for use as a therapeutic or research tool. In certain embodiments, radioactive isotopic substitutions may make the compound suitable for research or diagnostic purposes such as imaging.

EXAMPLES

The following examples illustrate certain embodiments of the present disclosure and are not limiting.

Moreover, where specific embodiments are provided, the inventors have contemplated generic application of those specific embodiments. For example, disclosure of an oligonucleotide having a particular motif provides reasonable support for additional oligonucleotides having the same or similar motif And, for example, where a particular high-affinity modification appears at a particular position, other high-affinity modifications at the same position are considered suitable, unless otherwise indicated.

Example 1: Effects of modified oligonucleotides on human Tau mRNA in transgenic mice

The modified oligonucleotides shown in the table below are 100% complementary to human Tau pre mRNA (GENBANK Accession No. NT_010783.14, truncated from nucleotides 2624000 to 2761000, designated herein as SEQ ID NO: 1). The efficacies of the modified oligonucleotides were tested in human Tau transgenic mice (Duff et al., Neurobiology of Disease 7:87-98, 2000). Each mouse received a dose of a modified oligonucleotide listed in the table below, or PBS vehicle only, by ICV bolus injection. Each treatment group consisted of 2 to 4 mice. Several days after oligonucleotide administration, the mice were sacrificed and tissues were collected. RNA was extracted from the cortex and analyzed by RT-qPCR in order to detennine human Tau mRNA levels. Primer probe set RTS3104, with the following sequences, was used: forward primer 5'-AAGA TTGGGTCCCTGGACAAT-3', designated herein as SEQ ID NO: 5; reverse primer 5'-AGCTTGTGGGTTTCAATCTTTTTATT-3', designated hereinas SEQ ID NO: 6; probe 5' CACCCACGTCCCTGGCGGA-3', designated herein as SEQ ID NO: 7. Results are presented in the table below as the average percent inhibition of human Tau mRNA expression for each treatment group compared to the vehicle treated group. The half maximal effective dose (EDo) for each modified oligonucleotide was calculated using nonlinear regression analysis.

Table 1 Percent inhibition of human Tau mRNA levels in hTau mice

Compound Dose Human Tau mRNA SEQ ID No. (Ig) (% inhibition) NO.

10 10

30 17

m 623782 Ces mCeoGeOTecTesTdTds mCasTdaAdsmC 100 54 94 8 dsmCdsAeOmCeCCsmCesTe 300 79

700 90

30 48

814907 mCesmCeoGesTesTesTdsTasmCdsTdsTsAas 100 79 25 8 mCdsmCdSAesmCeOmCesmCeST,

500 88

Subscripts: "e" represents a 2'-MOE nucleoside; "d" represents a 2'-deoxynucleoside; "o" represents a phosphodiester internucleoside linkage; and "s" represents a phosphorothioate intemucleoside linkage. Superscript "m" preceding a "C" indicates that the cytosine is a 5-methylcytosine.

Example 2: Tolerability of modified oligonucleotides targeting human Tau

The tolerability of the modified oligonucleotides described in Example 1 was tested in wild type

mice. Each mouse received a 700 g injection of Compound No. 623782 or Compound No. 814907 at 700 g dose, or PBS vehicle alone. Eight weeks after the modified oligonucleotide administration, the mice were sacrificed, and tissues were collected. Histopathology was performed on sections of cerebellum using H&E, IBA1, GFAP, and calbindin stains, and no abnormality relative to vehicle treated mice was observed for Compound No. 814907 treated mice. In a comparable experiment, Purkinje cell loss was observed in calbindin stained cerebellum sections in 3 of11 animals treated with Compound No. 623782.

Example 3: Effect of Compound No. 814907 in cynomolgous monkey following repeat-dose intrathecal injection for 13-weeks

Cynomolgus monkeys were treated with Compund No. 814907 to determine the local and systemic tolerability and phannacokinetics at three dose levels, following repeat intrathecal lumbar bolus injections for

13 weeks. Compound No. 814907 shares complete sequence homology to the monkey Tau mRNA and has demonstrated pharmacologic activity in this species.

Treatment Cynomolgus monkeys ranging in age from 2-4 years were treated vehicle control (n=12) or Compound No. 814907 intrathecally (between L3-L4). Animals were dosed on Days 1, 14, 28, 56, and 84. Treatment groups received 4 mg (n=6),12 mg (n=6), or 35 mg (n=14) of Compound No. 814907. Animals were sacrificed either on day 98 or 155 (4 animals from the vehicle control group and 4 animals from the 35 mg treatment group).

Tolerability Assessment of tolerability was based on clinical observations, body weights, food consumption, physical and neurological examinations, neurobehavioral observations (modified Irwin test (Irwin, 1968)), electrocardiogram (ECG) and blood pressure evaluation, ophthalmology, coagulation, hematology, clinical chemistry (blood and cerebral spinal fluid [CSF]), cell count (CSF only), blood gas evaluation, urine analysis, and anatomic pathology evaluations. Complete necropsies were performed with a recording of any macroscopic abnormality. Organ weights were taken and microscopic examinations were conducted. Blood was collected for complement analysis. In addition, blood, CSF, and tissues (at necropsy) were collected for toxicokinetic evaluations. Intrathecal administration of 4 mg, 12 mg, or 35 mg Compound No. 814907 for 13 weeks (bi-weekly for the first month, then monthly thereafter) showed good local and systemic tolerability in male and female cynomolgus monkeys at all tested dosing regimens.

Activity Brain and spinal cord tissue was analyzed for inhibition of cynomolgous monkey Tau mRNA. Brain

slices and spinal cord samples were collected and flash frozen in liquid nitrogen and stored frozen (-60°C to 90°C). At time of sampling, 2 mm biopsy punches were used to collect samples for RNA analysis from the frozen brain slices. Punches were taken from multiple spinal cord and brain regions. Total RNA from brain and spinal cord samples from cynomolgous monkeys treated with control or Compound No. 814907 were purified using a Life Technologies mini-RNA purification kit and subjected to real time PCR analysis. Monkey primer probe set rhMATPT LTS1278 (forward sequence AGGACAGAGTGCAGTCGAAGATC, designated herein as SEQ ID NO: 9; reverse sequence AGGTCAGCTTGTGGGTTTCAA, designated herein as SEQ ID NO: 10; probe sequence CACCCATGTCCCTGGCGGAGG, designated herein as SEQ ID NO: 11) was used to measure RNA levels.

Tau RNA was then normalized to the housekeeping gene Cyclophilin A. All qPCR reactions were run in triplicate. Data is reported relative to mRNA levels in animals treated with artificial CSF. As shown in the Table below, there was a significant and dose responsive decrease in Tau RNA levels in spinal cord and multiple CNS regions after treatment with Compound No. 814907, as compared to control treated monkeys. Table 2

Percent inhibition of cynomolgous Tau mRNA levels in cynomolgus monkeys

Treatment BrainRegions

Thoracic Lumbar Cortical Frontal Temporal Hippocampus Pons Spinal Spinal Spinal Cortex Cortex Cord Cord Cord

aCSF 0 0 0 0 0 0 0 4mg 51 63 31 41 29 18 29 814907 12mg 60 60 47 60 56 52 43 814907 35mg 58 71 60 77 70 74 66 814907

Example 4: Phase I-Ila HumanClinical Trial with Compound No. 814907 Multiple ascending doses of Compound No. 814907 are evaluated in a randomized, double-blind, placebo-controlled study to evalulate the safety, tolerability, pharmokinetics and pharmacodynamics in patients with mild Alzheimer's Disease (AD) aged 50-74 years of age. Eligible patients will have CSF AD biomarker evidence of amyloid and tau pathology in addition to meeting clinical criteria for AD. Four ascending dose level cohorts of mild AD patients will be enrolled sequentially and randomized 3:1 to receive

Compound No. 814907 or placebo. Each patient will receive 4 doses of Compound No.814907 or placebo with a 28 day interval between doses. Patients will receive 4 intrathecal (IT) bolus doses of Compound No 814907 at 4 week intervals during the 3 month treatment period (on Days 1, 29, 57, 85). Each dose of

Compound No. 814907 or placebo will be administered as a single 20 mL IT bolus injection. Administration will be via lumbar puncture using a small gauge needle inserted into the L3/L4 space.

Safety and Tolerability Evaluations Patient safety will be monitored closely during the study. Safety and tolerability evaluations include: physical examination and standard neurological assessment (including fundi), vital signs (HR, BP, orthostatic changes, weight), ECG, AEs and concomitant medications, Columbia Suicide Severity Rating Scale (C

SSRS), CSF safety labs (cell counts, protein, glucose), plasma laboratory tests (clinical chemistry, hematology), urinalysis, and neuroimaging assessments will be conducted using a 3T MRI scanner. Clinical and volumetric neuroimaging measures will be used to monitor for unexpected deterioration.

PharmacokineticEvaluations A CSF sample will be collected pre-dose on each administration day (Days 1, 29, 57, 85) and during the post-treatment period for PK analyses.

Exploratory Evaluations Biochemical, neuroimaging, functioning/ability to perform activities of daily living, cognitive, and

neuropsychiatric parameters will be evaluated. Biochemical parameters include potential CSF and blood/plasma biomarkers, including target engagement, neuronal and synaptic injury markers, innate immune activation markers, complement components, and lipid-related biomarkers. Neuroimaging paramers include structural MRI (hippocampal, whole brain, and ventricular volumes), Arterial Spin Labelling (ASL), diffusion tensor imaging (DTI), and FDG-PET (Cohorts C and D only). Functioning/ability to perform activities of daily living parameters include evaluation by Functional Activities Questionnaire (FAQ). Cognitive parameters include evaluation by Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and Mini-mental state examination (MMSE) Neuropsychiatric parameters include evaluation by Neuropsychiatric Inventory - Questionnaire (NPI-Q).

BIOL0285WOSEQ_ST25 12 Nov 2020

SEQUENCE LISTING

<110> Ionis Pharmaceuticals, Inc. <120> COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION

<130> BIOL0285WO

<150> 62/450,469 <151> 2017‐01‐25 2020267230

<150> 62/401,723 <151> 2016‐09‐29

<160> 11

<170> PatentIn version 3.5

<210> 1 <211> 137001 <212> DNA <213> Homo sapiens

<400> 1 caaaaattag ccgggagtgg tggcatatgc ctgtaatccc agtagctggg aggctgagac 60

aggaaaatcg cttgaacccg ggaaacaggt tgcagtgagc cgagatcgtg ccactgcact 120

ccagcctggg caacagagcg agactccatc tcaaaaaaac aaaacaaaca cacacaaaaa 180

accaaaaata aataaataaa atgatcactt ctgaatactg atctaactag gggttgcagg 240

gtgggctgat atagggagaa actggagagc aaggagatca ctaaggtccc tacatgtcca 300

gaaccaagat agaggtcttg aactaggatg gtggcagtta gaacaacaac aacaaaaagt 360

caattccagg ctgagtgcag tggctcatgc ttgtaatccc aacgctttgg gaggctgagg 420

tgggagttag aaagcagcct gggcaacact gcaagacctc ctctctaaaa aaaaaaaaaa 480

aaaaaagtta gccaggtgtg gtggtgccca cctgtagtcc cagcaactca gaaggctgag 540

gtgggaagat tgcttgagcc ccaggagttc aagcttgccg tgagctacga ttgtgccact 600

gcactccagc ctgagcaaga ccttgtctcc aaaaaaaggt caattccact gacttttcta 660

aggtgtacac catcaagggg cagctccatc tccaggccat tggctcatga gacattctgt 720

agtcagaagg ctagggcaga ttgctttgag caagccccca tggtggttct cactcctact 780

tctttgggta tatgcccctc tgtttaaaaa taaagttaat atgcatttaa aaaaaaaaag 840

Page 1

BIOL0285WOSEQ_ST25 12 Nov 2020

gagaaaaagg tcagttccag aaactgtgtg aataaagcat tttacttgct ttttctatta 900

atctataaca tatgttgatt ttttaaaaag aatataagag ctatgcaaat tggagcttca 960

agacaacttc ccatctccct aggaggagat ggctgcccta aaccccccta catagaaatc 1020

atcccactgc ttgggcttaa acttgatgtt ggggaaatga aaaatccaag ctaaggccga 1080

agcctggggc ctgggcgacc agcagaatga ggaccactgg tcagtttcag gctgaggtgc 1140 2020267230

gtcttccagg ggacaatctc tagctggccc ttaaacattc agacttcaag ctctatttac 1200

agcataaagg tgtttcaaaa gacgtgatac aaataactgc aaatgctctg cgatgtgtta 1260

agcactgttt gaaattcgtc taatttaaga tttttttttc tgacgtaacg gttagattca 1320

cgtttctttt tttttaagta cagttctact gtattgtaac tgagttagct tgctttaagc 1380

cgatttgtta aggaaaggat tcaccttggt cagtaacaaa aaaggtggga aaaaagcaag 1440

gagaaaggaa gcagcctggg ggaaagagac cttagccagg ggggcggttt cgggactacg 1500

aagggtcggg gcggacggac tcgagggccg gccacgtgga aggccgctca ggacttctgt 1560

aggagaggac accgccccag gctgactgaa agtaaagggc agcggaccca gcggcggagc 1620

cactggcctt gccccgaccc cgcatggccc gaaggaggac acccaccccc acaacgacac 1680

aaagactcca actacaggag gtggagaaag cgcgtgcgcc acggaacgcg cgtgcgcgct 1740

gcggtcagcg ccgcggcctg aggcgtagcg ggagggggac cgcgaaaggg cagcgccgag 1800

aggaacgagc cgggagacgc cggacggccg agcggcaggg cgctcgcgcg cgcccactag 1860

tggccggagg agaaggctcc cgcggaggcc gcgctgcccg ccccctcccc tggggaggct 1920

cgcgttcccg ctgctcgcgc ctgcgccgcc cgccggcctc aggaacgcgc cctcttcgcc 1980

ggcgcgcgcc ctcgcagtca ccgccaccca ccagctccgg caccaacagc agcgccgctg 2040

ccaccgccca ccttctgccg ccgccaccac agccaccttc tcctcctccg ctgtcctctc 2100

ccgtcctcgc ctctgtcgac tatcaggtaa gcgccgcggc tccgaaatct gcctcgccgt 2160

ccgcctctgt gcacccctgc gccgccgccc ctcgccctcc ctctccgcag actggggctt 2220

cgtgcgccgg gcatcggtcg gggccaccgc agggcccctc cctgcctccc ctgctcgggg 2280

gctggggcca gggcggcctg gaaagggacc tgagcaaggg atgcacgcac gcgtgagtgc 2340

gcgcgtgtgt gtgtgctgga gggtcttcac caccagattc gcgcagaccc caggtggagg 2400

Page 2

BIOL0285WOSEQ_ST25 12 Nov 2020

ctgtgccggc agggtggggc gcggcggcgg tgacttgggg gagggggctg cccttcactc 2460

tcgactgcag ccttttgccg caatgggcgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt 2520

gtgtgtgtgt gtggaggggt ccgataacga cccccgaaac cgaatctgaa atccgctgtc 2580

cctgccgctg ttcgccatca gctctaagaa agacgtggat cgggttctag aaaagatgac 2640

tccctgcacg cccctccctg cacctcccga gcagtgattc cgacagggcc ttcactgccc 2700 2020267230

ctgattttag gcgggggccg gccccctccc cttttcctcc ttcagaaacc cgtaggggac 2760

atttgggggc tgggagaaat cgaggagatg gggaggggtc cacgcgctgt cactttagtt 2820

gcccttcccc ctgcgcacgc ctggcacaga gacgcgagca gcgccgtgcc tgagaacagt 2880

gcgcggatcc cactgtgcac gctcgcaaag gcagggttca cctggcctgg cgatgtggac 2940

ggactcggcg gccgctggtc cccgttcgcg ggcacgcaca gccgcagcca cgcacggatg 3000

ggcgcggggc tgcaggtgca tctcggggcg gatttctttc tcagcgctcg gagcgcaggg 3060

cgcccggcgt gtgcgctccc tgccggaggc gcggggctgg cgcgcagggc tcgcccctca 3120

ctgcggcagt gggtgtggac cctggtgggc gaggaagggg gaggataggc tgtgcctcct 3180

cccactcccg cccccagccc cccttttttt ccccctcgga acgcgaggtg ccatcttttt 3240

tcggcgtgtc acgtctttac ggtgccatgc caaaccgggt ggccgggctt cataggacag 3300

ggcggggcct ggcattaaag ggagggggac aatcagcgct gaaatcttgg cgttttgctg 3360

ctgcgggcgt gagcactggg ggcgttcgcc cagcaccttc ttcgggggct ctttgctttg 3420

tctgtagagg ttacgtgatc tgcgctccca gccctggttt ctggctttta ttctgagggt 3480

gttcagtcaa cctcccccct acgcccatgc gcctctcttt cctttttcgc tcctcatttc 3540

cgagcccatt gttggatctc gaggcttgct gggttcgatg aactcgagtc aaccccccga 3600

cccccggcac gcatggaacg ggcgtgaccg cgcgcagcct cgtctcggag tctgccggcg 3660

ccgggaagct tctgaaggga tgggattcga gtctccgtgc gcgctgcggg cggcggcaga 3720

gggatctcgc ccctccctac accccaagtg tcctgagggc cacgccacac caggttgccc 3780

agcgagggac gctggctacc catccgggga tgggtgggga gccctggcgg ggcctctccg 3840

gctttacgcc ctgttgcttc gcctggccgg agaatgtgag gaaggggcat aaggttactg 3900

gtgcttcggc cacacccatc tttctgagcc cactggactg ggcgcagagg ggggattgcc 3960

Page 3

BIOL0285WOSEQ_ST25 12 Nov 2020

atggaaacca caggtgtccg gagaggggat cttggggctg gcctcacccc ttccctgcgg 4020

agattgggga ccctggggta gggggagccg cgcccagtcg gcctcctgga ggacacggga 4080

ggaagccccg aacccccgcg cctgaggctg tttctgattg gcccctggag gccgcagaca 4140

cgcagatagg cggccctggg tgtattttta ttaatattat gtccgtactg attaatatta 4200

tttatcttaa ataaatttca cccgtgtcca agttcaccgc gcccccaaaa ccgagtctgg 4260 2020267230

ggcggcaggg ggaactcctg gccaacgaat ccatgcctcg ccctcctgtg atgaacctgg 4320

tacgcacggt tttctggtta attctatcgc tgaaaactgg tgcggggggc gcacttctga 4380

gacggaagag catctaggag ctgaatcctc cacgcgggtc gcccaggttg atctgaattt 4440

ctggggaatg gcttggctgc ccgcccggga ccaggccgac cctccttgac ggtggcgtag 4500

agggctggag cctgggtact gcgaggctcc tcgcatggct gggcccgccg cgaggggttg 4560

cagagcggct cagggatcga ttcaagcatc gtctctcctc cctcgccccc agacagagct 4620

gggcgcgggg ttccccttcc agatggagcg agggtctcgg ggtggccccg gaaaagggga 4680

gcccgcggcc acggctacgt attgccatct cgcgagcaga gatgtcacct cctgcctttg 4740

gaggaaaggg agcccggtgg ggatgagcgc atttagccca atgctgggaa caaagcgcac 4800

tccgcgcttc tgcgatttcg ctccattttg aaatgtgttg gcgctttggt ggggccgctg 4860

cggtgggcaa ggccgggggc gctgttaatg gaggaacctc agggggacgg tccttcgtag 4920

gaaactctat cctggctctg cgcgcgcttt aaggaaatgg cttccctcca ggacctcgag 4980

ggatgcagct tttgcgcgga tgacggtggg gtgctgaacc agccggtgcg cctctggaaa 5040

tgtctgggca cggatcctgg ggccatcgac gactcctccc cattcccagc aggcgggagc 5100

tcttacattc cgagcgagtg acccctctca ccctctggcg ctcacacacc tgtaactcca 5160

aacctccgtc tcagaatggt ccaggctgga agggatgatg ggggctccga cagcgactgc 5220

ctagctcacc cctctgcgtg ctcaggctcc aggctcagca ggaccaattt gagttctatc 5280

tgatccccct cggcccctta actgacccat cctacaggag acagggaaat gtctttccta 5340

ccgcggttga ttctggggtg tcattttgtg ttttgtgatg gctgcttata tttactgtat 5400

aagcattgta tttactgtat aagcattgta ttataattac tgtataagct gcttatattt 5460

actgtataag catctccaaa tcctccctct acgtaaacaa attaatggat aaacagataa 5520

Page 4

BIOL0285WOSEQ_ST25 12 Nov 2020

gtgtatcccc tgcccccacc cctgctacgc aggtccggag tgactcttga agctcataca 5580

ttccttggcc aagtttgctt ctctaacaga tgtttatata gcaataacct ggcttggctc 5640

ttgggttcac ctttggacga tttggggaag gggcttgttg gctttgctgg gttttggatg 5700

agtgacagtc catgactgtt cctgctggaa gggcgtgact tttaagtggt ttctaatatc 5760

aggcattgct cctccgacag gaacaaaaga aatggatact gcccataaat tgttagaaaa 5820 2020267230

cttagaatcg ctttgattga ggaaaggtta gatttattcc ggttggaaaa agtggccttt 5880

ctattaaacg tgccctttga ccctcatgcc cttggaggtc ggtgccagcc tggagatggg 5940

ataagattgt ggttttcctt ctgccttttt aacatctgtt gttacagtcc atttgttgaa 6000

aatttaaaga aactgtttta ttccactttc cctcagcatt tatgtgtgtg gtttcagtag 6060

ctctgtggct atatgtacga acacgtgtta tttttccaat tggacatgtg ataattttcc 6120

aactggacct tgccttctat tgatgtattt atttagcatc ttccttactc cctccttgaa 6180

aaagaatcac tcaaaaacaa ataaaaacag ccgtaggggc ctaatacagt gctagacata 6240

caagaggtat tcggtccata ccaaatggat tttatccatg aaggataaat ggggaaatac 6300

agtgggaagc aggtgggaaa ctgcgtttga ctctgctctt tcctccacca ccactttcct 6360

catcaccgtg ttcagagacc cccaaagccc cctcacactc ccagaaacac ccccctggcc 6420

actcctaact tgccatgccc aggagttagg tgcttccact agtgacatgg agctggcgtt 6480

tggggggcac ctcagcaggt gacgggaaga gaagacccca gcctcaccag ctgggctgca 6540

gcagggagag gagtcctcat gttccagcag ggactctcag ctgttttcct gtaaaaccat 6600

ggttctcaac tgggggccac tgagatgtct agagagatgt ttttgttttc acaactcggg 6660

gagggtgcta ctgacatctt gtgggtagag gccaggaatg ctgttaaaca tcctacaagg 6720

aaggcacagg acagtctcct acatcaaaat atgacccagt cccaatgtca ccactgctgg 6780

ggttgacact ggcactgcta tcttaattac attcattgag tgtcttttag gaggccctat 6840

tctaagtgct tgctaagatt atctcattta atcctcacaa cacttccgct atgtagcagg 6900

tgctgttatt atctccgtga tggggaaact gaagcacaga gagggttagt aacttgctaa 6960

aggtcacaga gccagtgggt ggtggagctg gttgcctgac actagttccc tcccctctca 7020

gccacatgtg ggtttacttg gccattgtgg actagtctgg gaacccagat atgatctata 7080

Page 5

BIOL0285WOSEQ_ST25 12 Nov 2020

acattgaccc agtagaatat tgattccaaa accactgtct cacaaatgaa tttttacaag 7140

agtctgtaat cggagcatga cccagaataa ggttagggag atgtggagtt aaagctctca 7200

atttcttatc tggccccgac acagagagca aggcatttca ctctacattg gtgctctgtt 7260

tataaaacaa agagcaaata tctcttccta aggtccttaa acctcttccc ccaatccagg 7320

gtttctggac tgctctgcca tatgacgggg cagctggttt gattgaccca gggaaggctg 7380 2020267230

gaaatcaaga ctgggggatc aagacgtaga ttcagtgtgg ccaaggtcaa gtctctgagg 7440

tttagggaca tcagatcccc agcttaggtt ctgtacctcg gcaaggtgaa agcgttggcg 7500

cccactgatg aggcctgctc tgagattgtg ggtgtgggtt gagttgggtg ggcataggca 7560

agtcctcttg taagaatctt ttggcaaaga tgggcctggg aggcttttct cacttcctgg 7620

ggcccaggct ttgcaataag tattccatta tactgtggta ccttggggct acctgagaat 7680

cctctgtctc gcccctgttg ccttgccaaa gagtttgctg tccaagaatt cctttcctgt 7740

ctccaggtgc catgctcctg ccacctctgc caggttccct gcctgcccag atggctccca 7800

actgagtgtg aggaggaatt tgagacaggt tttgagcttt ctgggttctc cagttaggaa 7860

actttctgta agcatgcaga tagaatgggc ttcagcaaaa tacaaactcg aacaacttcc 7920

atgtatagtc ccttaatttt ctttgctttt ttcatatttc atcaggctcc atgctgagcc 7980

caatcaggga cccgatagaa atccaaacac catgtcagcg agtccccaag aaatgcattt 8040

tgtgccaagg ctattcaagg aaggtttggg agcagctcaa gggcagacac tgttaccctc 8100

ccccaggtcc ccagtgcagg gcagtgttct gcatgtggag gcagtttggc ctaatggtta 8160

aggaggtagg ctctgatcgg gcctcctggg cacaaatccc agctccctgc tcactgtgag 8220

acctaagcca tattgtttag ctgcttggag agttttttgt catccacaac ttggagtatg 8280

atggtacctg tctcacgggt tgccatgggg ttcacacaag ctaacccggt actcactagg 8340

gccaagcaca tagtaactgc tcagtaaatg gcatcatcgg cggtgtcctg tggatgagtg 8400

cttgtgattg gctgaatgac cagaggggtc taaagatcct ggtgatggaa tcagttgtac 8460

agataaattg ttacactgag tagggatcaa gataggaaaa gtcggcaact acccagctcc 8520

cctgcaccaa actgggcaga agtggatcct ctgaaaattg cacacaccca tgtttaaatg 8580

tacacacaga actcttgcca caggcaagcg gagatttgtc atctgctgtc cctgcctcat 8640

Page 6

BIOL0285WOSEQ_ST25 12 Nov 2020

cttcttcctg aaatccactc catgccagga ataaactgca tgctctccac cagcccaaac 8700

tgacctgcct tcccgccagc catcccgggc agggtgacct ggcttagtac atcgggttca 8760

gagatctttc cagtttactc gttgaataaa aagtgagggc tgatcgagaa agtaatggca 8820

gtcagggaag gcgaaggagg taaagaagag attttacaaa tgaagtaatt caacagagtg 8880

ctgacattgg taaactggca aacagatttc agggtggttg gttgagagta gagtagaaaa 8940 2020267230

ggattaaata aagcaaactt gtggtgtact gaatcttagg aattccatgt atccaataag 9000

tatagtcatt tatgaattaa taaattcggc ctaagaagcc ttcttatcgc ttaaatcaag 9060

actaagtaac aatatatcag ttttaaaaag tcattatatc agaaaatcat ttaaatgata 9120

cacatagatt tccaagattt tactttaacc gaaactatat aaatgtgaat ttgttcaccc 9180

atcttttgac acagggctca ggtcttctct tggtgtctgg atcagccagt tgaaatttct 9240

tgtctgtttt gcctatgcca cattaataat gcactgtctg ggtcctccga tttcagtttg 9300

gattttgggt ttacattgtg gagtcatctg aatgcagaat ccttcaggga ttttactttt 9360

tttttttttt ttcatggtct ttaccatccc atttgatagt aaatattact cacctttatg 9420

aagtctttcc aaaacattca actaaatttt cttaaaatca ttgaatgatt tgaagagctt 9480

attcctcagc acttttactc catcagcttg caccttattt tttaatcttt ttttgagacg 9540

gagtctcgct ctatcgccca ggcttaagtg caatggcgcg atcttggctc actgcgacct 9600

ccacctcctg ggttcaagca attccgcctc agcctccgcc gtagccggga ctacaggtac 9660

acaccataat gctcggctga tttttgtatt tttgtaggga tggggtatcg ccatgttggc 9720

caggctggtc ccgaacttct gacccaagtg atccacccac ctcggcctcc caaagtgctg 9780

ggattacagg tgtgagccac cgcgcccggc cagcttgcac cttatttagg atatgtgatt 9840

attatagcaa gtctggtgta catacaagat tttgaatggg cacagatgac ctttagtaag 9900

tgcttggctg tgataagagg cagtcctgac tgcagatcag gctgtgtgga ccccagcctt 9960

gcatgtttac agaccttcat gtcttattct tacagggtat cagaagaaca cctactgggg 10020

aaacttataa attagtaaaa ggtgggcatt ctccccgccc atcttctgtc tgtctgccag 10080

gactagcaca gcactttgaa gtcattcaca tagaatccca acttaagagg gtaaaatcct 10140

cctcaacaga ctgaaaataa gtttaaattc cctttgctat attaactccc ctgaggaaag 10200

Page 7

BIOL0285WOSEQ_ST25 12 Nov 2020

agtcttagat caatgtccaa cactaaaaac agttttaaat cagcaagtga gaattaaatc 10260

tgaagcaatt gataataatg tttcattcat tcctctcctt tggccccgtc caccctactg 10320

ctaaatccag gcatcaaaga gaagagggac ataattatct ctagtcccag ctgctggttt 10380

tccttccagc ctatggccca gttttctgtt ttactgagaa ggctggtgat gttatcttgg 10440

gatctaagtc tgcagtttca ccacaaaaag tccagggatg cactttcatg cttgtgtcct 10500 2020267230

cctccctggg atagcaagga tattagaaga cccctggctc tgtaattgct tgtcatgtgc 10560

tctacagacg ccacagaatg ccaagaacga agtgctggga aggacaaatt catggaaccg 10620

tgggacggtg ctcctccccc agcgtaaagg acagctcctc ctcctgaatt ggagccagcg 10680

ttctaaatca tgtgtcaaca gagttgtcct ggatcggatc cagttctgcc attgatttgc 10740

aggtcatttc agtggtacct gtttccagtt gttcttaatt gaacagtggc accaaactat 10800

tgtcttgcct catccccctc ccatggcctg tcccccaaaa agagacttct tgggtaatta 10860

atcagggcaa catcaggcag tctgggcgcg gtggctcacg cctgtaatcc cagcactttg 10920

ggaggccgag gcgggcagat catgaggtta ggagattgag accatcctgg ctttgtgaaa 10980

ccccgtctct actaaaaata caaaaaatta gccgggcgtg gtggcgggcg cctgtagtcc 11040

cagctactcg agaggctgag gcaggggaat ggcgtgaacc cgggaggtgg aggttgcagt 11100

gagccgagat cgcaccactg cactctagcc tgggcgacag agctagactt cttctcaaaa 11160

aaaaaaaaaa aaaggaatct ctttggtttt atatattttt ttttatatat ataatatata 11220

ttaaaatata atatatatat ttatataata taatatataa atatattata tattatatat 11280

ttttatatat tatatattat atatattata tattatatat ttatatattt atatattata 11340

tatatttata tattatatat ttatatatat tatatattta tatataatat atattatata 11400

ttatatatta tatattatat attatatatt tatatatatt atatattata tatattatat 11460

attatatatt tatatattat atatttatat atattatata ttatatatta tatatttata 11520

tattatatat ttatatatta tatatattta tatatattat atattatata ttatatatgt 11580

atatattata tatgttatat attatatata tttatatata taatatattg tatatattat 11640

atatctaata tattatatat attatatata ttatatatta taatatatat tatatattat 11700

atatattttt atatatataa tatgtataat atataatata tataaaaaca tatataatat 11760

Page 8

BIOL0285WOSEQ_ST25 12 Nov 2020

atattatata ttatatatat attatatata ttatatatat taaatatatt ttatatatat 11820

tatatatatt atatatatta aatatatttt atatatatta tatatatata cacatatata 11880

tatataaatg aggccaggct cggtggctca cacttgtaat cccagcactg tgggaggatc 11940

acttgaagcc aggagtctga gactagcctg ggcaacaaaa caagatcctg tctctacaaa 12000

aggaaactgt aaaaattagc tgggcatgat ggcatgtgtc tgtagcccta gctacttggg 12060 2020267230

aggccgaagc aggaggatcg cttgagccca ggagttcaag gctacagtga gctatgattg 12120

tcccatagca ctccagcctg ggtaacacag caaggccctg tctctaaact tttttttttt 12180

aattctattt atatttacat gtatttaaat gtgaatattc actacctatt tgttgcatgc 12240

ctgcattttt tatactgggc ttgccaaaaa cccgaacagc tttctacttt gacaatgtat 12300

cagaatttaa atcagcaata tgttaataag ccaagcaaag gttatatatg caaataaaac 12360

tgttgtctat aacctcctgt tacactgggg cacagcaaaa gtcatggtgt agtcgcatgt 12420

gaacctgtcc ctttcatagc tgctcattgc caggaaacat caggaatagc catttggaag 12480

agtcatcagc cctcccacca tccgttttct gtcttgtctt ttccctatga gcaggggaaa 12540

ttccacgctg gccccaatcc ccagtgcagc ggctcagcct ctgcctctgc tgctggtccc 12600

catgaggcca gcttagaaac ggaggatttt gcagaacatc cctaaatccg cttgaataat 12660

gaagtgatca ttcataaact cacctgaacc ttattaaaac ctatttaata tttttcctgg 12720

ataatcctat agggataact tgcctcctgg gcttctctcc accgggttca gttcttcctt 12780

tagtggtgaa gttcctccct tcttagcatc tcaactgtgc ctgagaaaag gccagtggcg 12840

gctgcactct gttccctgtg gagtgttaat aaagactgaa taaattgaaa taaatccctt 12900

tcaatgtcat taagtgctat aaataatcat gaaccaatgt tcgatggctg atgagaaatg 12960

caagaaaaaa tttttaatca gtaggattca taagttgaca atctgggcca agttaaaaaa 13020

aataaaaata aaaagacttt taaaaagatc ttatcgtttg ttaccagtaa gactgaattc 13080

cagaagcaag ctactccctc atttgtgggc ccctgttatc actggctgct tagggttgcc 13140

aagccctgaa ttcatttgtc aactaagaga tttttggcca agattaagat ttcccatgcc 13200

tccatatttc catctgagaa atggagatta tactgtcttc cccctcagaa tggatgataa 13260

tgtggtctct cttctgttcg catagtcata gaactgaaat aaaacaactt aagagaattc 13320

Page 9

BIOL0285WOSEQ_ST25 12 Nov 2020

ctttgagctt ctcagaagtg ctgcagggct gggggatgcc tcccaggagc cgcagtcagg 13380

tgctgatctg aagtctttgg tgggctgact ttagcctgac ctgaaatagt atagctgctg 13440

ccacctggct cccttagcgt cagtcagacg gtgcagctgg ttcctagggg tgagggctga 13500

gccagcaggg tccgtgccca ggagggatgc atgggtggcc acagcccagc ctgcactgat 13560

cttgtctgtc cccttctttg gaaggaagga gccccaaacc agggtgcaag acagtgggtg 13620 2020267230

ggggtgcctt gagcatgacc tcaagtgatt tccagcccct gccagtgctg acttctctgg 13680

ggaagggctg ggacttcctt ctgggctcaa gtcacgaccc ttggatggaa tttcctggga 13740

gcttttctgt tttttctgga gttttcagtt ttttcctaac cagacaggga cttggtacag 13800

aatctcatat tctaattatg cctaggagca gcctctcccc accactcaca gtgtttagca 13860

tgtgacagga atcgattaag gcatgagtga ttaaattaaa gccaggcatt gacttggatg 13920

gtgtaatatt ctgacatctg tttggtgtca aaggcacggg gcaggcgcgt taattgaact 13980

gcttgcacct ggcatttgaa ttgagccaga gcggggctaa agtcagtttg ccttcaccct 14040

gtaaatggag ggtttctccg gagcgtggat ggtgggaggt atttcagggt gtatgcataa 14100

cccccaccct gacaatggcc catctcttct ccagcgtggc caggtttgag tgccagtcct 14160

gggtgtccag tggccccata gccttgcgtt ttagtaaaat gctgccccca ttaccacctg 14220

gtctgtgcac ttcggtcact ggaatttgcc atcttccagt cccgaatgtg gcaagccatg 14280

gagccttaag ctcttctccc tccacatcct ggaacagacc cgccagtttc ttccaggcat 14340

tgcctcagtt tgcccctctg tttccagtca cactctcacc agcgataaaa tgattttaga 14400

ccttatcatc tcaccctcgg atccttatgg aaacaataat gagttgttcc ctgtttcaat 14460

tccaaaattc atatccaatc cgttttgcat gccattgcca aattcctccc agagcaaccc 14520

cgtcacctgc cctggccctc tccaagtgtg gtcctgccat gggcatcgcc tgctaagcca 14580

agctggcctc gagctgcctg cccgggtccc cacaccttgg ctcacctccc tgcccagtcc 14640

cgcctcctgc cagcctgccc tgtggctcct tcatagatgc cgtgctcttt ctgccccttg 14700

ctcacccatg gcagccttgc ccctctctcc ctgccccacc ccctatttaa attgacctga 14760

ccttcctcag tgtccatctt ccccgaagct ttccccagcc ttggcactca aggtccagag 14820

gctacgcgtt tcctctcacc tgtggcagcg ccgtgctccc cagtgcctca cagtttcctt 14880

Page 10

BIOL0285WOSEQ_ST25 12 Nov 2020

cttgcccccg cttcctgtgt aggactcatc tgcccacagg ttgcacgtcc tgtgagggca 14940

aggactgtgt cttatgtgac tttccttctc cagtcacaga gctgggcaca tagatagctc 15000

aaaaccctct ttattaacac agttggatgt tgagaaatca aacaggccaa tgtcaaatga 15060

gctctcctta tttaaatcaa gtcagttctc cacctcctag cactcagttc cagtactcta 15120

tatacatgga aataataaaa aacacatttc ctttgaaaca ttctataatc gttcctttgc 15180 2020267230

cctacttcag accaacttaa cgcactcccc attggtccaa atgagttttg ctatacgaag 15240

atgctgataa taatagcagc agtggattat tctgctaaaa ccattgcctc gttaatcctc 15300

agtcccgagg tggggattat tatcctcatt ttgcagagaa gcaaactgag actcagagat 15360

ttcacagctg gggagggagc cagctcatcc ctctgtccag gcccaagctc tctcccgctt 15420

gccttcctgc ctctgcaacc tcagagcatc ccccatctgg ttctactgcc tgtgctagtc 15480

gtgcaggagc caaaagacac gtctttagtg ctaaggactg gagaagccat gccctccagc 15540

ctctgtgaat gggtcatatg taacatgagc ctggagaaat tatttgaaac caaaggcaag 15600

cctctaaacc aggctgctgc ttcatggcgc cggtgacggc agaaccaaat ttagtgctgt 15660

gggcaggtcc acacttatca aatagagaag ctcatttttc ttccggctca catcaagcat 15720

gaaaaatgtt cacacatacc ccccacacac acatgctttc cggaggggtc catgtggcta 15780

gaggctggaa gatgtggatg agaggagcct ggcaggtaag cccagggaag atgacattca 15840

gcttcccaga cagcatctac agggagaaat ttaattaaaa gtggggcggt ttccctgagc 15900

aaggcagaca aagtcagccc tctactgtta agaaaaaggg tcacagtgag aggggaggtg 15960

aggagactga gtctgtattt tctagtctgt tgggctacac tacctgatcc cccttcctca 16020

aaaatccact ttactttccc catgtctaca ccaatgtggt tcacactctg ggaccaggaa 16080

aagggggagt gatggggaac agagaaggga ggagctcaca cagctgaggc tggggttatg 16140

catatcgaat tacttagaat ttgcaacctc acagggtact ttcatggcgt tgaaatacac 16200

ttcccacagc caccctccct ctaactaaaa gcaagagtca tttctcagtt ctggtcttgc 16260

ctcccacgtt ctcctccaca tttaagaaaa tccaccagct acaaagtgaa gataccatat 16320

gtgatatccc accctagttt ctgttttatc agggtttgga gcaggtggag caggcagagg 16380

gatcatttca gcctataaat tgtattaagg gtgagtactg agtcattctt caagaaaagt 16440

Page 11

BIOL0285WOSEQ_ST25 12 Nov 2020

tttagaagca tccaaaactg aagggtggag ccacctggag acagtatcat cagtcctggc 16500

cccgagcatg gcctgcatag gcccccatgg atcccagcgg gagctgcaga gtgcgggcac 16560

cttggcacac agccctgagt gcaaaattag gagctgggca gagggcatct ctctgtcgcc 16620

attgggcagc ccagggcaca ctggtcatag ccttagacca cgaacaccct gtgcccgggg 16680

gacagatgca accagtgtgc cctgggctgc ccaatggcaa cagagagatc gacacctgga 16740 2020267230

ccccatgtca cggggactcc actactaagg ctcctaagac tgccaccttc cagtgggata 16800

agccctgcct cctactgggc ccacaatgtg cagagaacac ttgggactac ctggctttct 16860

ggatacacaa atattgatcc aatctggact aattagaagg tcagtcccaa taacaaatcg 16920

aagtcagctg ggcgtgatgg ctcactccta taatcccagc actttgggag gctgaggtgg 16980

gcagatcatt tgaagccaga agttcaagac cagcctgggc aacatagcaa aaccctgtct 17040

ctactaaaaa tacaaataat taggctgggt gtggtggctc atgcctgtaa tcccaacagt 17100

ttgggaggct gaggcaggtg gtcacctgag gtcaggagtt tgagaccagc ctggccaaca 17160

gggtgaaacc ccgtgtctac taaaaacata aaaattagcc aagcatgatg gcatgtgcct 17220

ataatcctgg ctactaggga ggctgagaca ggagagaatc gcttgaatcc aggaggtggt 17280

tgcagtgagc tgagatggtg ccactgcact ccagcctggt tgacagagca agactctgtc 17340

tcaaaaaaaa aaaaaaaaaa aaaaaaagcc atgcctggtg gagcactacg tgtaatctca 17400

gctatttggg aggctgaggc acgagaatca cttgaacctg ggaggcagtg gttgcagtga 17460

gctgagatcg cgccactgca ctccagcctg ggcgacagag tgagtgagac tccatttcaa 17520

aaaaataata aatctgagtc actttaatat tgttatttgg atgtcaacct ctaggtgttt 17580

gagacaggag agtgatatgg gggcactgga aacacacagg cacggggtgt cctcacactt 17640

gggtagccca cacgatgtga tttcagggtg ctgggaggtc cccccactcc ccaaattact 17700

aacaagtgga tagtacttta cagtttatat gatctcattt gattcttaac atgagcctgt 17760

gagtgaaaaa ttccttcccc tcttctacag attaggacgt tgagattcag ggaggttcag 17820

agggattcag ggaagtcaag tggcacctgg agtcccgtgg ctaatttgag gccggtaggg 17880

gattcgaacc caggatttgt gcttcttatg cctgggcttc tgctccctgg ggcatggtct 17940

tccccctagc tttcccattc actgctttag cctaggggtc ctacccttta ttaaactgcc 18000

Page 12

BIOL0285WOSEQ_ST25 12 Nov 2020

agtgcctcac tgcttttctc ccccaaagac aaaaaaaaag tgtttttgct tttgttttgt 18060

ttttcatggg cagagacctg gaatttcagc ttgagaattt gtgccatatg ataaataaat 18120

caacagatgg ctttttcctt aaaaaaaaaa aaaaaaaaaa ctaagatgta tttgcagtga 18180

ggcataattt gtaccaaaaa gtgctcacca cactgtagtc atgggggcag gaggcagccg 18240

cgggtgaagg gagaaatctt ggagtccagg cagccccctt ctgggctgaa ctggggagct 18300 2020267230

gggggtgctg ccagccctgc caggttctcc taggaggcgg cagctcatat ggctgtggga 18360

ggaggcagag ggagcctcat atgcacccac atttccaggg atctagaaga cagaaggagg 18420

aaaaccacca tcatgttaaa gcagacagtt aggtaacaca tcctgtaata caagttattt 18480

tttccacatc taaaggctaa aaatagttgt tagaatttaa agataattgg taaatgagtt 18540

tctatccttc tagtttcaca tcaaatggaa tcatgctgcc ttcacatcac tagtgcccgt 18600

tatttgtgtt taatttccac aatgttgtct aattccactc tttgggcttc cccagggatc 18660

cagcctccct cactcgccca tcgcagggag atgctttatt catctttgtg tcttctgtgc 18720

cgggcatagc gcatggcaca gaataagcac tcagtaattg attcacgagt gaataaatgg 18780

atgagtgggt gagttcaata ttgactacaa aaaccctaag gccacactgg tgagtggctg 18840

cgcctgtagt cccagctgct ggggaatctg aggcaggagg atctcttgag cccaggagtt 18900

tgaaactagc ctgggcgata tagcgagaac ctgtctcaaa tgacaaaaac agggccaggt 18960

gcagtggctc acgcctggaa tcccagcact ttaggaggcc aagatgggag gatcacttga 19020

ggccaggagt ccgagaccag cctgggcaac atagggagac cctgtctcta caaaaaattt 19080

tttaaaaatt agctgggcat ggcggtgtgc gcttgtagtc ccagctactc aggaggctga 19140

ggcaggagga tcacttgagc ccaggaaatt gaggctgcag cgagccatga tggcaccact 19200

gcactgcagc ctgggcgtca gaacgagacc tgctctcaaa aaaacaaaca aacaacaaaa 19260

aaaaaggctt tcttaaagag acttgagaac agaaagggga acagatacat aacttatata 19320

tttatttgtt catctttcca ccttcctgga gggtggaggg gaacaggtct gtatttggag 19380

ttttgaatgc taaaagtggg aatacatgta ctgtttgcca tgatctgttc aaaagttaag 19440

ccaaatgcct tagattctcc tgaaaactgg aatgccactg taaactataa gccccacttc 19500

aaagataaaa gatcttgatg aacagggctg ggtctgtgga ctgggcctct ccccaccaca 19560

Page 13

BIOL0285WOSEQ_ST25 12 Nov 2020

caaggaaggg tggtgccagt tgaaggaaaa tcacttaaat ccttgctgtc tcctaataag 19620

gtgtggtccc aggtagggct gtcagaatta gcaaattaaa acacagggca tctgtgaaaa 19680

ttagaatttc agataacaac aaataattgg cataggctgc ataatgtccc tcaaagatat 19740

caggtcctaa tctccagaac ctgtaaatgt gatcttattt ggaaaagggg tctttgtaga 19800

tgtggttaaa ttaaggattt tgagatgggg ggattatcct gtattatcta ggtaggtcct 19860 2020267230

aaatgcagtc acactcatcc ttgtaagagg aaggaagaga gagatggaaa acacagaaga 19920

gaagacaatg tggtgatgga ggcagagatt ggagtgaggt ggccacaagc caaggactgc 19980

tggcagctac cagcagccag aaaagtccag gaaccaattc tctcttggag ctccagaggg 20040

agtgtggccc tgctgacacc ttagcttcaa cctagtgatc ctgattttgg actttggcct 20100

tcagaagtgt gagggaatga atatctgttg ttttaagcca ccaagtttat ggtcatttcc 20160

tacagcagcc acaggaatca aaaacagtaa gtatgtccca tgcaatgttt gtgacacaca 20220

ccaaaaatat tacttgttgt tcacctgaaa ttcaaattta actgggtctc ctgtatttta 20280

tttggccaac ctagttccca ggcccaaaga aagaggcttt tgaaatttgc aagaaagctg 20340

gttggagctg tcagaaagtg gactttgtaa acacagtacc accgaaccaa tttgaactgt 20400

actacctcta gacaaaagag agggcagtca gacagttgtt cgtgatttct tctttcaaca 20460

gtcatttgag cacttactac aaaacagaag ctatgtgtaa gggtggaggc gttagctgtt 20520

aatcaggacc tccaggctaa gtttctgtat tagtccgttt tcacgctgct gataaagaca 20580

tacccgagac tggggaattt acaaaagaaa gaggtttaat tggacttaca gttccaagtg 20640

gctggggaag cctcacaatc atggcagaag gcaaggagga gcaagccaca tcttacatgg 20700

atggcagcag acagacaggg agagagagct tgtgcagggg aactcctctt tttaaaacca 20760

tcagatctcg ttagacttat tcactatcaa gagaacagca cagaaaagac ctgcccccat 20820

gattcagtta cttcccacca gatccctccc acaacatgtg ggaattcaag atgagatttg 20880

ttaccatatc agttaccaac ccttccagat aaatcacgtg aaatatcgcc attaacagag 20940

tgagctcagg tggttcttca gtgcatttct gatacctgaa ccttccctgg gaatttcaca 21000

gaccatcagg ctctccaccc tttgatagca ggatagcagg gcccaggttc tgcaggagga 21060

gatgttacca caggcctgaa agggagggag gggcagatgc tacaggaaga tgctggctct 21120

Page 14

BIOL0285WOSEQ_ST25 12 Nov 2020

ggattcgctg gaggagcttt caagggaagt agatacacac tgtctccatc atttcatgtc 21180

catcacactc taaaatgctt tggacaagaa gcaaatgtta aagacaaatg tggcccattt 21240

tcctgtacaa agagggctgc tcccatgcca ggctattggc actggtgggc atgaggcttc 21300

tctgctgccc tggccggggg gttctctcac tcaccattgg ctctctgaca cctggagaga 21360

ccaccaccct tgggctttca tgatgctcac agaatccaca ctgttggagc tttaaggagc 21420 2020267230

ctggatcaac tggaacaggc agggagtact aggacagccc agcattgccc caaaatatcc 21480

aggcctgata aaagagaaaa acaggtagct cacaggaaaa ggataaaaaa aggaggaggg 21540

atttaacatg aaaaggtgct tgatctccct cataataaaa agactgctga ttccatccag 21600

gcaagtgaca gaaaaaaaaa atttaattta aaaagactgc tgataaaacc acagcgagac 21660

actgctgctc agggatctga gggtgtgggc agccaggctg ccacgcatca tgggtcggag 21720

aggaagacca cacccctgga gcagagggcg gctgatctgt cagatgccct ttgacagcac 21780

ctcagcttcc aagaattaac cctttctatg tgagcagagg catccatggg gggacacact 21840

ggtgaatcat ctgttatgta gaagtctgga aaacatcagg atggaactgg tgaaataagt 21900

gtggcctctg acggaatgga gcggtccgtc tgcactgctg cgggtgcccc tcagatcctg 21960

tgggtcagtg agaaaagcag tgaggaacaa ggcaggtact gtgtactgtc ctctgcgtgc 22020

aaggaaggcc agcgcatgca acagagtcca cacagacata gcctaactct ggaaggaaga 22080

atgagaatgc agtttcagtg gtggcctctg gtggggagaa actgggtgaa gggagatgtc 22140

atttccattt ctctactatt aattttgtat taccatgctt aaatgttact ttttaccttt 22200

tttttttttt ttgagacagg gtctctctct gttgcccagg caggagtgca gtggtacaat 22260

catggttcac tgcagcctga acctcccagg ctcaagcaat cctcccacct cagcctcctg 22320

agtagctggg actataggca cgcataccac cgtgcccagc tatttttttt aatcaagatg 22380

gagtttttct atgttgccca ggctggtctc aagctcctgg actcaagcaa tcctcctgcc 22440

tcagcctccc aaagggctga gattaaaacg tgagtcaccc tgcccagcca attgcttttt 22500

aaaaaagatt aaatgcatgt atacgctcag gcatcagcac acttggaaag gatgaaaata 22560

tccggaagaa gggttctttt aaaaggctcc tcaagtgatg ctggcaggca tgacgaatgt 22620

ccctggtcac aaaagctctg atctggccta accctgtcat gttagagact ggagtgcgtg 22680

Page 15

BIOL0285WOSEQ_ST25 12 Nov 2020

tgtgtgcgcg caaagtgtgg ggggatgggg gtgagtgtgt gtggtgtgta agcatgagtg 22740

tgtatgtgtg tggtgtgggg gtgtgtgctg tgtgagcgtg tgtgagtctg tgtgtgtagt 22800

gtgtgtgtga agtatgtggt gtgtatgtgt gacgtgaggt gtgtgtggtg tgtgagttgt 22860

gtatggtgtg tgcatgagca tgtgtgtggg catgtgatgt gtgtgtggtg tgtaagcatg 22920

tgtgagtgtg tatgtttgag catgtgtggt gtgttgtgat atgtgtgtgg tgtgtgagca 22980 2020267230

tgtgtgtgtg atgtgtctgt gtgtggtgtg tgtgagcatg tgtgttgtgt gtgtggtgca 23040

tgtgtgtggc gtgtgagcgt gtgtgtgcat tgtgtctgtg agcatgtgtg agtgtgtgtg 23100

tgttcagcat atataaggca tgtaactgaa cacagcactt tagagggctc tcctggagtc 23160

agagggggtg ggtaggagga gaagggaggt gggctagtgt gctgaagtat ctactccttg 23220

tcatagtctg tgacaaccca gactagccca tgagccaccc tgttccctgc atttccaatg 23280

agacctcggt ggacatgttc cctgaggtga ggctgactga tgtcatttga cgatcttgat 23340

gccaaatcct tttatatcaa aaacaaccag aacactctct tttctcttag tgctttcacc 23400

cagatgacca catttcatcc tcccagccac tctgggccag gtggcactgc tggtttgaaa 23460

gggaggtctc ccctggagta acttccgtgg gcggattcac accctgccca cagtcctgtc 23520

ccagtcagcc caccatggtg gtctccggtt cctccagaat tcccgctttt cagctcatcc 23580

ccacattccc ggagggactg agagcgcagc cccagggccc tgctctttgg gggccgtctc 23640

tacacccaga gaagcagcaa ggcattccta ggtttctctt tcagatgcag aacttcagtg 23700

ttcagagatg ttcccactgg tcctgagagg gctcagttca gctttaatga ctgcgctgtt 23760

gcgtgtgctc tgcagagggc gggtggccca gcgtggctga ctgcagtttt cctgacgtgg 23820

agcccgagcc tgccccgctg tttattaatt aaggatcact ctgcttgcag aaccctgaac 23880

tccccagaac tgtgaggtgg gagaaccccg agaggccacc tggccccact tcccacctgc 23940

tgcccaaacc ccctctctgc cttcctgaca gtcaccccaa ctcccagtga tccccatcaa 24000

ccatctgaca aggggactga gagggaagag aaaggagggg cccaaagagg aaggtaaaac 24060

tgtcgggaac agcccccaaa tgtgtgacag ccttcagtgg agttgcccac tttccctttt 24120

ctcctccctg caggacctcc cttctcccca gtcctcccca acttctgagg ttacattgag 24180

aaaagtctgc agagaggtgc cagcatcaca aggtgttaag gaccacgagt ttggcatttt 24240

Page 16

BIOL0285WOSEQ_ST25 12 Nov 2020

aacagatgcc agagccactt gagaaatgtg gtaactaagc ccagagaggt acagttaacc 24300

tccccagagt cacacagcag gttcatggca aagctggact agcacaggtg tccttcccct 24360

gcagatcccc ttctgtgccc cacatcacct ccctccagtg tctgggccac ctggagatgg 24420

gccctcagac tcacccggcc agaggtgcca tctcatggga gaggtctggc caggaagcat 24480

cgatatttga gatcccaaga aatgaagact tggcctgtca gatgacagac ttcggtcatg 24540 2020267230

ggaacacgtg atctgtttta cacatgcgtc ccctcagcag cagctttcca gaacattccc 24600

actttcttct gtagtgagaa gaactctttc cctgcagcct cctgcccaac tcctccttca 24660

gtgtctttgc ttcagtgtct ttgataaacc attctgcttt gcagagtgcg agctctgcct 24720

tgcagggttc gcatctgcct gtgctgagta accaacgcta aggtcgagtg gtcggtcacc 24780

tctcataaga gctagggttg tctcatgctg atgactagga cttgccctca aggagaaaaa 24840

taaatcaaaa caaaagcaaa aacagcaaac atgcatctct taaagaaggc tctgagtcca 24900

ggtaaatttc cttccactga agcagccagg ctgaattcga attatctttg cccctgctta 24960

aaaactaatg caaattttcc tagagaatat ccactaattc ctggaggggg catgggcatt 25020

cctgatgccc atgagaggac catttgctct tccctcagta tgctaaataa cagaagcgac 25080

atttgttgct ggaaagtatc agtgaagtta ataaggtttt tcttgcccag ggtgagggaa 25140

cagttcccaa tgacaaatgc tgtatgggaa ggggctgtag aactgccagc ccctttggtc 25200

catccgtaaa gtgaactctg tggatcctgg aggattccag cgtctttttt tttttttctt 25260

tttttttaag acagagcctt gctgtcaccc aggctggagt gcagtggcac gatctcagtt 25320

cactgcaacc tccgcctccc gggttcaagc gattctcatg tctcggcctc ccgagcagca 25380

agactacagg tgcgcaccac catgcccgac taatttttgt attattagta gagacggggg 25440

tttcactctg ttggccaggc tggtctcaaa ctcctgacct caggtgatcc acccgcctca 25500

gcctcccaaa gtgctgggat tacaggcatg agccaccatg cccagccagc atctttcatt 25560

tttctgtctg ctttggccct ttcctctctc actgtcttcc ttttccattt ccaaagtcag 25620

tccatctcac tattagcaca aaaactgcta gagcgcttgt cattggtcat ctctccctgc 25680

acctggctgg tctgttcttg gccactgaag cgtttccccc agctgttgct ttaatcattt 25740

tattgttatt atgccttact taagaaatgg atatgagatg catttacctg tctcttcctg 25800

Page 17

BIOL0285WOSEQ_ST25 12 Nov 2020

ccactctgca gagccagtaa gatgtggtgg aaagggccca ggctttggag gagggctggc 25860

tggggttgga tcttggctgc cccctactag ctgtgtgacc ttgggtaagt agctggacct 25920

ctctgagcct ggttcggaat catagcacct ctctttcagg gctgctgtaa ggaatagcag 25980

tggtgtgtat aaagcagagc gcacagccag caactggccc ctagccacac tgctgagcac 26040

ctactgtgat aagctgccat tgtggtgtgt gaagcaaagg ggaaacatgc ctgctgtagt 26100 2020267230

gagcttcctg tagggcaggt tgtagaacca gaggtgggtt ccaaggttac aaagggactc 26160

ttagtgtatt agtctgttct cacattacta taaagaccta cctgagactg gatcatttat 26220

aaagaaaaga ggtttaattg gctcacattg gctgggtgcg gtggctcacg cctgtaatcc 26280

cagcattttg ggaggccaag gccggcggat cacttgaggt caggaatttg agaccagcct 26340

ggccaacatg gtgaaaccct gtctcttcta aaataaaata caaaaattag ctggccatgg 26400

tggtgtgcgc ctggaatccc agctactcag gaggctgagg tggaagaatt gcttgagccc 26460

gggaggtgga ggttgcagtg agccaagatc gccccactgc actctagcct gggcagcaga 26520

ctgagactct gtctcaataa aaaaaaaaaa aaagaaaaga aaaagaattg caagaaataa 26580

attattgttt atgagctata tggtctgtgg taccttgttg tgggactggg agtcttggcg 26640

tctccctgac cctgcctgtt gctgcagcac cgctcagccc tgcctgctcc ctacctgcct 26700

cccctcggcc tctcctgcct ccaccgggcc cctggtgcct cctctagaga cagtcctcct 26760

gggaccgatt gtgttctcac ttacacgagg catccaggac tacagataac cagaggaagg 26820

ggcgcccccc ccgcctgccc tcctccctgg catcctcacg ctgcagaggt cagagcctca 26880

tcccagcccc ttacctgccc ctactctgtg gagaaccgtg gtcagttcgc caggccggat 26940

ccacgaacgg ccttgtggaa gatggtgagc tcacacccag agctggctcc gatgaccctg 27000

tctcctttac atgtttctac cttcccctcc ctaccttccc ccactgctgg gcgcagagtg 27060

gaggcagatg aggtttaaag ctcagaaggg cttaaacggg ttggggcgca gtggctcatg 27120

cctgtaatcc cggcactttg ggaggccaag gcagaggatc acttgagccc aggagttcga 27180

gaccaacctg agcaacatag tgagaccgcg tctctacaaa aaataaaata aataaaatta 27240

gctttgcagg gtggcatgca cctgcagtcc ctgctactca gaaggctgag gtgggaggat 27300

cgcttgtgcc caggagtttg aggctgcagt gagctatgct ggcaccacag cactccagcc 27360

Page 18

BIOL0285WOSEQ_ST25 12 Nov 2020

tgagtaacag aatgagatcc tgtctcaaaa caaacaaaca aacaaacaaa agaaggctta 27420

aagggggctc caggtgggct tggcagcaca aagctatgaa gttctatctt agacacaagt 27480

tctgttactg ggcctttgca ggctggcctg ggtacctggc tgccatagac agggaacctt 27540

ccagatgagc tgcaggcgtg gagcacagga gccagggtgc tcttcctggg ctctgtccac 27600

aggcagaacg tacacagtct ttgtacacgt ccggcggctc tggtgcctat ttttgtttgt 27660 2020267230

gtttttcttt tgtttggggg gatggatttg gtttcccccg agccctctgt cctcctgtca 27720

cctggctggt gctcggcaat gttgaccagc tgcctggctg gagttggcag tggctaaggc 27780

tgtgacagct aacatgttcc tgagtcctct catttcttca ccataatgcc ctgttgagtt 27840

tgcagatact gtctctgttt ttatctcccg gggaaactga ggctcagagt ggctaggcca 27900

ccttcccatg gtccctcagc tcatgagggc cacacagggc attgcggtgg ccttctcctc 27960

agccttgacc ctccggcccc agcattgctg cctcaagggg tctcctctgc tgagccgtgc 28020

accttctgcc tggcagctcc aactctgtgg ctgtgttcag tggctcagca ctgccccttg 28080

accctccctg gccttctgcg gatgccagac tggagcactc tgacaaggtc tggggtggtt 28140

gtatgggtcc tgtgacctct atacacctcc cagtgcctgg gaatcctgca gatacaccct 28200

ccttagccgt ccctaaccat agaggacatt tctgaggtcc ccgagagagt ggggcacccc 28260

tgcaggatcc aactgctggg cccaggaagg atagcagcag catgaggggt tccattagcc 28320

acaaactcac ggcatggaac cttcacccac ctcgcccctc atctgctgtt tagcacctgg 28380

cacgccgtgt atacttactg attattacat tttaatggca aattatagtg gcaaacgtat 28440

gcatctttgc acaattgttg tacagcatga tgaacaagtc attaatagta aagaataaat 28500

gtgaaagtga gaaaaatctg actgccaaag tttttactcc ttccttccct ccccagactt 28560

ttaaatgaaa gtttagggat aatcccttag ttgtcctgct agtaggactt gcaattaaaa 28620

gaattgggcc aagaacactt ctacgcttct ccttttaggt ttgggtgtaa attcggggta 28680

tttctcactg atgaaagcct ggtgcagggc agaccgtggg aagctttcat ttccggaatg 28740

gaccatcaac atcccttgga gaagaattct cttctccaga cccagacctg gtgtcctggc 28800

acccattggg caagtgggtc ctagaagaca aacctggtca gagcctggag gctgcttagc 28860

attccccacg cacattagca gctcggagag ctcaggaagc cgcagcccct ccttgcctca 28920

Page 19

BIOL0285WOSEQ_ST25 12 Nov 2020

ccagcctgga tcaggacagc atcccctgga agacacacag ggcctggcct ctgattaccc 28980

agcctggagg gaaagctcaa tcgagcatca tgtcacccgg tgcccccatg cagggtggca 29040

ctggtgagac ccccaagcca atgataccac ctcacaggag tgcaggccca ttgtggccag 29100

atcatcttga cttttcaaga taaatcagaa atcgtatttc catgagatat ccctatttgc 29160

aagtgatggt gactaaatta gaagtttttg aatattgtaa catgttcgta ggctgtttgt 29220 2020267230

ctggtttaaa ctctatctgg aggaattcaa gctagacttc aggaataact tcttgaggca 29280

aggattttga gaccttaggg aaagaaggac gtcttggggg tattctgact gttgtcctcc 29340

tggaagggaa gaacagagaa ctagaagact gcccttagcg aagttcaaag cacctaagcc 29400

cgggaccctc agcaagtgtt cttgagtcac agattctccc tgaggcgcct ctttctggct 29460

ccatagaatg gctgattctg taactcggtg agtttgcttt ttttttttcc tccatcaccc 29520

aggctggagt gcagtgaagc tggagtgccg tggagcgatc actgcaacct ctgtctccca 29580

ggttcaagca attctccttc ctcagcctcc caagtagctg ggattacaag catgcagcac 29640

cacacctggc taatttttgt gtttttaata gagacggccc gaagtgctag gattacaggc 29700

atgagccacc gcggccagcc ataactctgt gactcttgtt acaaaggcct tatattttgc 29760

tctttgaggg tggttttggt ttgatgcctg ttggttgcca tcttttaact agggatgttt 29820

tatcaaaatg cccagccaaa gtgtccaaac aaattatacc ttaaagtttg aaaatgtctg 29880

gcacttctaa ttcaatgcct gttgtgccag gcactgggct gctgaggaac tgagtcccgt 29940

ccctgcaggc tagctagaga acacacacac acacacacac acacacacac acagagtggt 30000

cttacaagtc agttttatat tctacctata tgcaataaag gtattattat gttgaggtgc 30060

cttgatataa aaatttttct taaaggagag gatgcctaaa acaggcatta cctgaaacct 30120

cctctctcca gcattggttg tcttctgtca tgactcaggg ttttcactga gaatgggatg 30180

gaaatgtggt ctaaagatag ggccaatgtt gggactggat cccctctggg aagtcagacc 30240

aggctagggc aggtccttga agccatcagg aaaagcctct ggagccagaa acaaaacaaa 30300

aaaaaaatgg tgttaactaa actcagtctc aaatcctgaa taggactcaa gtcaagcaaa 30360

ataattaaag gagttagcaa agggcaagtc agagagaccg agcaacacca atgtcttccg 30420

ggagccctgt ggcgagtgac agagcctgga ctctggagta gaactcatct tgtgtcttct 30480

Page 20

BIOL0285WOSEQ_ST25 12 Nov 2020

tctgccactc gttagctggg tgaccttgag ccaagcccct taacctcttg gaccctatgt 30540

tcttatctct aagtaggggc tggtaatatc ttcccctttg aggaatgccc tctaaggggt 30600

gttgtgaaga ttcggtaagg tggcaggggt aggactcctg gccagaaaca ggcacataat 30660

aaatgctaag tctctccttc tctccacctg ctggatgctg tagatactaa ggatttcgat 30720

gtgaatgaga caaaacccct gccttccagg agcctttgag aatcagagaa ctagacccat 30780 2020267230

ttccagaaca aggggatgca gggtctggat aaagttttgg ggatcaatag agcagagggc 30840

tcccagagga tcccataggg ttgactccta actcaagggc atgagacaac ccccaggaag 30900

ggcaccctgg aaggggtccg gctgtccctg atttacttgt gggcactggg ggaatgcccg 30960

gagccatcca gccctcaggg ctctgtgtga ttctgggttc ctcccataaa agataatcag 31020

attctttcac gttaatgtct ttctccacct cattgcacat catgcagcta ttcattgact 31080

cagcaagtat cagctttgca tgcgaccttg gcctacccac tttagctttt agtaatagct 31140

cccttcttga ataatacaac cagtggggaa acagaaccta actcttacct ctgggaggct 31200

tatttgcttt gagaacatat gtcctgcagt tttgttcata tggcagtgaa gtttcgtgca 31260

cacactctag agccaggcag cctgggttca aagcgcagct ctgccaggtc ctaactgcat 31320

gaatttgggc aagtcgctca acctctccat gcctgagttt cctcatctgt aagattggag 31380

caatggtaat acctgctttt tagggttgag aagagaatta aatgaattaa gatgggtaaa 31440

gtgcttagag tggagctttg caagtagtaa gtgctatgta agtgttcgat ttaaaatgaa 31500

agacccttaa atacattctt tgttcatttc acaagccctt catttcacaa ccttacattt 31560

cacaaccaag ctctgtctcc cctggaatcc agccataact ctgctcacaa gtgtgagaca 31620

ggccccagca gagctgcacg aagaggagag aaggcagccc cccagactcc caaccccctg 31680

tccaagatgg caaaaccaga acacagcctc tgtaccaccc cagcaggtat tcagaatctg 31740

caatctccaa agcccacttc aattgtaaat gtagagccac gtgcgcttta agtcacctgt 31800

cactctggag gctcttttgc tcagttcctc accattagca gggatgacag ggagtgcagg 31860

agtgcggtcg actcccagat attggagagc gctgggctag ctgcccattc tcccggcctc 31920

cactcctctt tgctgtccag ccatcacttg ctctttgaag gcaaacaaaa cagaaaacag 31980

tgccaaaagt atgggaagaa agccagcttc tcccctgggg tgcctgtgat gccatgccca 32040

Page 21

BIOL0285WOSEQ_ST25 12 Nov 2020

ccctccctga ccacgcagcc cctgtggacc ctcagggccc caagccccca tttccatcac 32100

atgcgtacac ccatgtgtgt ccatagccgc ccatctcagt caataaggct gctcctgccc 32160

acttggaata gtggtgacaa ccaggagtgg cttatgggaa ctatcccaat ggcctgacag 32220

catgtccgct gcaaaccgct gaggtaggac actgccctca tgtctagctg atcagcaaga 32280

ggcgcagttg ctttcttagg taacattgct gctgtgtcct ggccattgct ggggggtggc 32340 2020267230

acttaatcta caccagattt ttccctcctg tatcttccaa gctgcttgga tcttggtgct 32400

gaattaggtt ggactttgtc ttgtggggaa gggaggacta tagaccctca acgtaagcaa 32460

tggtcagact attctaagaa aactcgccga attaaagcat gaggtaaatt tagttctgac 32520

ttctgtccac cccactgcca ctgtcccctt ttatcccatg atcccttgct tttcttttcc 32580

tcctctctcc ctatctcttg tgtttgacgc atgataggaa ttcagaaata tatgtttgtg 32640

gatttgttta ttcacgtagc aaaccatttc ttgagtgcct accatgggcc aggtagaatg 32700

ggcggccccg ggctgcagtg gtttcttcag cccctctcca gggtttacac tgtgcaagac 32760

ggtttgtgat gggtcctccc atcgaggacc acactcttct ttctctgtgc cccttggtcc 32820

tcagtctctg accccacttc aaaggcagca ttcactcagg gaagctccca tacaatgcta 32880

gtcagagtaa aagtttggac aaattgccag gaagcagctt gtcagtatgc ataaacagcc 32940

tttaaaatat tactactctt tgacccagaa tttcacttct aggaatctgt cctaaggaag 33000

tagtcacatg caaaagattt atgtaccaag atgttcatca aagtgttgtt ttataacagg 33060

aagtctcaga agctggataa atatccaacc tctggaaatg gttagataga atagtatgta 33120

gccattagaa aattatgtct atggggttta aaatgtcatg ggaaaacact tctgacataa 33180

aagagcatga gaactgtata tttagcataa tcttaactat gttttagaat gcacaggaaa 33240

aaaatgtaca aacatattca tagtgatgtc tctggtggta ggattatgat cagtaagtac 33300

ttctgtctct tcatattttc ctgtatttga taatacatgc atatgttgtt tttaaaataa 33360

gaaaaatttt aagtttaaaa ttggagctga aaagtgtttt taggtcaggc gaggtggctc 33420

acacctgtaa tagcaccact ttgggaggct gaggcagtca gatcacttga gcccaggagt 33480

tcgagaccag cctggccaac atggtgaaac cccatctcta ctaaaaataa aaaaattagc 33540

catgtgtggt ggcacacatc tgtaatccca gctacttggg aggctgaggc atgagaattg 33600

Page 22

BIOL0285WOSEQ_ST25 12 Nov 2020

cttgaaccca ggaggtggag gttgcagtga gccaagatcg tgccactgca ctctagtctg 33660

ggcaacagag taagactcta tgtcaaagaa aaaaaaaaaa gaaaagcctt tttaaacagt 33720

agcagacata actatataat ccttactaag ctgtcggtca aatttttatt tatatattta 33780

ttttattcat ttattatttt tagacagggt ctcactctgt tgcccaggct ggagtacagt 33840

ggcgtgatca tggctctctt caaacttgac ctcccgggct caagtgatcc tcccatctta 33900 2020267230

gcctcccaag tagatgggac cacaggtgca taccaccaca cctggctaat tttttttatt 33960

ttttattttt agagatggtg tttactatgt tgcccaggct agtctcaaac tcctgggctc 34020

aagctatcct cccacctcgg cctcccgaag tgctggggtt accagcatga gccactgtac 34080

ccagccctca aatttttaaa aatctataag agacattatt ggacaattag agaaattcac 34140

atatggactt ataatagtat cagagtgtgt ggtgtgatgg ttctggaggg aatggacttt 34200

ttctttggag acaggctttt ctatgcccac ccttttatct tgctaactta tcatcatcca 34260

ggttccagca gaaacattac ttcccccagg aaatttctta agggtgcagt atcatgatgt 34320

ctgcagcaaa ttctcaaata gctcaggaaa aaagtacgtg tgtggtatga gtgtgtgtat 34380

gtatgtgtgt atatatatac acatatatac acatatatat acatatatgt gtatatatat 34440

acatatatgt gtatatatat acacacacat acacatatat atacacacac acatacatac 34500

atgtattttt atataattat atatgcagag agtgcaaatg ttgccaagtt aaagattggt 34560

gagtctaggt gaagggaata tggtatttat tgtattattt gtgcaacttt tcttaagttt 34620

gaaaattttc aaaacaaaaa attggaggaa gaaggcatgc cagtctaccc caagccctcc 34680

attggaatgc tgaaaatcta aacaatgtga tttggcaatt tcatttcttt tctgttgtgg 34740

gccagtagtc cttagatgtt ggggaagggg gtagtcgctg aggtgtggtt gacttaggat 34800

ggaagaagca gaagtcaaga ctcccagggt caaagtggtt tgctctgctg acccaagtgt 34860

gggaggccca gagtcagcgt ttcaggtgtg ctaattcagc atggttctat tcacggccaa 34920

agtccaccct gggcacctct ctggcagcaa tcttgggtga ctctactaag gccaggcctc 34980

catgacccta tgtctggatc ccatatctcc acctctccca ctgtctcagg aacggtgctt 35040

agctttttct tttccctctc ctgtcttctt tgccagcatg tagaaagttt aaataattcc 35100

cctctttaca acaaaacaaa acataccccc ttcagtcaac caccctagct ctcttctcct 35160

Page 23

BIOL0285WOSEQ_ST25 12 Nov 2020

tttcccagcc agattttttt aaaagcatcc taggccaggc gcggtgactc acgcctgtaa 35220

ttccagcact ttgggaggcc aaggtgggtg gatcacaagg tcaggagatc gagaccatcc 35280

tggctaacat ggtgaaaccc catctctact aaaaatacaa aaaagtagcc gggagtggtg 35340

gcaggtgcct gtagtcccag ctactcggga ggctgaggca ggagaatggc gtgaacctgg 35400

taggcggagg ttgcagtgag ccgagatggc gccactgcac tccagcctgg gtgacagagt 35460 2020267230

gagactccgt ctcaggaaaa aaaaaaaaaa aaaaaaaaaa agcatcctca gcactttggc 35520

aactccatct cctcccaaca tgtccctgtt actggaatcc agccaggact cagccccgat 35580

ctttctactc taaccagttg tctcagttaa caaggacagg tttatgctgc agtgacaaac 35640

aagatcccaa attcttgtgg cttcacacat ctggcaccac ctcatcttcc agccttagga 35700

gtcatctttt agttccttga aaactcttta cagttttctg ttggggcctt gtcatatact 35760

attcccctgg aatgttcttt cctatcccct ccctttcacc ttgctaactt gtgcccatcc 35820

ttcaggtctc agcagaaaca tcacttcctt ggggaagttt tctccaacac ccacactaca 35880

caggtgtccc atctacactc ctatgacttt gtggtacttg tctcacttca ttttccactg 35940

ccttccccac aaggcacctg cacaagggca aggaccgtac cactgtacct atgtcactca 36000

ttgctgtggt cacctgcact ctggctgcct accttaacta cacattagaa tcacctgagg 36060

agcttttaaa gccacaatgc aagactccac cctaggccaa ttggatccaa atccctgggg 36120

tagggccaga catcagtgga gttatatata catatatata ttttgtttgt ttgtttgttt 36180

gttttttgag acagagtttt gctctgtcac ccaggctgga gtgcagtggc gcgatcttgg 36240

ctcactgcaa gctccgcctc tcgggttcac accattctcc tgcctcagcc tcctgagtgg 36300

ctggaactac aagtgctcgc caccacgccc agctaatttt tttgtgtttt tagtagagat 36360

ggggtttcac cgtgttagcc aggatggtct cgatctcctg acctcatgat ctgcctgcct 36420

catcagcctc ccagagtgct gggattacag gcatgagcca ctgcacccgg ccatcagtgg 36480

atatattttt aaagcactgc agagaattct gttgcatcag cttgagaacc actgatctgc 36540

cttgtgcttc acatttaaaa ctttttttta atgaataaat aaaccccaaa aaattaatct 36600

ccctaagcct ccctagaaga taggatggta aggatatttt cctaggtaaa aatatgttaa 36660

tttcatattt catgaaattt catgtttcat ttcaatcaag ctctgtcata caccttacat 36720

Page 24

BIOL0285WOSEQ_ST25 12 Nov 2020

ggggcaagcc cagtgcctgg gcagggtgta attatactca ttacacaggc aaggaaaagt 36780

cacattaggt gatggagcac aaataggcag ttaatggttt cagggctagt taggatatgt 36840

ttgtctttca attgcaagta atagaagccc aaagaaattg gttatttata taatataatt 36900

gattggttcc caaatttgaa aaattcagga atagacccag cttaggtaca gctggatcca 36960

gtcactcaaa caatgtcaca aagaaccctt tgacaggaat gtatcctgtg ttgactctac 37020 2020267230

tttgctctga gtagtctttc cccaggtgat gataaaaatg gtcatcatcg ccaggcttgt 37080

gtcctgttta gtaggaatat acaagaagag ctcagtaaat gctggcccca ccactaagca 37140

aaaacaaaac ttttgttgtt gttattgttg ttttaaataa cagcttagac ctttcttctt 37200

tccttgttat tctctttcat ctgtaatcca gttttctact tctgaagtat agaatgttct 37260

gatgatttat tcttcattac ccacaacttg cacatgttta tttaaaaatg ccaggattgc 37320

ctggccgttg tgtgctgtta acctttgttt gctgttagtg gatccctgaa gttcaggctc 37380

ccaggggagc agataatggg tatccagttc ctgcaatatc caccctctgg caagccaagt 37440

tccttcctgg gtaaggtttt gcctacctgc attcctaggg aagtttctgg gcctgaccac 37500

caagccagct ctgagaaggg gtgcataagc cccaccatgc tttggctctg tccctataga 37560

atattttatg ttgttactga aaactaaagg aagatgggtg cggtggctca tgcctgtaat 37620

cccagcactt tgggaggcca agacagattg atcactcgat gccaggagtt caagaccagc 37680

ctggccaaca tggtgaaacc ttgtctctac aaaaacaaaa caaaacaaaa attagccggg 37740

tatggtggca tgcacctgtg gtaccagcta ctcaagaggc tgaggcacaa gaatctcttg 37800

aacctgggag gtagaggttg cagtgagccg agatcgcact actgcattcc agcctgggtg 37860

acagagcaag attctgtctc caaaaaaaaa aaaaaaaaga aaaggaaagc taaaggagag 37920

agactaaaat gatatcaggt tcctggagaa caaacagaca tgattttgct tcatggcagg 37980

acagccggaa gaagtgggat tatatcctca cattacaaat aagaaaactg agactcagaa 38040

tggttaagtc acttgtccca ggccacacag ccagtaaatt acagaaacag aatttgaacc 38100

caaatcttcc agctccaaag cttgtgttct tttcactacc tcctgcttaa ttttttaatt 38160

tctaagatta gacccttcat ctatccatga cacctgcctg tcatcccctg aaaaaaggtg 38220

aacgccgttc agaaattttt ctagcctgag ctcactccca gttcacttat ttttgctttg 38280

Page 25

BIOL0285WOSEQ_ST25 12 Nov 2020

tcatggctgc ccagtcccca cttgtagacc aggaataggt catggctgcg gggactacac 38340

gctgtcgctg ctgcaagggc cggcctctgt ttccggggct gagtgggggc cagacctgcc 38400

aggagcacca tcttctgtgg gtcctgcctg gatgtcacat cccggcccca agaagtcact 38460

gcaaaccttc gtattattga gcttcacatc ctagaatttg ctgtcactgt ggctgctgca 38520

tgaagttgtc ctgagagaaa cgggcattgt cattaacagg gaaattgatg gtctggggga 38580 2020267230

aaagtcatcc tcattctctt gcagatctat gggtgattga gactggctga tgttgaaggg 38640

gtttctcagc catcgtgtgc catgttatgg aacagtggtg tagccagcca tttgacaccc 38700

agcgctgacc tttgtttaac aacctcacct atatatgaca aaatgattgt cagaaataat 38760

cgtgtaatga aatgactgta ataatggcca gaaaagaaac gcagatagta aaatgtttct 38820

cttgttgaac tctgtacata taattgcacc aggatttttt tcaaataaaa agtaaatatt 38880

atactacaaa aaagggaaaa agcacaagca tttattaaat agctttctat atctttctga 38940

gttttgatcc tttgattgca gactgatgta atattttatg taaatcattg cttggttact 39000

aagtgaactt taagaaaagt gagacgtctg cagaagttgc ccataattta gcagctactg 39060

tattgtacca ttgatgtacg gctttatttt cttgattaat tatttaaaca atataattca 39120

caattttaaa ataataaatt tccacttaaa atggtattta aactcagcaa aatatatcat 39180

ctatgagtaa aatttgtatt taccaagcaa aaatattaca gtttgtggtt cacatgctgt 39240

ctcactgttt taaattttaa atacaaaaac tccaagtagg ctgggtgtgg tggctcacac 39300

ctgtaatccc agtactttgg gaggctgagg caggcatatc gcttgagttc aggagttcaa 39360

gatttgcctg ggcaacatag tgagatcctg tctctactga aaacaattag ctgggtgtgg 39420

tggcacatgc ctgcggtccc agctactcag gaggctgaga taggaggatc acttgaaccc 39480

tgggggacag aggttgcagt gaggcaagat tgcaccactg cactccagcc tgggtgacag 39540

attgagaccc tgtctcaaaa aaagaaaaaa aaaaaagaaa cacaaaaact ccaggtggtc 39600

gcacagaatg acaggactga agtaacttag ctccaatttc tgtcttcata atcactgtcc 39660

taccattgtc tgtgcttaga atctacttgc ttaatgcagg aacatgtgtt ctcacagaga 39720

tggaaaatgc aaatggcgcc agaagcaagc tggaaattct gaaccattaa gaatttactc 39780

tctgccaggc acggtggctc acgcctgtaa tcccaggact ttgggaggct gaggcaggca 39840

Page 26

BIOL0285WOSEQ_ST25 12 Nov 2020

gatcatctga ggtcaggagt tcaagaccag cctggccaac atggtgaaac ttcatctcta 39900

caaaaataca aaaattagcc aggcatgatg gtgggtgcct gtaatcccag ctactcggga 39960

ggctgaggca ggagaatcgc ttgcacctga gaggtggagg ttgcagtgag ccgagatcta 40020

tctgcaccat tgcacttcag cctgggagac agagtaagac tccatctcaa aaaaaaaaaa 40080

aaaaaaaaag aacttactct caaaataaat acgtgtggct gactccacat atggtagggc 40140 2020267230

caactgtata actagaagtt ctccaaataa cttctgtgga gaaaaaaaag tttattaaag 40200

gttaactttt ttaaagtgct aactagaacc ttactaacac tgagatcgca ccaattgttt 40260

ataacttaga cagggccggg tgcagtggct catgcctata atcccaacac tttgggaggc 40320

cgaggcaggt ggatcacttg atgtcaggag ttcgagacca gcctaaccaa catgatgaaa 40380

ccccatctct actaaaaata caaaaattag ccaggcacgg tggtacacgc ctgtaatccc 40440

agctactggg gagggtgagg caggagaatc tcttgaaccc aggaggcgga gattgcagtg 40500

ggccaagatc gcaccattgc actctagccc cagcaacaag agtgaaactc tgtttcaaac 40560

aaacaaacaa aaaaaaaaac ctcttggacc aggaaaatat tttttaaggg aggagtattt 40620

tatcactggc attgtttagg attgcaggca catgatgcta atgaaaagca gactaactat 40680

tagttggttt tattactgtt tttgaactct ctctctccct tttttttttt tttgagacag 40740

agtctctctc tctgtcaccc aggctggaat gcagtgactg cagtctcagc tcactacatc 40800

ctctgcctcc tcagttcaag tgattctcgt gcctcagcct cccgagtagc tgggattaca 40860

gggcaccaca ccaggctaag tttttgtatt tttagtagag gcagggtttc accatgttgc 40920

ccaggctggt ctcaaactcc tggcctcaag cgatctgccc atcttgacct cccaaagtgt 40980

tgggattaca ggcgtgagcc accgtgccta gccctgtttt tgaactctct agagacagtc 41040

cagcccctta ttacttgtcc tgaggcagct gctcccttca cctggccccc cgcattgtgt 41100

tccggaccct tgtcctggtg gtgctaaaga atatctctgt cgatcctttg gggactgggg 41160

aaactgaggc ccagtgccac gcgatgccat ttgttcaggg aagattaggt catctgctag 41220

gtccccagtc acttgacctt cttcccagac aggaagaagc tgctctgggt ctctcagtgc 41280

tccacgtgtc tttgcacatt gaaatgtttt ctgatttttt tttttttttt tttgctgtta 41340

catttacttt taaaaaataa caagcaataa aatgttacat ttgagaaggt tgaaatgaga 41400

Page 27

BIOL0285WOSEQ_ST25 12 Nov 2020

attgatttga gttaaattct agcagatttt tcttagaaga atgatatcat catctccagc 41460

tacctgcaat tgatctactc tgaattaaga aagagacttc catttgttgt ttatattttg 41520

cactcttgat gtgtttcttt aaattatggt catgggccag gtgtaggagc tcacacctgt 41580

aatcccagca ccttgggact ctgaggaggg aggatcactg gaggccagga gttcaagacc 41640

tcgtctgtac agtaaatttt aaaaattagc caggcatggt agcattcacc tgtagtctta 41700 2020267230

gctacttggg aggctgagat gggaggattg cttgagccag aactttgagg ctacagtgag 41760

ttattttcac gccactgccc tctagcctgg ctgacagagc aagacctgcc tcaaaaaaat 41820

aagtaaaaaa taaattaaat ttcaatcatt agcagtcatt aggatattta aatacagtat 41880

gttgaatcaa agttacgcat gtgtgtattt ttttttccag agagttgttt atcatgtggg 41940

ttttaattta actttaaaaa aatgttggct ggacagttgc ccaaatggta tcatcagcca 42000

tttggttgag aacgtatgtc ctgcgggctc ctctgtcact ggagttttgc tagctgacag 42060

ccactggcta gttagagact gcagtcagca cagatgcagg cgtggacttg cgcacgtaac 42120

catgtcaatg caaagccatc acttcttaaa aattctgaac cctgctgtct gagatggtgg 42180

tgcagcggat agaactctgc tctaagaggc agtagctaat tccatgtctt ctttgccctt 42240

gactagctga gtgactttgc acatggggct tgcctctctg ttgccttgtc tgcaaagtgg 42300

aatcatcttt tccttgctag acagaaggtg gaccctggac ctatggcctt tttgagtttc 42360

ccccccgctt cttagaagga cctctgatcc tactgagttt aatacccacg ggttaataat 42420

tgggaaaagc aaaggaagcg cttctgttta ggtaattata tgcatgtttt tgtctttttc 42480

tggctggaaa gatatccaag ccactgggaa ggtccgtggc tacccagggt agccctctct 42540

ggggagggct gctatatcca agagcccctc atgagaattt gaaaatcgac catggtaggg 42600

cctgctgact tttgacagct aatggtgtgc tgagaattgt ccctccaaag atgcctttcc 42660

attccctcgg gagagtctgg gcagccccta ctgggggctg ggatgctggc tcttccctca 42720

gcctccaccc caactgctct cttccctcct cccctcccca gccccctaat ttctctcaca 42780

aggctttgtt ctgcagcaac ctttcctaat gcagtcctgg cctcttcgca gcttcattac 42840

ataaccttcc gtggactcct ggtccaagga tcaccccaga aagccagtca gaggtaggca 42900

cgcagctggg gtccatttac ttaccttccc caccccctcg gaactcagag gtggtgcagg 42960

Page 28

BIOL0285WOSEQ_ST25 12 Nov 2020

aatttggact ccaagaatta acagctccac caccatcacc agagccaaaa ctcaggatgc 43020

atgtgcttca tctgctgctt atttccagct gagagccagt ggtgccatgg ttccttaggg 43080

agccggtccc ctgatgccgg ctcctggccc caaatctctc tgatccgggc tcttccagaa 43140

tgtcttgtct ccaccatcgc ctttgaccaa tggtgtccct ttgcctggta atgtcccctt 43200

tgcctgatga tggccctgtc actcctctct ttagcacaga ggaggctgtt tcatcccttc 43260 2020267230

aagcctgccc tcccttcaag tcttagctca agttcacctt ctccgcagag ccttctccaa 43320

tcttcttgac tacgtctcct ctcagctcca gcaacctctg tctctggcac tgattcctta 43380

cttagctaag agaatcacag acacttgggg ctcaggacaa tctgctttct ctcttcttac 43440

ccatggcctt ggactgtgtg tacctctttg tctccactcc caaacccaac ccccagaggg 43500

cagagagcat gttgtctgtc cctttgctca gcatgaagcc atgcgtgtgg tagatcggca 43560

gagttccata acttgtgttg accgaggggt cactttgctc tgaaattacc cctgtgtcct 43620

tcagtatttg cacagatagc ttcctggcca gaccgaatat atccaagggc atggcccacc 43680

tctgctcctg tttccaggtc cctggtgggg gttagttcat gccttcctca taatctgccc 43740

actggcctgg tcctcaaggt cttcccaact gctcagccag agttgagaaa atgggtcgct 43800

ccatcctgtt tgtgtcgttc tctccttcct ggcccactct cctgcccaca ggtatccagg 43860

ggctgcctgt agcattagag gacatacatg cacatgcgtg ggcatgggac actcacgtag 43920

cctccaagca cagcatcaat aatgcattct gtgctttata gcatggaaag ctgctctaaa 43980

ctttattaca cagtggacat gtctgaagca gctcccaaat ccacccctga gtgtgttgga 44040

attggcaagc ctatcacttg ggagtctagt ttttttgttc gttaataata gatgcttcct 44100

gtggccccag cttggcaatt ttgatttaaa gtgatcttaa ctgaagagac taatggacgg 44160

gtctgaattt gtgcctttta agcacaaagt attgctctta attaactgga ttctatcctt 44220

tgagcaggca gaggccttcc cccaagggcg tcattaacga tccacatctg gacatcttcc 44280

aaagccttct tctgtttcag gccaaccgca ggtgtgttcc tgaacaccca ggaggctatg 44340

agagccacat atgcctccca aatacacaca gtgtgcatgc ccagggacat agagcagtgt 44400

gcaaagtccc attccatctc tctccacctg ggagaggatg gctcttctgt ctgattcatg 44460

gctcaaagtg gtaaaggagc tccccactcc ccgtcccacg cctactcaga gtctgcaaat 44520

Page 29

BIOL0285WOSEQ_ST25 12 Nov 2020

atgtatgcga tatgagagct cgtcagttag ctgtcttcag tgtggcgcac atttgaggag 44580

tctgactccc ctccagcaca ggccaatgtg cactgctctc ctatctttgt acccccactg 44640

ttgcactgtg cagaggttgg agccatagaa gtaccagagc tgtgaaagga gaggccccct 44700

ctcacctctg ccctggtctc catccccact ttctctagga agctagtagg tgctgacagg 44760

ggagagaagg gaggggaggg gtccagaaac agtggctcat gcctgcaatc ctagcacttt 44820 2020267230

gggaggctga ggcaggagga tcatttgagg tcaggagttt gagaccagcc tgggcaatgt 44880

agcaagaccc tatctctaca aaaagaaaaa atgtaattag ctgggtgtgg tggtgggcac 44940

ctgtagtcct agctacttgg gaggatgagg tgggaggatt gcttgagccc aagagtttga 45000

ggttacagta agctgtgatt gcaccactgc actccagcct gggcaacaga gctgagaccc 45060

tatctcaaaa aaagaaaaaa aaaaagaaag gagagagaga gaaagaaaag aaaagaaaaa 45120

aaaaaaagaa gggaagggaa agcccagaag agtgtgggga gaggaggcgg ccgtcattct 45180

ggggccctca gtgtgcacaa ccagataaca catgctctgt gggcttttgt accattttgc 45240

ttgagcataa agaaaggaag gctgccccta aatagaaagc actctggagg caaacaaatc 45300

tgactccaat cctggccctg ccactttccc agctgaggac ttagacaagc accctagcct 45360

cttggacatt ctcagagcca tctgctgcaa gtgggtgctg ccatacccac cttactgggc 45420

aggcttgggg gaccaagggt ggtaaatggc tcagtctttc atgatgcggc cacacagcag 45480

gtgcgccatc caggtccatt tctttccttc ctttccccca aatcaagttg tcattaaagt 45540

actagtccac attaatgaaa tcaactgtat taattttcta tttgctgcta taataaatca 45600

tcagaaattt agtggcttaa accaacacaa atgtattacc ttacagttct ggaggccaga 45660

agccctccat aggtgtcact gggctgaaat caaggttttg gcaaggttgc ggtcctttct 45720

ggagggtcca ggggagaatc cattttcttc ctttttccag cttctaaagg tttcatgcat 45780

tccttggctc atgatcttct atagctatag tcagaaaaat tttccatcaa tcatcttcaa 45840

agccagcaat ggcaggatga gtcctcacat caccttgctc tgacaccagt tctctgcctc 45900

cctcttccac atgtcaggac cctcatgatt actttgggct cactctgata atctgggatg 45960

atctctctat tttagagtca gctgactggg aaccttaatt ccatctacaa ccccaattcc 46020

tctttgccat gtacagtgac atattcacag gttctgggga ttaggacgag cctgtctctg 46080

Page 30

BIOL0285WOSEQ_ST25 12 Nov 2020

aaaggctact ttacatgaaa attcattttt ttaattaaga tttttttttc ctcttgagac 46140

aaggtctcac tctatggttc aggctggagt gcagtggtat gatcacagct cactgcagcc 46200

tcgacgtctc tgggctcagg tgatcctccc acctcagctt ccctagtagc tggaactaca 46260

ggggtgagcc cccatgccca gctaattttt tttttttttt ttttttgaga cagagtctca 46320

ctcagtcacc caggctggtg tgcagtggtg caatctcagc tcacagcaac ctccgcctcc 46380 2020267230

tgggttcaag tgattcttgt gcctcagcct cccaaggagc tgggactaca ggtgtgcacc 46440

accacgcccg actaattttt gtatttttag taaagatggg gtttcaccat gttggccagg 46500

ctggtctcaa actcctgatc tcaagtgatc caccaacctc agcctctcaa agtgctggga 46560

ttacaggtgt aagccaacat gcccggcccc agctaatttt taaatatttt ttttgtagag 46620

atggggtttt accattttgt ctaggctggt cttgaactcc tgggctcaag caaacctccc 46680

accttggtct cccaaagtgc tgggattaca gcatgagcca ctgcactcgg ccttaagaga 46740

agatttaata attaatactt tacaacaaga tctggaagag gtgggatgag taactaaatg 46800

aggatacaag taacccgggt catatttgct aatacccttg gtcacattga acttgatatc 46860

ttatcagatt ttcctaatca gctcctttag cagcagtgtt gcagcatctt atctcatttt 46920

gttttttgtt tttttgccta gcacatgcct gtaaatcact ggattgaggt gtttagatgt 46980

ttgttgtcct ttggatgctt cttataaatc catatttcat ggctccctgg aaagtgctat 47040

gcaaatgata agctgcaagg atggaaagga aattgcagtg ctcctgaatt gtaaatgggc 47100

ttttacgagg aggtttctaa ttactcgctc tttctcttga actgaggagt tgaagtgtag 47160

gtggcagatc cataacagat aatcatgtgt gtgatgtgac ttcagcctga gcgtcgagga 47220

ccaagtcaca gagcaggaac agccactctc cagtgtcctt ggggctacgt ctgaggagaa 47280

cctgggattt catatatgac ctgcactggc tggggggctc tcttgacgta acgtgttccc 47340

tctgagcatg ttacagattc tgacattctt atgttccttc tgtggagaga catgtactta 47400

gtgacctaac tcactttagc atatttttgc tcatcgtttg tgtagcttaa aggaatcaga 47460

taattacccc ctccccacta ctttcggaag cacaaatgca atgccctaga attgtactgg 47520

ggactcaaaa agaaaagaga gtagtaaaat ctattaaagg ggacaaagac agcctatata 47580

ctacaagctt tctattttta tggcagagaa tgccattttc taagtaaaca gagaactgca 47640

Page 31

BIOL0285WOSEQ_ST25 12 Nov 2020

tttgacctgc aatatcaaat gcatggattt gatgctttgg aaagcaactg ttttctgcgt 47700

taatctgggt gtcttccgtg aaatgtcctc ctgcctttgg cttaaacact agctttgtct 47760

acagccattc catcctgaac ctgcccaatc ttgtctgaat cctggtttca ccactgacaa 47820

gctgtgtgtc cttgggcaag ttacttcacc tgtctgtgct tcagagtcct catctgtgag 47880

ttggggaatc tggacagaat ctaccccata gggcgtagtg aggatgtgtt gaattatccc 47940 2020267230

aagtggctac acagagtaag cactcaaatg atgtcatcgt tgtcatgatt gctgttacca 48000

gagcctagag ttcattctga tactcgagtc tgtggcccat ccagcccagg taaggaatag 48060

ttggaggagt tgggcatgtt cagcttgaag aggagacgac aggggatatg ggatagttga 48120

atctgtgaag ggccccctgg gatgaagaac tggcatgttc tgtgtggctc cagggcactg 48180

agcaggaccc atttgccaaa gtctcaggga cacagtttct agctatagac agaaaaattt 48240

tctgtcactc agaggatgaa aatagaatga gcccccttaa gaggtaatga gctccctgtc 48300

attggaagga ttccagaaga gctaggtaac cactttaggt gctatcaagg ggcttttttc 48360

tttaaagtcc tttccaaaag cttctgagat tgcataaaca ataggaagcc atcttggtgc 48420

tttaacacaa actctcccca gtgatgaggg ttgagccaaa gccagattgg caagcagaga 48480

ggagacttgt gtacaaggag ttcctcgagt caattgcttt ttccttgttc tagccagcca 48540

gagggctcct gttggaaaac aggagaccgg agaggctgag gcctgaccaa accagcttct 48600

gcaggccagc tgggaggcca caactcctac ctacgggaaa actgaagggc atctctattt 48660

ttagattagc aaaagaaaat aaatttaagt ttgagtctcc tttgcaactt ttaaaagaca 48720

tctttattga gatgatcatt cacattctat aaaattcccc cactttgagt tacaattcag 48780

tggttttagt cttccttgat gattttgatg gtcttttctt aaggctcttg gaagacccag 48840

aagcctctca gacacaggtg ggtgtggagg gcgtagcaca gaggcagact tctcatttcc 48900

tgggtctccc ctttaatgac tctcagagac ccctccttcc ccctgcccct ggcttctacc 48960

ccaggggtgt agagttttgc cattttccaa gcagaacttc atttcctctt ctgtgtctac 49020

actctttgtg cttctttctt gccagctttt tctcctttgc ccgcccttcc ttccttcctt 49080

ccctccctcc ctccttccct ccttccctct ttccctcctt ccccccttcc acccttcccc 49140

ccttcccccc ttccctcctt ccttccttcc ctccttcctt ccttccttcc tgccttcctt 49200

Page 32

BIOL0285WOSEQ_ST25 12 Nov 2020

ccttcctgcc ttccttcctt cctgccttcc ttccttcctt ccttccttcc ttccttcctt 49260

cctggtatgt gactaatttc tgtttcagga cataaatgtt gtccaggctg ttctttggtc 49320

tttctgttgg ataatggaca tttggcattg agagaggctg ctttttctga aatcatgttc 49380

ttggggccca gaacctaggt gtgtgcttct gactttgttt tcttcctgat ccaaattctg 49440

atatgtccat ttaaattgat ctagacccac agggcactgt gggacagatc ctcagtggaa 49500 2020267230

catgactctg taacgagagc attttgtttt gtcaaaatga gaacatatta ttgcctttca 49560

tctgattgta aacataatac atgtttataa aacagtataa tgagacaaaa atgtagacac 49620

taataaggga aaatctccct aattgtattt ctcttcacag agaaagcccc tgttgggcat 49680

atatactcta gtttgtttat ttgtttgact acacatatat gtattctttt cttatgtata 49740

aaaattctga acatgcacat ttctgcaact actgttttca cttgatgatg catggacctc 49800

tctagagtgt acgtttcttc ttccttacaa agcagttggc ttcgcccagg gtacaccagg 49860

acacggtttt ggctctgtcc ccagggtgtc acgggaccag gggatgatct cacagggtct 49920

gccatctgcc ctgcctggcc ggaggctgca tcgagagggc caaggggcac cacgtgtcgt 49980

gggtactgtc aaacaagagc cttcagagcc ttccacagtc tttcttttgc ttcccagcat 50040

tgcttccccg ctggtggact ctgaatctag aactagctcc aggcgcctct ccaaattcag 50100

acgggagctg gggcactatt ataatgcaaa tctaggcaaa gccctcccaa taccaggatc 50160

cagaatgggg tggggccctt tgccctgaaa agctgtttag tttgaaaata caaacaggag 50220

acagaaaagt ttggctaaat taatggataa agttttaacg atggtaacca tagtagggtt 50280

catcgacagc cagcgatggt tctgaacact tgacatgtat taactcacct aatccccaca 50340

ttttacagac aatgcaaagg aggctctggg aggttgagtg acttgcccca aagtcgcaca 50400

gctcctaagt gaaggattcg gagtggactc caggcagcct ggtctgactc cctgcactgc 50460

gctgtgctta tctctggccc caatgccgcc atgcagaagt gtctgggggc actttgtctc 50520

tgtcagacag aattcggaga tgtgtatgct tgccctggta tggcacttct ctttttttga 50580

gacagaatct cactctgtca ccctggctgg agtgcagtgg catgatctca gctcactgca 50640

acctccgcct cccaggttca agcaattctt gtgcctcagc ctcccaagta gctgggatta 50700

tagatgtgca ccatcgtgcc tagctaaatt tttgtacttt tagtaaagat gttgttttgc 50760

Page 33

BIOL0285WOSEQ_ST25 12 Nov 2020

tgtgttggcc aagctgatct cgaacttttg gcctcaagtg atctgcctac ctcagcctcc 50820

caaagtgctg ggattacagg catgagccac catgcctggc agtgtggcac ttcttacgtg 50880

tgttcagcgg acactgttta tcttctgtcc ctccaagacg gtgctgagct caggtcgttc 50940

attactggca gacaactgct gatttccaac agaattgcca tcctcttctc ccctgcgact 51000

ttcagagtgt gacctcagac tcaaaaatta gaagtgaaaa catcttaaaa actatcacct 51060 2020267230

tttcttccta atcctcctct cccctccctg tcttccttgt tgtccccatc taatgaacta 51120

tcatggcaaa aagagcccat ttctggtcat tttctgtggc ctttcaaact cccacctacc 51180

ccactgctcc tgggtgcatt acccgaaagc tgagacttca gtgcagaaag tgccaggccc 51240

tctgtccccc cagatcgcct tccttgtctt ccctgtgctt gcctgtcaca ttgtgtgggt 51300

tccagcgctg gaaggaatga ggaacagatt ctctggttct ccttttgaag tttaccttcg 51360

ctccaccact tctgagacct tcccggaagt tgccccttgt ttctctcctc tccagggctg 51420

ccccagagct gcctctcacc tcttcctgct gtcaccccac caccatcagg gcagaagttg 51480

ggacaaagcc tctcctactg gctcctgctt ttctccctta ggtccagcct cctcttctcc 51540

atcttcagga gtctccttct ccactcacac gtcatgactt cagcacctcg catcagtcca 51600

gaatatgact gcttgttcaa gtgccacctt tctcatgcat ttttttctag tgacaatcac 51660

agccaccctg tggggcagga gtgtcatcat ccccatgttt caaatgaaga attgcagttc 51720

agagagggca agtgactggc ccagcctcaa cagctagcca gtggacccca ccagggcttc 51780

tgactccagt ccgggttccc tttccaccca aatccatgga gggagctgag ccgagaacag 51840

gtgtccttca ggaagacgtg aagccaaagc ctccacctcc aaactcaggg gcccagggag 51900

tccaggcacc catccactca caaggctgga tatggtgcat tccaggagag gggttggggg 51960

cgagtggcct ctctgtgtac ccgtggggat agatgcgcaa gtggcatcgc cacatcgtga 52020

gtcctggctt catgggtgag ctccaggtcc aacgagaagc caagcagggg gcccttcaag 52080

ctcagctttg ggcccgggtc ggggtacagg gtagagcggg cctccccagc ccctgccatg 52140

aggccaaggc agtgcatcgt tcgcagcgta cattcagaaa ccaaagccta ggagctggtt 52200

atcattccgg tttacagctg atggaagagc aggtgcttcc gagaacccac agtgctcttt 52260

ggccagtgac ccaagggtgc ctctgagagg cctcgcagca cccggaggtg ctgctgaggc 52320

Page 34

BIOL0285WOSEQ_ST25 12 Nov 2020

aacgccctga ctgtaagaag gaccattcat cctcagagag tggccgtgat gctgctgcga 52380

cagtcccacc atccctcccg actctcactc ccaacagact tcccactgta aagctgaact 52440

ctccagcaaa tcacctctcg ccagactctc tcctcactct ctctgggtcc actagaggtt 52500

cctcagcctc tctttgcctt ggttttccca gctgtaaaat ggagcaaaga gggcctatgt 52560

acccacaaag gtgtggttgg agcgactcct cctacattag ggcctcgagt ggggcttcat 52620 2020267230

gattggttgg tggaggtctc caaacccacc cagtgccacc gaaggctgag actgcagatg 52680

caatgccaca ggtgtccttc ctcagcctgg gcagctgaac atcatgtgta aaacggggat 52740

aataagataa taacagcccc ttgcacctat gtggctgtga ggattaaaca agataaatgt 52800

gtaacagtgc ctggctatag aaatatttac tcttgttatt aagggaagaa tatgtgtggc 52860

taaaaaggga tcgaagatgt aaaagccaat ccctccccct ctagcatatt taagggtaat 52920

gttgagttgg tttgtggacc atttgctgcc tgttagagct ggaaggtagg gaccccctct 52980

caacagcgat gctacaaatt atacccattg gaggtcaacc aaaagacaaa gcttattggc 53040

tggacatggt ggctcacacc tgtaatccta gcactttggg aggccaaggc aggcggatca 53100

cttgagatca ggagttcgag accagcctgg ccaacatggt gaaaccccat ccctactaaa 53160

aatacaaaaa ttagctgggc gtggtggtgc acacctgtaa tcccagctac tcaggaggct 53220

gaggcaggag aatcactaga acccaggagg tgaaggttgc agtgagccga gatcgcacca 53280

ctgtactcaa accgaggcaa cagagggaga cgcaatctca aaaaaaagaa aaaaagacaa 53340

agcttgttaa taccagcata ttgttaaggg aataaagtag gctgcagaac aactggtgta 53400

atatggtgcc atgtagggaa aattacatgt gtgcatagga gaggggtctg caaggttgtg 53460

ccctaagatg ttagagtggt tcctttgctt ttctctttta taattttgta tttgactttt 53520

aaataaggac cataaatcac ttttataaaa tacattctct ccagccccta ctactccttt 53580

aaagaataag agtggtttgc ccaagaaaga cagttttttt tgctctggtt ttcttgattc 53640

tgacatcaga ggaaactcct tctcatccac ttggggctct gggttcaggg gattcatttc 53700

aggcagatta aagtggtgac caggggcatt cgtggacaca gggagggaca ggagcaccat 53760

cagtttgtct cacacaacca ctgtcatcct cactgaaggc tgttgcctga tcaaaaacag 53820

tattgggcca ggcacggtgg ctcacacctg taataccacc actttgggag gctgaggtga 53880

Page 35

BIOL0285WOSEQ_ST25 12 Nov 2020

gtggatcact tgaggtcagg agttcgagat caacctggcc aacatggtga aaccttgtct 53940

ctactaaaag ttcaaaaatt agccaggcgt ggtgggtgcc tgtagtccca gctacttggg 54000

aggctgaggc aggagaattg cttgaacccg agaggtagag gttgcagtga gccgagatgg 54060

caccaccaca ctccagcctg ggcgaccgag ggggactctg tcttaaaaaa aaaaaaaaaa 54120

aaaaaaaata tatatatata tatatgtcaa aaatggggta gtttttagat ctatagtagt 54180 2020267230

tctaaaaaca aaggccatcc aagcatgaca gatttacaag cactattggc tattccagta 54240

gttacaatgg aggagagaag cttttagtta aaacaaacaa acaacacaac aaacccagaa 54300

accttaggtc aaaaccaaaa ttgtcctctc agacacaatc tgggaatttt ctcatgacag 54360

tgggcattag ccaactgaca tcagcagcaa ccatccgtgt gcacacagtg gcaccacctc 54420

ctcccaaaaa gcagccttca tctatgccct catacaatcg ttgattattc tctttggatt 54480

gaggcccgga attatttaag tttcttcttg ccagcatgag tctttccttt ctgtatgctc 54540

cttatcttct ctctttaatt tggcagttct gcttgaaatc tgggtctttc attagtagta 54600

gttcaatttg gttccagaac attctgtggt gtgatgcaat gtgaccagag ctcacacttc 54660

agagctcttc aagggccagt cttactgagc acctcccagt ggctgcctgt gtgctgggcg 54720

ccacttgtgg tgggcaggag agaggagggg acacaaaagg agacacagct ccttcttaga 54780

agctcaaagt tggggaccag ctgccacaga agagtatgtt tagcatctga gacaccaaga 54840

tccagcgtca caagggtgtt tattaagcct cctcatctct ttctttttct tttttttttt 54900

ttttttcctc aggcagtctt actctgtcac ccaggctgga gtgcagtggc atgatctcgg 54960

ctcactgcat gcaaccacca cctcccgggt ttaagcaatt ctcctgcctc agcctcccca 55020

gtagctggga ttacaggtgc ccaccaccac acccagctaa tttttgtgtt tttagtagag 55080

acagggtttc accatgttgg tcaggctggt ctcgaactcc tgacctcaga tgattcaccc 55140

acctcggcct cccagtgtgc tgggattaca ggtgtgagcc accgcgcctg gccttgctgt 55200

tgattcatct atagtatgtt tgacttgatg acctccagtt accttagaca gaggttctca 55260

tctaagctcc aactttccat ttcctttgtc ctcgtctttc cccttaaccc ctccacattt 55320

ctctcaaaat caccccactt ctaaaaaata ctgtttattt ttcttttaaa tttcaaatta 55380

tctatactca ttgaaataaa tcaaaatagc atggaataag cgaaaaaaat ggatcccacc 55440

Page 36

BIOL0285WOSEQ_ST25 12 Nov 2020

cttccccact cccattccct agggctaacc atagttaacc atttaatgac taggtttttt 55500

tgttgttgtt attttttatt tatttatttt gagacagagt cttactctgt cacccaggct 55560

ggagtgcagt ggtgtgatct cggctcactg caacctctgc ctcccaggtt caagcattct 55620

cctgcctctg cctcctgagt agctgggatt acaggtgcct gccaccacac ctggctaatt 55680

tttgtacttt tggtagagac agggtttctc aatgttagcc aggctggtct cgaactcctg 55740 2020267230

gcctcaagtg atctgcccac cttggccttc caaaatactg ggattaaggt atgagccacc 55800

gcacccagcc ctcctgggct cttttccttt agttgcactc gctccccgct cctggagtag 55860

agggatttcc gagagactgt gggctccagc cttcacctag gcccaggact aggatgcctg 55920

ccctaacatt tatctttata ccttaaagca aaacagctgg accataagca ttcaagaaca 55980

aactgtgaat aaggagaaag ttctcccagg aaacaagagc tttagttatg ttgggccagc 56040

ccttatattc cttagctgtt accagtcact gcttgattta atctcggcta tcacttggcc 56100

tgacaggtct gctgctggtg ccaggatgtc tgggttttga agcctggctc cattacatac 56160

ttcctgtgtg accttgggca acttactcaa cctgtctgtt cctcagtttc cccagctgta 56220

ttatgtcagc ataatagttt gttgtgtgaa ttaaatgagg taataactgg aaatgcttca 56280

aacatggttc ctatcatgag aaatcctgct ttccgcctaa atgtgctgga aaattcctgg 56340

tggtgcagaa caggagacca gagcaaagga aagacagggt gcagaagcca aaaattacct 56400

tggagaacaa agcgcatgtt aaggttattt ttggattcta ggtttatctc tgcttggtct 56460

tcagttacct acaagagatc catttagggg atttttgttt gtttttaacg atagctttat 56520

tgagatataa ttcatatgcc ataaaagtca ctcttttaaa atgtttccgg tatattcaca 56580

aggctgtgca gccttccctg tccttgattc cagtctgagt ttttaactga agggataagg 56640

aggaccacgc tttccccaga ccagaaccgc gggccagggg gcgattccgc tgagtcaccg 56700

cgggcgcctg gtgcgcggcg gcggagcccg ggaccttcct tggctgcccc ctagcgaggg 56760

ccgcagcgca gcctgagaca cccgccgggg ccgctccacg gccgtcggat ttagactgga 56820

agctcggtcc aggtccccag cttgatgcgc ccgcggtgta ggagaccagc ccgactcgag 56880

cttcccctga gcccctggac tcttgactcc agcagggcct gggtaatgaa cgtcagctcc 56940

cctttcccaa aggggttgct ctgttgggaa ggcacccgtt tgatacagta gcatagagat 57000

Page 37

BIOL0285WOSEQ_ST25 12 Nov 2020

gggttttagc atcaaaatat cagaattcaa gccttgctct ctgcttacta gctgtgtgac 57060

cctaaaaagg tttctgaacg tctctgagct tcagtttcct catcattcct tctcacgggg 57120

tggttgtgag cattacagag atcctctctg tgaagcccct gtgagtggct catcctgagg 57180

gctgaaataa acatgttatt aataatccaa aactggcaag ggatgttgac tggtccccct 57240

cccttgccca aggagctttc tagaacctga gttatcatta ccaaactgta ctgccttgag 57300 2020267230

taagaaagtt agaaggaatg ggaaggatgg tggcaggtgg aggaaggcgg attggtcatc 57360

acctccttgc agcaagaaac agccccagat cgtgggaaac ctacagacct gctagacaga 57420

ctaggagcaa aagctggggc tttaagaatc cccagggagg ttctcctgag agagtagcca 57480

gttggatttt gtaagcagag atttgtttgg ggaggaggtg acaacgtagg gagcagaggg 57540

gcaaagctgt cgggaatcct gccttgaggg cagggatgtg tgttgggggg agttgggtca 57600

ctggggctcg gtggccttgg gcaagtttct acctctcagg tcctttaccc acctagggtc 57660

gccatcctgc ccacctcaca ggttacagtg agcctggatg cactgtcatg ggcaggtgcc 57720

caggaaaatg gcagacatgt tccaaacagc acgcagcatt ccccagtgat gcccagggtc 57780

accttggagg tgggcgagat gcctggggtt tctcgtccac cccacaacac ctcaggggac 57840

agccaaagct gtcccttcag gtaagctgca cagaagatgt gaactctgct gcaaagactc 57900

tattctttgg gagcaaaagg gacccagggt ctcacctgca catccctgtc cctgagggcc 57960

taggggttct tggaggcccc agccttggca aaatgaggaa gaaggtgaag gttgtctggg 58020

cccctgccag gctccttcct cggccacgca ctccccttcc tgcacacaca cccttctccc 58080

tccaccccat ctccattgtt gtcagaaaag tcacaataaa aaggtccata ttgtctagtt 58140

cccatacttt taatttttaa aattttattt atttatttat ttatgtattt tttgagacag 58200

agtcttaacc caggctggag ttcagtggca tgatctaggc tcactgcaac ctctccctcc 58260

tgggttcaag tgattctcat gcctcagcct cccgagtagc tgagattaca gatatgtgcc 58320

actatgccca gctaattttt gtatttttag tagagacggg gtttcaccat gttggccagg 58380

ctggtctcga actcctggcc tcaagtgatc tgcctgcctg agcctccgga agtgctggga 58440

tttcaggtgt gagccaccgc actcggctcc acacttttca cttattaaaa gactgtggtg 58500

tccatcaatg gatgaatgaa taaaccaatg tggactatcc ctcccattac ccaaggaatg 58560

Page 38

BIOL0285WOSEQ_ST25 12 Nov 2020

aagcacggag ccgtgccaag atctggattc acagtgaaag aagccagtca ccaaaagcca 58620

cgtgctgtgt gacttccctt atacgaaata tccagaagag atacatccat ggtgacagaa 58680

agtagatgag cagctgggga ctggcgaagg ggagaagggg gagcagctgt ctatgaggtc 58740

cagcctttct tctgggtttg gtgagaatgt tttggaacta gatagaggtg atagttgtac 58800

aacattgtga atgtactaaa tgccactgaa tcattcattt taaatcgttc tttacgttgc 58860 2020267230

atgaatttta agtcaatcaa aaacagttgt ttgaaaagag aaaagcctat gggtagcggc 58920

agcagtgatt ggatttatga ttcgattcca tggctcatcc ctcccctgcc tcaccccctc 58980

gccctccgac gtcttcttct tttactctga actgttatct ttgttctcat ctctctctct 59040

ctctctcaac cctgcagaca cttttccctt tctttgtctg cccccaccct ccagatttcc 59100

gtgtctccag tgtctcccta cgaggcatga attgagactg ggagggtgtg attctgaaga 59160

aggcaccaac agtgactcag ctagcccctt cccccacccc gccccccggg cctcaattta 59220

gctaaaaaac cacagggacg gactcaggag gcaatacctt tccaagggtc cctaaaaaat 59280

gtcccatttt agtgtccagg tttcactcaa ctttagtgcc tcccctaaaa tgtgttcctt 59340

acctcccacc ccactgcatc taagtcactg cctgagaaaa caggattgag gaaaggagaa 59400

aggaagagag agagagagga ggagagagag agagagggag gaaggctgat ggatttagaa 59460

aagaagaaaa caagtggtct gaggaaaaca gccttggtgt gtttattttc ctgtctgtgt 59520

atcgcttctc ggccttttgg ctaagatcaa gtgtattttc ctgtctgtgt gtctcgctta 59580

gattacaggg atctgtgggt gatgacacgt ctggtccagg ctgcgtagtc acctcaaggg 59640

catgcttatt gatgtgtttt tcaattcact atctttgcat gggagtccca ggccaagagg 59700

cacagctgcg ccatttgtct gttggtttag atatccttta tccagttctt ccagagaaat 59760

catcctgccc ttctggagga ggtgggcagc aggggtcaga gatgggaggg aaaggaagga 59820

gccaggtcct tggctaggat gccagggtcc cctgcctctc acctggcctg ggctggaggc 59880

ctcctgctgt cctgtcactg atcactaccc cgccccagcc tcctgagtta gaagacacag 59940

gctaaagtag agtatttctt cattgaaaaa cccatacaaa ataaaggttc ataaaaaata 60000

aaaatttaga ctgggtgctg tggctcacac ctgtgatccc agcactttgg gaggccaagg 60060

caggtggatc gcttgagccc tggggttcat gaccagcctg ggcaacatag tgaaacccca 60120

Page 39

BIOL0285WOSEQ_ST25 12 Nov 2020

tctctacaaa aaatacaaaa aattagccag gcatggtggt gcatacctgt ggtcccagct 60180

tctcagccta tggacccaca tagaatacaa tgtcagcata agaagggagc cctggggtca 60240

ccaaatggtt tgggcggcaa agaacctgaa ggttgagaga agtggcttgg ttacccagct 60300

gttggatgtg agacctggcc actgcttctt ccatacccta gacctgcacc ctgacatctc 60360

aagtaaaaag ttgggggatg ttttatggtc caggatgaag gaagggcagt gaggggcagc 60420 2020267230

ggagcatcac tttgcatttc tgtctgcctc ttactggctg tgtgacctgg ggcaggtaac 60480

ttcccagact cctgggaatc ataacaccta tgatgatgat gatgatgatg atgatgatga 60540

tgatgacacc tacctcaagg attgccctga agggtcacag agatgcctgc aaggcacctg 60600

catggagcaa gcgccccttc tctggcaggt gctgggtgag cactacctgc tgccaggccc 60660

tggggctatg gcactgcgtg accctgcaag tcctacctgg cgaagctgtc gttcttgtgc 60720

tcagtcagtg ttggttgtaa gactgagaag agtcacttca ttttgctctc cagggacatc 60780

tttctgggtc ctattttctg cctatgtcaa gtagcgcctc aaggatgctc ctgaaaatgg 60840

gcttgtcttt cttaacatgg caggtaggtc ccaaagcatt agcatggggc agctgaccta 60900

gcccagccaa tgcagtgcag tgactcttgc aaccgagtct aatcagaagg tccatgaacc 60960

tacgagcatt tcctgtccca ggatcagggt ggaggctgag cctccctgct tagagattct 61020

tcccatgcat tccacttttt tccccaaaag aaaatattga cccttgagag gcacacagtt 61080

tatttatttt gcatagtaaa tagtagcctg tattttaagg atgagttgat ttctgcatca 61140

gcccctgtag gtcatcagcc ttctattggt gcatctgact ctctctagcc ctgcagggat 61200

ggtggagggg gaggggaagg agggatcttt attggaaacc aggacagtga gactcattgc 61260

cctgtcatct gctctgtggt gctgaatgag gcagcccaac agagaaatac cctgagcgag 61320

catccccagc ctccaaaaca gtggcgcatt gccctgagtc ctgggaatga cctttgattc 61380

tcctgctcct gacttggaac ccatggaaac ctctagaagc agctgaggaa aacccaacat 61440

gaaaagcaga actccacact gagaatatag gaggtgatcg gaacatacaa tgattcttgc 61500

taagaccgat tcacagtttt tctttttttt cgatcgaaga aatactggag aagcctaaag 61560

aaggagtcta aaaactctgg cacgtgggcc aaaactgtcc ttgagctaag aatgattttc 61620

acatttttaa gtggttgaaa aatgaaataa aataagatga tgttttgtga cacatgaaag 61680

Page 40

BIOL0285WOSEQ_ST25 12 Nov 2020

ctatgggaaa ttcaaattct aatatctata aatagtgttt tatcagaaca cagtcatgct 61740

catttattta tgctcgatgg ctgctttccc gctacaatta cgttgagcag ttacaacaga 61800

gaccacgtgg cccacaaagc cttacaatat ttactatctg gccctttcca gaaaaaaatg 61860

tgccgactct tgaccttaac ctcagcaatt tgggaggccg aggcaggcgg atcgcttgag 61920

ctctggagtt catgaccagc ctgggcaaca tagtaagact ccatctctac aaaaaataca 61980 2020267230

aaacattagc caggcatggt ggtgcacacc tgtggtccta gccactcggg agactgaggt 62040

gggaggatcg cctgagccca ggaagtcgag gctgcagtga gctgtgatgg caccactgca 62100

cctcagcctg ggcgacagag caagaccttg tctccaaata aataaataat gcaaagtaaa 62160

ataaataaaa ccatataaaa aggaatcaat ttaaaattat aatgaaagct ggccgggcat 62220

ggtggctcac gcctgtaatc ccagcacttt gggaggctga ggtgggtgga tcacgaggcc 62280

aggagatcga gaccatcttg gctaacacgg tgaaaccccg tctctactaa aaatacaaaa 62340

aaaaaattag ccgggcacag tggcgggcgc ctgtagtccc agctactcgg gaggctgagg 62400

caggagaatg tcttgaaccc gggaggtgga gcttgcagtg agccgagatc gtgccacttg 62460

cagtccagcc tgggcgaaag agcgagactc cgtctcaaaa acaaaaacaa aaacaaaaac 62520

aaaaaaaaat tataatgaaa gccaaggggc atagtagaac aaattttcta gagctcatta 62580

agtcaaatga gtcaccagtt agtaaaacgc agtcacgggg aagagagggc aggattcttt 62640

gaagcagcgg ctctcctaaa aacaacccac ccttgtccag ctgccttccc tcctgagggt 62700

gttccctttg actgtgtgac ccccatcccc tatttcccaa ccgtccaagc ccacctctag 62760

cataatacga gcttttaatc cctctccctg accccaaccc gattttgaag cccagtctag 62820

tattttctca aatacacttc ttggctccat tccttccttt ccatcacctc tgccttttca 62880

ctgcatgctt ggaccactgc agtcagctcc ctatgaacag ttgctctcta cccatccaat 62940

cggccccgcc tgctgctgcc aaattcaccg agggcacctc tgtggtgctg cctgtggaca 63000

aagtccaagc cagccacctc acccacctac aggtgagtgg ggagcagcca gcgtgtccag 63060

tggtttaccc catcgccaca gacttggtga tgtgtcgatg tgcagagaag gggtgttggc 63120

agccacaaca caagcaaccc cgccccatgt gagatctaag atgggcgtgc tgggagccac 63180

ctctgagaat ccaacagaag gcagagggga gaacggctca cacggcacaa acactccttc 63240

Page 41

BIOL0285WOSEQ_ST25 12 Nov 2020

cttttttttt tttctttttc ctttttgaaa ggagtctcac tctattgccc aggcaggagt 63300

gcagtggtgc aatctcagct cactgcaacc tccgcctcct aggttcaagc gattctccag 63360

cctcagcttc ccaagtagct gggattacag gtacactcca ccatgcccgg ctaatttttg 63420

tgtttttagt agagacgggg tttccctatg ttggccaggc tggtcttgag ctcctgacct 63480

caggtgatct gcctgccttg gcctcccaaa gtgctgggat tacaggtgtg agccatgggg 63540 2020267230

cctagcctcc ttccatttaa atgtatgcct aatttgccca ttgagaacgg ctgagacgca 63600

ttttaagtgg ccagggtcta cttagagtta gtgctcatga ccaggcccag gtcaagcctg 63660

gctggccaga tggtgccttt gacctgctct gtctctgtgc aaaggaatga gctgaaggat 63720

gggggtgcag tgtgtgggca gtgggctggg gctggcagga ctcagtgact aagggaagag 63780

aactttcctc actaccagcc tgtcttttca gggcaccgcg gggggctttg ggacttggtg 63840

atgaacacag cacagagagc tgtccagcat gcgggtccct ggcttctcac acttcccagg 63900

ctccttcaga ggctctctcc aaagggagct gctctctcta gaacccatga atttggaata 63960

taggcaacca ctgcattggg gaccactgac ctcaaacata gagaccagag caaatggggc 64020

tcatcacgtg aaactcatct ggaactctag caggttcttt tatatatata tatatatata 64080

tatatttttt attattatac tttaagttct agggtacatg tgcacaacat gcaggtttgt 64140

tacatatgta tacatgtgcc atgttggtgt gctgcaccca ttaattcatc atttacatta 64200

ggtatatctc ctaatgctat ccctccccac tccccccacc ccacaacagg ccccagtgtg 64260

tgatgttccc cttcctgtgt ccaagtgttc tcattgttca attcccacct acgagtgaga 64320

acatgctgtg tttggttttt ttgtccttgc gatagtttgc tgagaatgat ggtttccagc 64380

ttcatccatg tccctacaaa ggacatgaac tcatcatttt ttatggctgc atagtattcc 64440

atggtgtata tgtgccacat tttcttaatc cagtctatca ttgttggaca tttgggttgg 64500

ttccaagtct ttgctattgt gaatagtgcc gcaataaaca tacgtgtgca tgtgtcttta 64560

taacagcatg atttatattc ctttggttat atacccagta atgagatggc tgggtcaaat 64620

ggtatttcta gttctagatc cctgaggaat cgccacactg tcttccacaa tggttgaact 64680

agtttacagt cctaccaaca gtgtaaaagt gttcctattt ctccacatcc tctccagcag 64740

ctgttgtttc ctgacttttt aatgatcgcc attctaactg gtgtgagatg ttatctcatg 64800

Page 42

BIOL0285WOSEQ_ST25 12 Nov 2020

gtggttttga tttgcatttc tctgatggcc agtgatgatg agcatttttt cacatgtctg 64860

ttggcgaact ctagcagctt cttttcacaa gttcatggag agaggtttcc cactgaggga 64920

atcacatctg tctgatcaaa agaggcttgg gaaatggctc tcctgttcat tccctgaaaa 64980

cctctgatgg aaccactgcc actgtggcag ccccagcact ggcaccccag ccatgattgg 65040

tgccccagcc acatctctgc tgtgagcccc agagccctgg ttaattaatc atccacgtgt 65100 2020267230

tgatggggag aggcccattc acaaaagcga cataaagccc agggagacgt ggccgtggca 65160

agaagggtgt gggactacat tccgccccca actgagagat tcagaaacca gaaaaaaatg 65220

gaaaaacata ctgtgctctt gggtgggaaa actaaatatc atgaagggag caatttttat 65280

agttttggcc tataatacaa ttccagccga aatcccagtg gaactttgag aatttgcagg 65340

aaaaaaaaaa atgtctaaag tacatctgga agacaaactt acaagaaggt caaataattt 65400

tgaaaaagaa aatgatatct aagcccacct agagaataag acttgagatc caaagctaaa 65460

tcaggaggct ctagcaaaat tgacagataa gcaggacaga gtgcatggtg cattcacctg 65520

gggaagaggg cagattggtc tacaaatagg cctgggtcca ctgactttag ctgttatatt 65580

tggggagaaa cttttcaacc tcactccatc ttaaacctaa aaatattcca gatgaattaa 65640

taaatataaa aaattagacc actaaaaatg tagaagaaaa tggatgatct ttctatacca 65700

tagagcaatg gaataaatca caaaggaaaa cagatttgac tatataaaac ttaaaccctg 65760

cccatcaaaa accatcagaa accaaaataa aaggcaacca actggagaag atagttgcca 65820

caaatatgat caagggttaa tgttattcat aaattaagag cccacacaag tcattagaat 65880

aagcactgag acctgaacag acaagcaaaa agaatgagag tgggtcggcg cggcggctca 65940

tgcctgtaat cccagcactt tggaaggctg aagcaggcgg atcacttgat cccaggagtt 66000

ccaacaccag cctgagcaac atggtgaaac cctgcctcta caaaagtcat aaatattagc 66060

cgggtgtgat ggcacacgcc tgtagtccca gctactcagg aggctgaggt gggtggatca 66120

cttgagcccg ggaggtagag tctgcagtga gccaagatca caccgctgca ctccagctgg 66180

agcaacagag tgagaccctg acttaaaaga aaaaaaaaaa aaaagaggag aaaaatgctg 66240

atctcactag taattaaaac atcaggccag gcgcagtggc tcacaccttt aatcccagca 66300

ctctgggagg ctgaggcagg cagatcactt gagatcagga gttctagacc agcttggcca 66360

Page 43

BIOL0285WOSEQ_ST25 12 Nov 2020

acatggtgaa atcccgtctc tacaaaaaat acaaaaattc gccaagcgtg gtggcacatg 66420

cctgtgatcc cagctactcg ggaggctgag acaggagaat tgcttgaaca cgggaggcag 66480

aggttgcagt aagctgagat cgtaccattc cagtccagcc tgggctacag agcgagactc 66540

tgtcccagaa aaaattaaaa catcacatat ttaaacaact ctaggatatc atttaaaaaa 66600

acattaatag actgtttttt agagcacttt taggttcaca gtgaaactga gtggaaggta 66660 2020267230

cagagacttc ccgtatgttc cctgccctcc acgtacagcc tcccccactg ccaacgtcct 66720

gcaccagagt ggtacacttg ttacaaccaa tgaatcctca ttaacatatc attatcaccc 66780

aagttcatag tttacattag taaaacatca tctttcatct ataagcacaa aaattttttg 66840

gcatttattt aggtgtatga ttaactcagt gttgacaaga ctcacacttc atacccactt 66900

gcactgcatc tgagaagcaa ttggtgtcta cagccgctac accctcaaca agcccgatct 66960

tgtttgaaaa gcaattggtg atgcttctca aaattctatg gacaaagtca gccgggcatg 67020

gtggctcatg cctgtaatcc ctaaactttg ggaggccgag gcaggcagat cacctgaggt 67080

ctggtgaaac cctgtctcta ctaaaaatgc aaaaattacc caggcatggt ggctggggcc 67140

tgtaatccca gctactcggg aggctgaggc aggagaatcg cttgaagcaa ggaggcggag 67200

gtttcagtga gccaagattg caccactgca ctccagcctg ggtgacaaga gtgaaactcc 67260

atctaaaaaa aaaaaattat ggacaaagtt tttcaaaaag atatttaatg caactttatt 67320

tgtaatattg gaacatctga ggccatttca gtgctaacta ttaggggatg gttaggaaaa 67380

tatggtacat atgtggaaag gaacatttgg tagttagtgc ccctgatgtt tacaaaggct 67440

tttagtgacc aacaaatgct catgctataa tcttatgtga aaaaagcaag tagcataatt 67500

gcaactatat ttttaatgca tagaataaaa ggctagaagg aaatatcaca gatccttgac 67560

atacattccc aaacctttgt aaatccgcgg attcatgaaa acagacacat ttgcacaagt 67620

gcctgatctt ttctgttata cattcattag aagtcaagcc ctggtgccac aaagtatctg 67680

ccttttcaaa tgtgatcaga atgttctctt ttgcttcaag gccatttttc acgaagcagt 67740

ggcatttttg cctcttcatc agagtcaccg tgtgccctgg aggactgaga acagcagagc 67800

cgttttagga tgggacaggg cagccaggag gattgggctc actccctact gagtgcctca 67860

ctcccgtaca gcccccatag aggaagaggg gttcaaattt attcctcagc cagatggcat 67920

Page 44

BIOL0285WOSEQ_ST25 12 Nov 2020

gtgccgcctg tcctggaatt tcacatcact tatgatggac caaaattcca aaagctgaat 67980

ccatgattgt caaagtctgg tatggcagga tgtcaacagt aatcgtttct gggcagaggg 68040

atgattttct cttcccatct tgctttgtat aaatacattt tctataataa ggttgtatta 68100

cttttctcat caagaaatag caaagtactg ttttactcaa aatatgaata gagccaggca 68160

tggtggcagc ttatgcctgt aatcccaaca ctttgagagg cggatatggg aggatcactt 68220 2020267230

tagcccagga gtttgagacc agcctgggca acatagtgag acccccgtcc ccactccccc 68280

aaagaaaacc cacaaagcat ttatcctgga ttattcacag gggccaaaaa aaaaaaaaaa 68340

ttcaggcctc ctatagccat gagctacgaa tatgaaaata tgcaaatgtg taagaaaagc 68400

cagcacatcc gatttttact tttactttca cacctctgtc caccatgttc caagagaaga 68460

aacttggtca ttgaaaggaa tagatcaaat ccaaagaaca aaaccactgt gctcattaaa 68520

cttcttagtg ttcacaaagc tttagctgca ggttgaatgg ggcaacccga attggctggc 68580

tcacctgggc tgcagggagc agagatcgcg acactgcact ccagcctggg caacaaagcg 68640

agactctatc tcaaaaaaaa aaaagttcat aaattcaaag ttatgaatta tttttaaaat 68700

aataataatt tacaataaag atgaggacaa agtgtgagta aatggtggtt tctatccagc 68760

tctgttgagc tgaagtggca tctccctgct ggggcttttg gggaagaagg gtgtgtgttg 68820

ctcttcagat cccaagcctc atgcccctac tgggccctgt ggggtgcttc tcagcccacc 68880

aggagagcca ccgttggaac acacacgtgg gggacctggt gggtgccggt gtggtgaatg 68940

ggggccacag cctgactcca ggaagccagc aaactcggag ctggaggagt caggacaccc 69000

ccgatgagtc aagagttggt tttgctgcca gttgacatct gattgaacca tctcttcact 69060

tctccgtgcc tcactttcct taccagacag gctctgctga tgctgtccct ctcctgttca 69120

gtcgtgccct caccgttaaa gagaaagagc aaactgctgg gcagcagcat tgattttttt 69180

aatgaagtgg aaagagagct gggaataaca agtcgggccc acctcacctg cctcacctgg 69240

tgggtttatt tgttttgttt tttttttttt gttttgagac agagtttcac cctgtcaccc 69300

aggctggagt gcagtggtgt aatctcagct cactgcaacc tccacctgcc aggttcaatt 69360

gattctcctg cctcagcctc cccagtagct gggattacag gcacctgcca catgcctggc 69420

taattattgt atttttagta gagatggggt tttaccatgt tggccaggct ggtctcgatc 69480

Page 45

BIOL0285WOSEQ_ST25 12 Nov 2020

tcctgacctc aggtgatcca cccacctcgg cctcccaaag tgctgagatc acaggcgtga 69540

gccaccatgc ctggccgtca cctggtggtg ttgaatatga actgctgcgg tgttggtaaa 69600

ttaagcaagc agatagatgt aaataacgct tgggcaggaa tatggagcac gggatgagga 69660

tgggcggcca actgttagag agggtagcag ggaggctgag atctgcctgc catgaactgg 69720

gaggagaggc tcctctctct cttcaccccc actctgcccc ccaacactcc tcagaactta 69780 2020267230

tcctctcctc ttctttcccc aggtgaactt tgaaccagga tggctgagcc ccgccaggag 69840

ttcgaagtga tggaagatca cgctgggacg tacgggttgg gggacaggaa agatcagggg 69900

ggctacacca tgcaccaaga ccaagagggt gacacggacg ctggcctgaa aggttagtgg 69960

acagccatgc acagcaggcc cagatcactg caagccaagg ggtggcggga acagtttgca 70020

tccagaattg caaagaaatt ttaaatacat tattgtctta gactgtcagt aaagtaaagc 70080

ctcattaatt tgagtgggcc aagataactc aagcagtgag ataatggcca gacacggtgg 70140

ctcacgcctg taatcccagc actttggaag gcccaggcag gaggatccct tgaggccagg 70200

aatttgagac cggcctgggc aacatagcaa gaccccgtct ctaaaataat ttaaaaatta 70260

gccaggtgtt gtggtgcatg tctatagtcc tagctactca ggatgctgag gcagaaggat 70320

cacttgagcc caggagttca aggttgcagt aagctgtgat tataaaactg cactccagcc 70380

tgagcaacag agcaagaccc tgtcaaaaaa aaaagaaaag aaaaaagaaa gaaagaaatt 70440

taccttgagt tacccacatg agtgaatgta gggacagaga ttttagggcc ttaacaatct 70500

ctcaaataca gggtactttt tgaggcatta gccacacctg ttagcttata aatcagtggt 70560

attgattagc atgtaaaata tgtgacttta aacattgctt tttatctctt acttagatca 70620

ggcctgagtg gcctctcttt agcaagagtt ggttagccct gggattctta ctgtagccac 70680

attaataaac aacatcgact tctaaacatt ctataatacc atcttttggc caaattgact 70740

tcgcctcttc ctctctcttt ccaaatgaaa tgtgtttcat ttcactgtca gaccacatgg 70800

ttggggaccc cacagagcac acagccctcc ctctgccttc ccatgctggc ccttcaccca 70860

ctgctggagt gccaggttgg tccaagggtt ggaccaagtt gtctgaggtt gtctcaaggt 70920

tggtcgaggc tgtctccgcg ctgggttgtg ctacaaggag cccttctttc catgggtgtg 70980

gctggcagtg agtgctcaca gcaacagccc acagtgcagc ccgagggcag gatggactca 71040

Page 46

BIOL0285WOSEQ_ST25 12 Nov 2020

gtccctgcct ccatacccat ttctaaggag gcaaaatggc aaacactcta cttttctctt 71100

ttaatgctaa aaataagaaa acaccttgca gcccagggta tgggtagtgc atggaagccg 71160

tggagttgtg aggtgggaag tgacctctgc tggatatgtc tattcaggaa gattgctgga 71220

gtgggtgggg tctctgggag gtcccctgag tgtgggaagc tgggaccacc agctttctcg 71280

cacagggagt ggccatccca gcttggagag gttccaggac tggttgggag gcacgtttca 71340 2020267230

gatttctatc tgttgaatca gcgaagatat tggattatga ggaatttggg aattaggaaa 71400

gtgggtgcag gtgggttggg ggtaggtgaa ggaagacatg ggcgtattgg gggagcaggg 71460

gctgctcaga ggtgttccag aagctctggg tgaggaggtg agagggaccg gggaatgcag 71520

ctcggcccag cctccctgcc tgaggtcagc catcacgtgg tgatggcaag atggaaatgt 71580

gctttctgac tgctccagcc agtgctgcca gattcagctc cccagggagg gcacctgaga 71640

ggctccaagc caggagatct gttttctcct ttgttttgtt tttttttgtt ttgttttgtt 71700

ttattatact ttaagttcta gggtacatgt gcacaacgtg caggtttgtt acatatgtat 71760

acatgtgcca tgttggtgtg ctgcacccat caacttgtca tttacattag gtatatctcc 71820

taatgctatc cctcccccct ccccccaccc cctgttttct cctttgaatc cttcttagag 71880

gccgggtgcg gtggctcacg cctgtaatcc cagcactttg ggaggctgcg gcaggaggat 71940

tgcttgagcc caggagttcc agaccagcct gggcaacata gtgagacctc gtctctacag 72000

ataataattt taaaaattat ccgggcatag tggcatgcac ctatagtccc agctactcaa 72060

gaggcagagg caggaggatc acttgagccc aggaggcgga ggttgccgtg agccaagatc 72120

ccaccactgc actccagcct gggcgacaga gacccccatg tcaaataata ataataataa 72180

ataaatcctt ctcagtccct tcctcactgt gtccccctcc actgaatttt tccacctcct 72240

ctcccacttc ccccactccc gctttccctc tccttctctc cccactccat ctttttcttt 72300

ctctgctgtt tctcgtccct ccctcctctc catcccacaa cactgcctac cctgtccctg 72360

ccccaccctg gtgctcagga tgtgtgaagt gaggggtggt agcccccaag acctcaaccc 72420

cgaaggttag cctgttgaaa ccactttctc ccagctgccc ccctggcagt tggtgctgct 72480

gggggaaact gggattgggg gccagatttt gcctcttttc ctgacaaaga gagatgaaga 72540

gttctctcac caggtgcctg ggactggggt gtgggtgtcc cagcctatcc cagcgcatct 72600

Page 47

BIOL0285WOSEQ_ST25 12 Nov 2020

gttctgcatc atgattaata gtgctgcttt cagccgggcg cggtggctca cacctgtaat 72660

cccagcactt tgggaggcta aggtgggcag atcacaaggt caggagttcg agaccagcct 72720

ggccaacatg gtgaaacctc gtctctacta aaaatacaaa aattaaccag gtgtggtggt 72780

gggtgcctgt agtcccagct acttgggagg ctgaggcagg agaatcactt gaatctggga 72840

agcagaggtt gcagtgagcc aagatcgtgc cactgcactc cagcctgggt gacagagcga 72900 2020267230

gactccgtcc taaaaaaaaa ggagttttgc tctgtcgccc aggctggagt gtagtggcgc 72960

catctcggct caccgcaacc tgcgcctccc gggtgcaagc gattctcctg cctcagcctc 73020

ccaagtagct aggattacag gcgcctacca ccacgcccgg ccagttcttg tatttttaga 73080

agagacgggg tttcaccctg ttggccaggc tcgtctggga ctcctgacct caggtaatcc 73140

gcccacctca gcctcccaaa gtgctgggat tgcaggcatg agccaccgtg cccagtcaac 73200

tccttctcaa aaaaaaaaaa atagtgctgc tttctctttc aagtgtcctg atttgggtga 73260

tagtaaatgc cactctactt ataagggatc tacctcagaa tgctaattgg gacatttttg 73320

tagcactcta ctgttggcag caggtgatgc tcacaacagc ccgtgagggt ggatgacgtc 73380

cgcttcacag atgacaaagg agcctcatgc tcagaccgtg ggctgccaga gcaggtccat 73440

ggctgcagcc ccacatggac catatttccc ccttgtcact ctttccacca agctcccttg 73500

gaacttcagt tattaagctc tcttgggtgg aatccaagtt agaatcacaa catgtgcctc 73560

atatggattg tgccagtgaa aaatgacatt ctatttagag gcagggcagc ctggcttaga 73620

gtcagtttaa aatatgtatt atgctgcaac aaatgtacca tgatcctgta agatgttcac 73680

aacaagggaa ctggatgtgg ggtatactgt ctgtactaac ttcacaagtt ttctgtaaat 73740

ctaaaactgt tccaaaataa caagttcgtt taaaattaac tccaggagac caggtacggt 73800

agctaatgcc tataatccca gcacttcgga aggctgaggc aggtggattg cttgagccca 73860

ggagtttgag acaagcctgg gcaacatggt gaaatcctgt ctctaaaaaa aatcacaaaa 73920

attagccagg tgtggtggcg cattcctgta gtcccagcta cttgcggggc tgaggtggga 73980

gaatcatctg agcccaggag tttgaggctg cagtgagctg tgattgtacc actgcactcc 74040

aacctgggca acagagcaag accctgtctc aaaaaacaaa aatgaaataa agtccaggaa 74100

agaagtaggt tttaccactc ttattttctg aagagaaaac taaatttaat gtgtaaagtg 74160

Page 48

BIOL0285WOSEQ_ST25 12 Nov 2020

aggacaagtt caccaagtta gtgtttgagt tgcctaaaat atgtttgcta aaactattca 74220

aagctttcac ataaaacatg atcagaagtt ctatgccaaa acatatgtgt gtgtatatat 74280

atatgcacta tatatactgt atataaaaat gcaaaatcta aattgccaac cttttagaaa 74340

ttgctctgaa aggaaagcat ttcaagataa tttgcttacc caaagaatat actttccaag 74400

aaagcaagta atacttaagg tgttcataat cctcatcaaa ttaattcttg ctactgaaag 74460 2020267230

cttacaagga gctgttttga tgtcgggtgt gacaggtttg acttggcaga aggtgtcact 74520

ttactaacaa cattttaaat aagtgacaga agacaagaaa ctacacgtta aatgccagaa 74580

caaagagtgt ctaagtggat gctaagagtt gaaatatggc tggatacctg cccaagagag 74640

ctgaaaagta gatgaaagtt ggttacctat aaactagtgc accctaatga attaaaaggt 74700

gttgatgagt taacttgtta tgccttccag ataagacatg caaatggggc ttcttcctcc 74760

ttcactactt ccaagggatt taacaaggag accaatgcaa atgataagga ctgtagggct 74820

caagctgggg acagattggg gaaaggggga ccatcatgcc catatagatg tccctgtgcc 74880

ctggcagtca aggctgctga aaaataacaa aacccagaag tctgcgtgat gctgcctctc 74940

catttgtcca aagccttctt gcggcagttt gcaggctttt gcaaaagctc caggaccaag 75000

gagctatgtt catgctggaa gcttgttcag gattagctgt tctttgtggg atgggtgcag 75060

ccagggccag gtgtccaggg acagtgtttt aacaaagggc atgaggtgtc tgatctcaca 75120

gtggaactcc acttgccttt ttttcatctt ctcattctgc ttcatgcaca gaaccagccc 75180

catcctgaaa ctgactctaa attactcccg ccccaggtgg agtgcctttc tcggagttca 75240

acagagcctt cctgtcgccc aagggacaac tccactgaat gcccaagcca cacccaaaac 75300

ctaacaagta aaaaccaaat tctgtgctcc cccatcctgg gccattcctg gtttctctac 75360

tgctgttggt gataccacca tcagcttgtc catcatgacc ctggccagtt cctcccacaa 75420

ccctccacag cacccaggga cctcacctcc attccatccg acacagatct cctcaccaca 75480

aaccttggtt ttgcaacagc agccatgaga cctttacacc ctccgccctt catcctgtcc 75540

cccactgagg ccccagagcc attccttaaa gcagcgcgcc acaaactata acccacaagc 75600

caattctggt acccagcctg ttttgcacag ccagtgaact gacaatgatc ttttcataca 75660

gccagaaaaa caaaacaaaa caaaaaacaa caaaaaaaaa ccccaccatt ctgagcatgt 75720

Page 49

BIOL0285WOSEQ_ST25 12 Nov 2020

gacttccatg ttcaagatgt ctcatgttca gaaaggcccc tggaaaagga ggaaggggag 75780

ctgggcacaa agggagaccc tctcagctga gctcctccca tccagacatt ttcctggact 75840

tcctatccaa tgacttccct tagcttctta tcagccaccc ctgtctgccc aggaggctgg 75900

aagatgtggc cttttaactg ggcacagctc tgtcctctat catatcaggg ctctgttccc 75960

aaggagggta gagagaatgg acaccaggtg gaccctcagc agtctgtgcc acagagggag 76020 2020267230

tgtttgcaat ttccagacta aaagtcccca tgtgcttgac ggggtatgtg actacaacgt 76080

gatgcttgac ttttcctcat atgaccagag ccactttgtc catctggtac aatgtcagct 76140

atctgctagg ggccctccag gattcccagt caattccata tctgcatcac caccattggc 76200

actaaataaa ataaaatact caagttcctg ctggtgagca tgagcagtgc tacactgggc 76260

ccttcaacca aggtgacatg ataatgactg aaaataatca ctgccactta ttggggacgt 76320

ctcatctgcc aggcatggta caaagtgctt taaataagca ttcaacaatt tcatgctgac 76380

agaagccctg tgagccagtg gagctactac tatgcccatt atacagggga gaaaactgag 76440

gcagagagag gttaggtaat tcgctcagcc tcacacaacc aataggtggt ggagccagga 76500

tttgggcccc atctgcctga ctctctagag gctctatctt ccagtcttcc agagttgagt 76560

ctaagccatg aataggacaa ttagacagca gaggaaaccc attcagccac catgtgcatg 76620

aagagtaagg aatttctgtc atacagaggg gagtgaattc actgagctga gagctgagga 76680

accattgatc tgatggctga gacaccactg ggaagactgg agaggctttt ctgggcatgc 76740

agtgccaggc acaggaggag ctgagggaag atgactaaga ggtactggca aagaattcag 76800

aaattctgat ggaagcttta catgttacca tcacatccat ccatctatcc acccatccat 76860

ccacccatat cttcctccct ccacccaatc atgcatacat ccagtcatct atacaccacc 76920

cacccaccca tccatccatc catccatccc ttcatccatc ccatcatcca tccaattata 76980

catacatcca atcatatatc tgtacataat ccattcttcc ctcggttcat ccatccatcc 77040

attcatccat ccatccaccc atcccttcct tcatccttcc tatcatccat ccaatcatat 77100

atctgtacat aatccattct tccctcggtt catccatcca tccattcatc catccatcca 77160

cccatccctt ccttcatcct tcctatcatc catccaatca tacatatatc caatcataca 77220

tctgcacatc accagctcat ccatctatcc atttatccat ccatccttcc ttccatccat 77280

Page 50

BIOL0285WOSEQ_ST25 12 Nov 2020

cattcatcca tcatacatac atctaaccat acatctctac atcattcatt cttccatcga 77340

ttcatccaat tatccatcat tccttcctcc atccatccca ttatccattt gatcatacat 77400

atatcatcta tacatcatcc attcatccat ccatccatcc atccacccat atcttcatcc 77460

aatcaatcat acatacatcg aatcatctac acatcaccca tccatccatc catccattca 77520

tctatccacc catccatcca tccatccatc cattcatcta tccacccatc catccatcca 77580 2020267230

tccatccatc catccatgta accatccagt catatatcca attacacatc catccagtta 77640

tacattcata catgcatcta atcattcaat tatacataca cacatccata taattctaca 77700

tccaattata cctccatcca attacacatt catacaccca cctaataaat tattaattca 77760

tatatccatc catataatta tacatcaatt atacatccat ctaatcattc agtaattcac 77820

ccaccatcca gtcatctatc caataataca ttcatccaat catccatcca tccatccacc 77880

cattcatcca tccatccgtc cgtccaccca tcatggtatg agccatgatt taccacgatg 77940

gtcccctgtg gacagcccag gtggggcaga actgaaggga agcccagggc tgcccccata 78000

aacatttgcc tcctttacat ggatgagaac tagatccaca tgtataaatc ctcatgattt 78060

gaaggtgctt ttaccaacat tcactcatgg gattctccca ggagctctag gaggaggcag 78120

gtagagttga ggtcatctca cgcattttac agatgaggaa acggaggccc tgagaggcag 78180

gtccaaggcc acctgaccag aaagaagtgg aactgggact tgaacccagc catcttgccc 78240

cttggtccca tgctctctag cctgtaactc ctgcttcctg gtggggcatc tccaggagga 78300

ccctatcggc tggccatggg cctgccctgg agtcttttgc tctgtgtggc catccttcct 78360

ccctcaggag agtgtgtgct cccagagcac aggctgtatc ttctgagcat tttgtccctt 78420

cccagtacct agcactcagc tctgtataca ttgggctctc aagaattctc aaccttccag 78480

agtgtaaggc cttgacctgc tcagccctgg atactgcatg atgcattgat aagcccataa 78540

aataaccagg gcagattgac tcccagtggc caaagtgcca cagggaaggg acaattcagc 78600

ccttctagga ggaggaggag gtagttttct catttctatt aaggcaacaa aagctgcctt 78660

actaaggaca ttcttggtgg agggcgtgac tgtcaaccac tgtgatcatt tgggcctctc 78720

ttgcccaggc ttcccattct gaaaggacag ttttattgta ggtacacatg gctgccattt 78780

caaatgtaac tcacagcttg tccatcagtc cttggaggtc tttctatgaa aggagcttgg 78840

Page 51

BIOL0285WOSEQ_ST25 12 Nov 2020

tggcgtccaa acaccaccca atgtccactt agaagtaagc accgtgtctg ccctgagctg 78900

actccttttc caaggaaggg gttggatcgc tgagtgtttt tccaggtgtc tacttgttgt 78960

taattaatag caatgacaaa gcagaaggtt catgcgtagc tcggctttct ggtatttgct 79020

gcccgttgac caatggaaga taaacctttg cctcaggtgg caccactagc tggttaagag 79080

gcactttgtc ctttcaccca ggagcaaacg cacatcacct gtgtcctcat ctgatggccc 79140 2020267230

tggtgtgggg cacagtcgtg ttggcaggga gggaggtggg gttggtcccc tttgtgggtt 79200

tgttgcgagg ccgtgttcca gctgtttcca cagggagcga ttttcagctc cacaggacac 79260

tgctccccag ttcctcctga gaacaaaagg gggcgctggg gagaggccac cgttctgagg 79320

gctcactgta tgtgttccag aatctcccct gcagaccccc actgaggacg gatctgagga 79380

accgggctct gaaacctctg atgctaagag cactccaaca gcggaaggtg ggcccccctt 79440

cagacgcccc ctccatgcct ccagcctgtg cttagccgtg ctttgagcct ccctcctggc 79500

tgcatctgct gctccccctg gctgagagat gtgctcactc cttcggtgct ttgcaggaca 79560

gcgtggtggg agctgagcct tgcgtcgatg ccttgcttgc tggtgctgag tgtgggcacc 79620

ttcatcccgt gtgtgctctg gaggcagcca cccttggaca gtcccgcgca cagctccaca 79680

aagccccgct ccatacgatt gtcctcccac acccccttca aaagccccct cctctctctt 79740

tcttcagggg ccagtaggtc ccagagcagc catttggctg agggaagggg caggtcagtg 79800

gacatctgat cttggtttag tatccttcat tttgggggct ctgggtgtgg cctgggcctc 79860

tggactttgg ccacggtgtt tgttccagcc cttctcctaa cctgtccttt ccagacactc 79920

ggcatctagg ttattagcac ctcgcatact ttctgacatg ctcctcagtc ctgattttga 79980

ccatcttctc ttgcttccca tctgtgtcag tcaagactgc atttggctgt aagaaacaga 80040

aaccccaact aactgtggca tttacatgaa gaggtttact tttctcacat aatcagatgt 80100

ctagacttgg ccagcacctc aagggtcatt gatgctctcc tgtctttatt ttctgtcatc 80160

tttagtggtt ggattgttgc ctcatggtta caaagtggct gctgcacttc caggcatcac 80220

atctgccttt gaagcaggaa caagttgcaa agtaaagtgg ccaaaagggc cctgaaacta 80280

aatgtgtccc cttaggaaag caggagtttt cttgcaagtg gcaatcttct gcttatgtct 80340

cattggccag agctgggtct tacggccacc ccttgctgcg agcaaggctg ggacattgag 80400

Page 52

BIOL0285WOSEQ_ST25 12 Nov 2020

cattttgccg tccaacctct ttagcagaat aaaccaaggg ggaagaacgt taatagtggc 80460

ttttgagtca ctagttggca gtatctgccc ctctatcttt ccatcctccc catggagttt 80520

caaggttcct ttctcagtac ttcttcaggc tctgcacgtt catttggatc ttgtgtcttg 80580

gggtgaaaaa ctggcccaag tgtctcccca agcatccacc tttggattaa tttggaaaat 80640

ggctgtcaag tgcccgcctc ttgcttggta taatgctaca gctttagagg acgcagcagg 80700 2020267230

catgggcctt gccgctgagg ttcttagcct catgagaata tccagatcag attctcttgg 80760

ctccttctta gagccagtga tgcaagacac ttcctgctca tcttgtcggg acggttttac 80820

aagttgcctg ccatcctgag aaagtctaca aaacgatgcc agacctcatg ccagcttccc 80880

aagccttgac tctcagtgct ccctcaacag gattctggaa gaatctccca aacaagtcgc 80940

aatcccctct ggaccctgtg caggcatgag actcaagagc attggctccc acccctggtg 81000

gagggaacac tgctggggct gggatcttgc ctggttgctc cgcctgcacc caagacaacc 81060

ataattaaaa tgtccttcat tgaacttgga aagccttcaa agctgacaac tccttatgtg 81120

tacccggaaa ggcctgggag tgtgccaggg cattgctcgg gagggacgct gatttggaag 81180

catttacctg atgagagact gacagcagct cctggtagcc gagctttccc tcctgcctct 81240

gctgtgaagg tggacccatc caacagtcaa atgcctgact ctggacagga gcggacctat 81300

ttattgccat gcaagggact ctgcactttt gaattgtggg tcatgggctt ggatttaggg 81360

gttagagctg ggagaagtct tggaagtcac ctagagatga cactgccatt ttgcagatga 81420

ggaaaccgtc caatcaaaat ggaccaagga cttgcccaaa gcctcacagc aaaaccatag 81480

gcccccgcac taaccccaga gtccctgtgc tgtcttaaga atcaaatagt tgtaagcaat 81540

catctggttt tcagtatttc ttcttttaaa atgcctgggg ccatgcccag cagtctgttt 81600

cactgcagcg tttacacagg gctgccgggc tttcctggtg gatgagctgg gcggttcatg 81660

agccagaacc actcagcagc atgtcagtgt gcttcctggg gagctggtag caggggctcc 81720

gggccctact tcagggctgc tttctggcat atggctgatc ccctcctcac tcctcctccc 81780

tgcattgctc ctgcgcaaga agcaaaggtg aggggctggg tatggctcgt cctggcccct 81840

ctaaggtgga tctcggtggt ttctagatgt gacagcaccc ttagtggatg agggagctcc 81900

cggcaagcag gctgccgcgc agccccacac ggagatccca gaaggaacca caggtgaggg 81960

Page 53

BIOL0285WOSEQ_ST25 12 Nov 2020

taagccccag agacccccag gcagtcaagg ccctgctggg tgccccagct gacctgtgac 82020

agaagtgagg gagctttgcg tgtttatcct cctgtggggc aggaacatgg gtggattctg 82080

gctcctggga atcttgggtt gtgagtagct cgatgccttg gtgctcagtt acctccctgg 82140

ctgcctgcca gcctctcaga gcatttaggg ccttctggac ttctagatgc tcctcatctt 82200

gcctcagtca gcgcgtcagt tccagagact tctctgcagg gttttctggg gcaggtggtg 82260 2020267230

gcagacccgt gccttcttga cacctgaggt cagtccaccc tcctgctcag actgcccagc 82320

acagggtcac ctcccaaggg gtggacccca agatcacctg agcgcacaga gggtgcagat 82380

gactggacca caccttttgg tgatcttaat gaggtggtcc cagaggagct cagacatgca 82440

atctagcatc cagttctggg actctgtctc cttttcaaac gtattcatgt agaacaggca 82500

tgacgagaat gccttgtcaa catgggtgat ggggaatcaa tcagacaggg cgccgggctc 82560

aaggctgcag tcacccaaga gtggctcagc ccaccaggcc ctaggaaacg cctgcacagc 82620

ctggagctcc tggagtcatt tccttcatgt cttcttcact gcacttacgt aaagatgcca 82680

gccattggtt tggtgatttg gagggtgccc agttgcccaa caagaaatgc agaagaggcc 82740

tagccaggat ttcaccagca gtggagagta gagaagatgt ggccagaaaa gagtttcctt 82800

tccctcctaa agatggtact ccctgcagct actggggaag cctgcagcat tctctagggc 82860

tctgtgtgtt gagagcagcc ccaccctggc cccttctgag tgcatttctg ctttgtgact 82920

tgatccgtga agtcccctga gatgggcaga ggggatgtcc tcgaagctgg ggcagagcct 82980

catccttgaa cgtgaaggac gtttgaagac tgtggcatga tcacaggatg agatcacagg 83040

gaacttgagt ttctctcctc ctctcccttc acagttattt cactgaggga aatccctccc 83100

ctgcccagaa tgaaaactct agccaactct tgacttttcc atcactccaa agtagttgaa 83160

agtacattag tctccacagt ggcaaaacag tgtgcaaaag ctaaataatt agaacagcca 83220

gtcccatgtg acagtcaaag cttctaactc cattcaaagt tgcagccatt cccctcgagg 83280

gctggcaggg aggggagggg taagagaaac aggaaggttc ttactgagtt ggtcctggtg 83340

tgagctgcgt cacactccct gcagaggttt caaggagact ctctctctct ctgtctccat 83400

ggggacctta tttgaattct tctactctta ccccagcctg ccatctccag ctatcctccc 83460

ctgaagagcc cttctgctgc gctggattct ggtggccatg tcatctcctc ggccccgtgg 83520

Page 54

BIOL0285WOSEQ_ST25 12 Nov 2020

gagtctgaag atctggctgc agcctcacct ctgaggtcct gctagttgcc acctcttaaa 83580

catgatctga ggctcccatg cactctgacc tgtgcccaca tggggcccac gggaaacacg 83640

ctggcaagca aactgtgggt gtgcagacgg ttctcagggc tgcagcacct gtcctttgct 83700

ctgcccccaa agcaaggcca gcccatcttc catcctctag tgttccttgg tggggccctg 83760

accacagtcc accaggtccc taaccagagg ggacacacac caggtgtcct caatgtattg 83820 2020267230

ccttgaaaca gttgtgctgg gactgtgatg gggggtggcc atgtagccac ccccaccacc 83880

cccaagccac tctctccaag gaaatcctcc taaagatccc tttacatcct ccatgtggtg 83940

gggaggttct agagttgggt gcatgtgtct tcagctactg acaatgcaga ccttagttgg 84000

cacctcgctc tggcctatcc tgtttgctgt tcttggcgct ccagtgaaac tccccatggg 84060

ccatccagtt ggggtgcagt gtggccaccc ccttgcaggt tcctgccttg ctggagagca 84120

cagggccctc ctggctcttg taaaacactc cccatggtac agagaggcca gcagtgatgt 84180

gaggcccaac ctccctccat ggtgttccca agcagctccc tttctggggt caaggggtgg 84240

caaagacagt gcagcgtcca atttctgact caagccgggc ctggctatcg cagctctgca 84300

ctgtgtgtga cagcaaggca actcacccag tgccgtggca gtgaccgtgt ccgaggaagc 84360

ctcctcacac cctctgtctc aaggactctg gcatttagct ggacttgctg tagctctgag 84420

cctttctgcc attgccatca ccttgtcaga aactcaggcc gaatctgcac tcagagttgt 84480

gcccaggcag ttgagccaac acttgctcag cgatattgtc acatgacaag gcactgtcac 84540

cactgggcgt cgtgggtagc gcagtgtcgg ctggatggac ccggagggtg tctgtgtcat 84600

gctagtgcta gtgatgggag ccccgtgagc ccattgcccg ccctcccatg ccctcagcag 84660

ctgcctgggg acagccaatg gcctgggtgt ttctgaggct accacatggc ttccaggaaa 84720

ctcgagaacc tttctctccc ttgcctacac tcttcacaca ggcctgtgct ggccagcggt 84780

ggggatccgg cattcctatc ttaggtgcag aaagtgactg actcattgca ggcctgggag 84840

ataagactga tggcccagcc agcaagatgt atggatttct cagaggcagt ggcctctgtc 84900

attgtcctca ggaaatgctg gtgattctgg tggcctgagg tcaatgcatg tcaacgtggc 84960

caacttgcct tataaacttt ttttctggac aattgcgtgc actgtcctgt aacagtgtcc 85020

tgttgtttat gatgcagaaa taggtgtttt taaagcctat tgattttggt actattaatg 85080

Page 55

BIOL0285WOSEQ_ST25 12 Nov 2020

tggtcaggaa ctttctcagt ctttcttgtt tggggtgagc tgtggcttcc taaacaggaa 85140

cccaagacac ccccaaaagc tgctcaccag cactgccagc ctccctctta ccaagtagca 85200

cccgttcagg acattctgcg aaaggcattt gcccagaagt tgggaggaag gaaatgtaac 85260

attttggggc acctaccata tgccaggcac caggctaaac gtgttcacac aaattctctt 85320

actaaccctc accatccttc tacaagacaa actagtatct tcatcttggg gttcaagatg 85380 2020267230

aggaaatgga ggctcagaga ggttgaatga atgccggtgc ctggatatga accccatctg 85440

cctgactccg caacccaggc aaagtctttc cttgaacttc ccagcagcca ctgcttagac 85500

acagcctcca caaccatggc tcagcagcaa attgcttctc tgacctcact cagcctgtgt 85560

gtccttgttg agtgaggcat tcaggaccct ggtcccaaag tggagaaagt ctttcctact 85620

aggtcatagc tacacctgca tgtgggtgct gtgccttttg tttagtgaac ttttatcacc 85680

agcatcctca gcaatgacat ttgcagagaa gccagagctg aggcaccttg gtattcttgg 85740

gatgtgactt tcctgaatgt ttaagggaaa atgcccgaag gtacagagag cttggtttct 85800

agtaaacaat aactgtcttg cttttacccc ccttcatttg ctgacacata caccagctga 85860

agaagcaggc attggagaca cccccagcct ggaagacgaa gctgctggtc acgtgaccca 85920

aggtcagtga actggaattg cctgccatga cttgggggtt ggggggaggg acatggggtg 85980

ggctctgccc tgaaaagatc atttggacct gagctctaat tcacaagtcc aggagatttt 86040

agggagttgg ttcttatcaa aggttggcta ctcagatata gaaagagccc tagtggtttt 86100

tttctaatac catttctggg taattcctaa ggcatttagt gttctgaaag atgctagcct 86160

tgtccagcct gggagttgag aatgaatgtc taacagaaac tctaggccgg gcgtggtggc 86220

tcacgcctct aatcccagca ctatgggaga cccaggtggg cagatcacct gaggtcagga 86280

gtttgagacc agcctggcca acatgtgaaa tcctgtctca ctacaaataa aaaaattagc 86340

cgggtgtggt ggtaggtgcc tataatccca gctactcagg aggctgaggc aggacaatcg 86400

ctcgaaccca ggaggtggac gttgcagtga gccgagatcg catcattgca ctccagcctg 86460

ggcaacaaaa gcaaaactcc gtctcaaaaa aaaaaaagaa actcaaatat gtgtgacagg 86520

cgattctcac tgcaggctgc cctgtggctg atccaggagc aaggccttaa ccatgtcatc 86580

cccaagcgat tgcttgtaaa ctttcttctg tgcagccttc aacccttatt atgattttct 86640

Page 56

BIOL0285WOSEQ_ST25 12 Nov 2020

tctcaggaac caaactgctg tattcaagaa aggcagcttt gtgtaatcat ttatcataaa 86700

tatcttaaga aaaatcctag agattcctaa ttttaggaaa tgggagacct atggtactga 86760

tataatgtgg gctgggcttg ttttctgtca tttgctagat aaatgaactt gagagcctac 86820

tgtaaaatgt ggaagcttct agattgcaga agggctggaa agacactgtt cttttctccc 86880

gagtgatggg atctgtccag tatttagagc tgcctctgag gccatctgat tctaggagac 86940 2020267230

tctgcctcgt tgaggatatt ttgaggccta actacacatt cctgccccca gagaggtcac 87000

agcctatagc aggctgatgt ttctcatgtc acatggcaca gaaaggcaca ttttcgttct 87060

caggctaaca aagagcttca aaaactatta gaagggacag tggctataag agaagaacct 87120

cagtcaatgt gtgaaattaa ctaggaacct ggctcctgtt tcttttaggt catgtttttc 87180

agcttaggta aaactagagg ctttgataaa gcatgacctc tagaaatcat tgcttttcat 87240

aaatggaagt gggtttgagt tttttctact gattgttagt gcaggtgatg tctacatgcc 87300

cccagaacat attccatgca acaaaaaaag cccaggtcac cgtctttgct gggaacttga 87360

cttttgtgct cactgaattt taagctttct gacagcagcc tggaatcatg gagggataaa 87420

gtacctatta gtaagatgga aaaaggtgtt tcaggttgga gctgcagtct gttgagagta 87480

agctatggga aggcctgtat acgaggggtg gacttttctt ctgtaagtgt ccagagacca 87540

ggcctcctga agagggcatg ggggcttaac ttacctggac tactgtgttt acaatactca 87600

tttatcttga actcctccta acccctgaga attgctacat ttagtatttg ctgagtactt 87660

cctagcatcc tagggaatca atagaacatt ctcccaacca ggctgggtgc ggtggctcat 87720

gtctgtaatc ccagcacttt gggaggccaa ggtaggcaga tcccttgagg ccaggagtgc 87780

aagactagcc tggctgacat ggtgaaaccc cgtctttact aaaaatacaa aagttagcca 87840

ggcatggtgg tacacacctg taatcccagc tacatgggag gagtaggagg caggagaatt 87900

gcttgaacct gggaggtgga ggttgctgtg agccgagatc atgccactgc actccagcct 87960

gggcgacaga gtgagtgaga ctctgtttaa aaaaaaaaaa aaaaaagaac attctcctaa 88020

cctggcttct tcctccaggg gtgtaattaa tcatgtcagt ttcctcattg atacacacac 88080

acacacacta caatcctgta tccattactt ttcaaggtac atttactatt tacgtttggg 88140

gtccttgtct cttttttaat agtgtttctt aaagtcttgt attatatcag agtacagtaa 88200

Page 57

BIOL0285WOSEQ_ST25 12 Nov 2020

catcccagtc aagagcactc tagtaagctc taggaggaaa gcgacttccg gaaggcagtg 88260

gagacctgtc ctgttggggc agcatagggg cagcccctgc ctctggtcag ttctggcgct 88320

caggctcagg gttgcctctg ggctgttctt cccagagact gacaaagggc tcccataagg 88380

cacctgcaga gcctgtgaga agctgaagtc aatgttttcc tgacaccagt tgatctgtgc 88440

aggatccatt gatttaacca cctgctgtgt ggcatgcact gtggtcgatg ccaggaacag 88500 2020267230

gaattggagg ggcccatgag catggccagt atcacaggct ggaggtgctg ctgcgctctg 88560

accgggcctc ttggggatga gcccatgtca accaccttgc ctccgatggg gtcgggccca 88620

caggttacct ttgtgtgtcc atgaccacac cttcctcccc gacctcatcc aaatctcttt 88680

cttttccaag cccctgaatc cttcagggct gcaggttttg tttaaagcag agctggtgag 88740

ttgcataggt tgttgcgttg ggactagatg gggtgttcaa agagttggga gttaaaaaac 88800

ataaagggta tttattagga gaaccaagga gtgtaattct cctgttctta atatgcggcc 88860

aggttaatga atgtcacgtg aatgaaccag aaaaaaatga agtgtgccct tgatcagctg 88920

ggttggtgtg cagcaagctg tgtgaccagg ggacagcagt ggtcctgagg gccgtcactg 88980

tctgccgtgc agagcccttc ctcccacggg ggcctacctc acctgtgcca agggcttgtc 89040

tgtggtcagt gacctggata gatctgaatg gggcttcttt ttcgaggagt cttatggcag 89100

gtctctcagt aaagactcca ttcttgatga tcacacattt tggattttcc aaatctgtca 89160

gagaatgggc ttgaggcggg gtttgtgggc actagtttca ctggtttcat ttaccaaaaa 89220

ggggagcaga agtcaagtat ggtggctcat ccctgtaatc ccagaggcaa gagaattgct 89280

tgagcccagg agttcgagac cagcctgagc aacataagga gaccccgtct ccacaaaaat 89340

gaaaaataac attttagtca gacgtggtgg catgcatctg tggtcccagc tgcttgggag 89400

ggtgagatgg gagggttgtt tgagccctgg agttaaagtt gcaatgagct gtgattgcac 89460

cactgcactc tagcctgggt gacagaacga gaccctgtct caaaaaaaaa aaaaaagaaa 89520

gaaaaaaagg aaaaaaaaaa ctcatgcctg taatcccagc actttgggga ccggggtggg 89580

cagatcacga ggtcaggaga tcaagactat cctagccaac atggtgaaac cccgtttcta 89640

ctaaaaatac aaaaattagc caggtgtggt ggcacgtgcc tgtaatccca gttactcggg 89700

aggctgaggc aggagaatcg cttgaaccag ggagtcagag gttgcagtga gctgagatcg 89760

Page 58

BIOL0285WOSEQ_ST25 12 Nov 2020

tgccactgta ctccagcctg ggcgacagag tgagactctg tctcaaacca aaaaaaaggg 89820

gtggggggcg ggggcaggag aacagtgaga ggtagggaga ggaaagggga ttctcgctac 89880

acccaaacca gataccatct agaggctaga atctttggga ggctcaaatt ccctagaaag 89940

caggagaagc ttctgtagcc ctcccgcttt cccagtagat taagcccagg gcggctccag 90000

atgtgtgaca tgctctgtgc ccaaccagag cccatcatag gcagaggaat aacacccaca 90060 2020267230

ccagaagggc cctcggaggt caccacgtcc aagaaccctc tttacagatg aggaaactga 90120

ggcccagaga ggggagagcc acctagcgag ctggtggcgg ctagaccagg agagctgtca 90180

ttccaagcaa gcaaaggcaa cgagacgagc ccagagctgt gctcccatct ctttgttagg 90240

gggcctggga tgccctctca gtgtcatttt gtccaggatg atgctccctc tcttaagcga 90300

ttaatgcgcc cttgctaacc ttttgctatc gctgcctctt caaaccagag gagttgagag 90360

ttccgggccg gcagaggaag gcgcctgaaa ggcccctggc caatgagatt agcgcccacg 90420

tccagcctgg accctgcgga gaggcctctg gggtctctgg gccgtgcctc ggggagaaag 90480

agccagaagc tcccgtcccg ctgaccgcga gccttcctca gcaccgtccc gtttgcccag 90540

cgcctcctcc aacaggaggc cctcaggagc cctccctgga gtggggacaa aaaggcgggg 90600

actgggccga gaagggtccg gcctttccga agcccgccac cactgcgtat ctccacacag 90660

agcctgaaag tggtaaggtg gtccaggaag gcttcctccg agagccaggc cccccaggtc 90720

tgagccacca gctcatgtcc ggcatgcctg gggctcccct cctgcctgag ggccccagag 90780

aggccacacg ccaaccttcg gggacaggac ctgaggacac agagggcggc cgccacgccc 90840

ctgagctgct caagcaccag cttctaggag acctgcacca ggaggggccg ccgctgaagg 90900

gggcaggggg caaagagagg ccggggagca aggaggaggt ggatgaagac cgcgacgtcg 90960

atgagtcctc cccccaagac tcccctccct ccaaggcctc cccagcccaa gatgggcggc 91020

ctccccagac agccgccaga gaagccacca gcatcccagg cttcccagcg gagggtgcca 91080

tccccctccc tgtggatttc ctctccaaag tttccacaga gatcccagcc tcagagcccg 91140

acgggcccag tgtagggcgg gccaaagggc aggatgcccc cctggagttc acgtttcacg 91200

tggaaatcac acccaacgtg cagaaggagc aggcgcactc ggaggagcat ttgggaaggg 91260

ctgcatttcc aggggcccct ggagaggggc cagaggcccg gggcccctct ttgggagagg 91320

Page 59

BIOL0285WOSEQ_ST25 12 Nov 2020

acacaaaaga ggctgacctt ccagagccct ctgaaaagca gcctgctgct gctccgcggg 91380

ggaagcccgt cagccgggtc cctcaactca aaggtctgtg tcttgagctt cttcgctcct 91440

tccctgggga cctcccaggc ctcccaggct gcgggcactg ccactgagct tccaggcctc 91500

ccgactcctg ctgcttctga cgttcctagg acgccactaa atcgacacct gggtgcagct 91560

gctccactcc ctcggcctcc tcccgtgctc aggctgtggc cgcacgcgcc cctcacgctt 91620 2020267230

gcccgccact ctgcatgtca ccagcacccc cgctccgtgc tccccacctt gtttgactct 91680

ctggccactt gatttgtcca caacggccca tcagcccaca ggaggtttgg tgggtgcctt 91740

ccaccgacag gatgacgggt gccctcatgg tgtctagaac tctccaaccc tcccatgtag 91800

gcataagcag ccccactttg cagatgagga aacggaggct cagagaagta cagtaacttg 91860

ccgaaggcca atgagtagta agtgacagag ccaggtttgg gatccaggta ggttgtctct 91920

gaaagacacg cctgtcctgc atcccacaac gcctcccagg aggtgctgga gtgtggacgc 91980

ctaacacaga gatgtgcagg gcacacacag caggtgacac acacagcatc cagaggtggc 92040

ccagagctca tgctgtgcct ttggcccagt gccctgcccc cacccactct gccttgtggc 92100

aggaagacaa ggagcagaca caagatctcc ctggtccaca tgccaccacc tccctctgca 92160

gaggacaagg ggatcctcat gctggcattg gagggggttg agcagggccc accttgagcc 92220

ctcaggagca cgaccacagc agccctgcag ggagggattg gtgggaggag agtcccaagt 92280

atcagggaga ggagagttgg tgtcccacag gagacctcag agccacaagg cgagcttgtt 92340

cataaatttg ggacccttag catttcacag ttatttgcag agcccagaaa tggatgttac 92400

tgaagctcac agttgcaagc atctgttaaa tttttattag attttacttt tagggaaaac 92460

tttgaaatgc tataaagaag cctgtgttta aaagttaaga cagaggctgg gggcgatggc 92520

tcacgcctgt aatctcagca ctttgggagg ccaaggcagg tggatcattt gaggttagga 92580

gttcgagacc agcctggcca acatggtgag accctgtctc tactaaaatt acaaaaaatt 92640

agctgggcgt ggtggcgggc acctgtagtc ccagctactg gggaggctga agcaggataa 92700

gtgcttgaac ccaggaggcg gaggttacag tgagccaaga tcacaccact gtaccctaag 92760

cctgggcgac agagtgagac tctgtctcaa aaaataaaat aaaataaagt taagagagaa 92820

aaaaatatat cctatatcct ttgttaaatt ccaaaacagt aggggacaaa taactgactt 92880

Page 60

BIOL0285WOSEQ_ST25 12 Nov 2020

gacaggttac tacaatattt cctgaaatga tgttttcttg aatactggcc tactagaggt 92940

tcataggtgt gtttggatta aaaaagagtt ccatggccca gtgactgggg gaaaaaaata 93000

aaagactaaa gtaagttaaa caggcttttc tgctgcagga cttgtcagag cctttaatgt 93060

actaatggcc attgtgaccc tctgagaagg tcacagagtg ggtttcccaa acttacttga 93120

ttctacctgc taacatttcc tggaggaagt ttgggaaatg ccgatttagc agattctttt 93180 2020267230

gttgtgccgt ggatggtgct ggttgatgtg ggcaaaacaa agaacacgtg agtcagatcc 93240

gcctggggct cttactaaag tgcaggttcc caggtgccac tttaggctta cagacccagt 93300

tgtggggtaa gcctgggagt cttttagcag gtgattctgc cacatagtat agttggaaaa 93360

cctctgggca tactcattgc tggtccctct agaaatccag gtgacaatag ccaatgagaa 93420

gctccaagag acccagttgt ccatggggta gagggaatgt gatattgaaa ccaaagaaga 93480

aaatctatga tcagttttca gcagtgactg tcaagagaag gagaagggtg agttagcgct 93540

gatgctggct gacaggtcag cgggttggtt tcaccaagga gtgtgatgaa ggctgatgtt 93600

gtctgtggga atgtatgatg gtaactggtt tgtagctaat ttggggaagc agtgagaatt 93660

cgtgcccttt gaagaccagt aagtggcaag aaacccacca ggcctggctc agggctgggc 93720

tgggcttggc tcgtctcaga gcagctgggg ctggtggcca aagccaccat tagtgagggg 93780

caggccctgg gggtacaacc agcaactagg ggacaaagac aaccctgcca gcctctccta 93840

ttctggaggc gtgtgaccag aaatggagat gggttggtca gcataagatg gccaggaagg 93900

tggaaatcag gactgctggc aatctagcca catgggcagg ggagccgggt ggttccaggc 93960

agtttccaag gccaagaggg tgagcaggca cctcacaggg aatcagggcc aagcctggct 94020

gcagtgtgga gacaatgcac ccacccccat ccttggatct tgcaggaggc tgggtcctca 94080

ctgagctacc aacatccatg gccctgaggc ttttaaaaca cccatccatg gagtggggct 94140

ggtcccagtg gggtgaggct gaccctggca gaaacagggc aggagcctgt gggttaggga 94200

gactgcacct tccttagata gcctccatgc catcatgtcc ccgtgacagt ttctgctgcg 94260

tcccctctgc atggtcccac cctcggccag cctgctgccc cctcttgcca ggttgcgcta 94320

atcagtgacc ccagtgtgct gtgttgatac taacaatgcg aggcctagca gattcaaggg 94380

aaaagagaac caactgggtt tccaccagac ccaactaaac aaacatggac ctatcccaga 94440

Page 61

BIOL0285WOSEQ_ST25 12 Nov 2020

gaaatccagc ttcaccacag ctggctttct gtgaacagtg aaaatggagt gtgacaagca 94500

ttcttatttt atattttatc agctcgcatg gtcagtaaaa gcaaagacgg gactggaagc 94560

gatgacaaaa aagccaaggt aagctgacga tgccacggag ctctgcagct ggtcaagttt 94620

acagagaagc tgtgctttat gtctgattca ttctcatata taatgtgggg agtatttgtc 94680

actaaagtac agctgtcatt taaagtgctt tgtattttgg ggcaggcttt taaaaagtcc 94740 2020267230

agcatttatt agttttgata cttaccccag ggaagagcag ttggcaggtt catgaagtca 94800

tgctcctaat tccagctttc ttagtgtact ttcagtgaga ccctgacagt aaatgaaggt 94860

gtgtttgaaa accaaaccca ggacagtaaa tgaaggtgtg tttgaaaacc agccctagga 94920

cagtaaatga agccatcttc tcactgcata aactgcaccc agatctttgc ccatccttct 94980

cagtatttca cttcacccat tgtttactgt ctcaatgact ggggaaatgt ctggggaaat 95040

gctcccgtaa ttgcacagtg gcgtttttcc tggaaaatcc caccatggct ctagataaga 95100

cctatttttc ttaaaggtat ctaaaatttc cagcataaat tctgtctgaa acacctgaat 95160

tttaatcagt actggagccc ggagggcatc tccagttgcc acatagctct gagcattcag 95220

tggtgtgttg agggctgctc ccggaagtgc ctgcagagtc agggctcccc agcctcatct 95280

agtgaggcag tggaagggcc tgtggggatt tggagagctg gcctgggtct ctgaagtgat 95340

agtgacagct gcttgtcaat cacggtgcac atttagtgcc gggggcaggg ggcagggaat 95400

accagcctca tgcatgcatg cattcatttg ttccttcctt cattcattca ttcagtacac 95460

atgggtacaa catccctgcc ctggagttgc ccagagtcta gggaggggaa agatctatta 95520

ccctgggcct cggccagctg gggagtgctg ctggtggaga ggggccgtgt gcagcgaggg 95580

aaggaggagt cgtcaatacc cccaccccag ctttgctttc ttgtcatcag ccccagggcc 95640

ccagcctgtg tccctcctct cccattgcta cttcatctcc tgggtcctcc ttaccaagcc 95700

tgaccacaca gagggccttg gccgcttcca tggggaattg gaaagcaata agatagcatc 95760

ccctagaagc ccagtgaagt ctgggacagg acccttctct gagctctgac ttgctcttgg 95820

aaacacttcg aggcttagcc tccccacttt gtttcccaag agtgtgacct gttcccctcc 95880

aaacaccccc ttctcctcca gggccatgcc cacccgtcaa aatcccccac gggcaggacg 95940

aactgtgggt gtcagtcacc atctatcctg catcctggtt ccagggcccc ccccagcccc 96000

Page 62

BIOL0285WOSEQ_ST25 12 Nov 2020

gcctccatag ggacaggcgt gcagacaccc gtccctggct gcttcctctt gtggaatggg 96060

ttcaaaagta agcagtgttg tttacactga caaactgaaa aaaaaagaaa aagagataac 96120

attggaggct tggcacagtg gctcatgcct gtaatcccag cactttggga ggctaaggtg 96180

ggaggatgtc cccagcccaa gagttctaga ccagcctggg caacatagca agaccccatc 96240

tcaaaaaaaa aatttaattg gccaggcaga ggtgggagga tcacttgaac ccaaagggtg 96300 2020267230

gaggctgcag tgagccgtga tggcaccact gcactccagc cagggcaaca gagggagacc 96360

ctgtctctaa aacaaacaaa caaacaaaca aacaaaagag ttaacattgg ccagattagg 96420

attcaccaga tagtgttaat attagtttga tttgagactt taatcagaaa gcacatgtgt 96480

ggtgggggtg ggtgtaacct aagtcaggta gaatctttcc aacttggggg gggcacactc 96540

ctgattgtag ccatatgagt ctgtcagtgt ggtggaagag accatgggtt aatgggcagg 96600

taaaaaagca ccttgcctgg aattgagtag aaagtaaggc ccttcagacc ccgtgacaca 96660

cttggggaca ttttcttgag taacatccta agattcatgt accttgatga tctccatcaa 96720

cttactcatg tgaagcacct ttaaaccagt cgtctccaaa ttcaggggca cagtaacatc 96780

caacaggctg gagaaagaac gtactagaac ttccattcct ttttcatgtc ctcttctaaa 96840

agctttgtca gggccaggcg cggtggctca cgcctgtaat cccagcactt tgggaggccg 96900

agacgggtgg atcacgaggt caggagatcg agaccatcct ggctaacaca gtgaaacccc 96960

atctctacta aaaatacaaa aaaacgagcc gggcgtggtg gtgggcgcct gtagtcccag 97020

ctactcggga ggctgaggca ggagaatggc gtgaacccag gaggcagagc ttgcagtgag 97080

ccgagattgc accactgcag tccagcctgg gcgacagagc gagactccgt ctcaaaaaag 97140

aaaaagaaaa agaaaaagaa ctgtgattgg ggaggacggt cactttcctg ttcttactga 97200

tcagaaggga tattaagggt acctgattca aacagcctgg agatcactgc tttcaaccat 97260

tacctgcctt atttattttt agttactgtc cttttttcag tttgtttccc tcctccatgt 97320

gctgactttt attttgattt tatttatgtt tatgtttaag acatccacac gttcctctgc 97380

taaaaccttg aaaaataggc cttgccttag ccccaaacac cccactcctg gtagctcaga 97440

ccctctgatc caaccctcca gccctgctgt gtgcccagag ccaccttcct ctcctaaaca 97500

cgtctcttct gtcacttccc gaactggcag ttctggagca aaggagatga aactcaaggt 97560

Page 63

BIOL0285WOSEQ_ST25 12 Nov 2020

aaggaaacca cctttgaaaa gaaccaggct gctctgctgt ggtttgcaaa tgtggggttt 97620

gtttatttgt tttttagcct caaagacctt tcttcaaatg agttctggca tagaagcacc 97680

gtgtaaaata gttagaattc tgggcaaagg ggaaaagaga gctgggggcc atccctctca 97740

gcaccccaca ggctctcata gcagcagctc ctaagacacc tggtgggacc ttggtttcga 97800

aatcgctact ctaaggctgg gcacggtggc tcacacctgt aatcccagct ctttaggagg 97860 2020267230

ccgaggaggg tggatcacct gagatcagga gttcgagacc agcctggcta acatggcaaa 97920

accctgtctc tactaaaaat acaaaaatta gccgggcgtg gtgttatgcg tggtggtaat 97980

cgcagctact cgggaggctg aggcacaagg attgcttgaa ccccagaggc agaggttgta 98040

gttagctcca gcttgggcga cagagcaaga ccctgtcgca aaaattgttt aaaaaacaaa 98100

cccaaaattg ctactctcat tgggttcctt tgcccattcc tgattttggc aagagaaatg 98160

cttccagatt gccctgatct gggtaggaca gcatcacgcc atagcaacac tgccccgtga 98220

gctcactgcc ccctcaacta gcttgtggtc cttggttaat gtcagtttct tttttgagtt 98280

tgtgttatgt ctaagggtca tctgctgggt aacggaaccc agggactgcc ctagtcccta 98340

gactgtgcca tgcccgactc tgccagcttt gtcagtgatg ctggtgctcg cctcctcggg 98400

tgctcgcctg gtctgagcac acccaaggag ttcttgaggc cttagggttg tttgcgagag 98460

aatgaaagaa cacgacctag ctctctttag catccttggt caggttcaac actgccccca 98520

ggggcctctg gtggagccaa ccaccatcag ccaaataaat ccataattag agtcagaaaa 98580

tggatgtctg catatgtgta gtgcactaat gtcctgccga tgattgacat ggagtggaga 98640

gtgacctgat cattgctgtg agctctgctg gccttggcac aactcatgct gataactaat 98700

gcacacagtt cctctgggag gaaatgtcct cagggaactt ggagtttggg tggggatgtg 98760

ggtttgtgtg cccagcaagc ccttgtggtt gtagcagaca ctagtggcat ctaggaggca 98820

aagggtcacc ccagtcttag ccacgttttg agtcaaggtg gcggagtggg gctggtgttg 98880

actcttggtg gcagtaactt ttcccaatgg tgaaaaaccc ctctatcatg tttcatttac 98940

agggggctga tggtaaaacg aagatcgcca caccgcgggg agcagcccct ccaggccaga 99000

agggccaggc caacgccacc aggattccag caaaaacccc gcccgctcca aagacaccac 99060

ccagctctgg taagaagaac gttctcttga atcttagagg aagctgaagc tctcagaggt 99120

Page 64

BIOL0285WOSEQ_ST25 12 Nov 2020

acagccttca ttttaggagg ccttaggcca ctgagaatga ataacccctg gcagctggtc 99180

agcagcttgc agtttactaa gcactggagt cttcattgcc ttctcagtcc ttttgatttc 99240

tgaggcaaat gttgaatccc tacctttttt tttttttttc ttttgagaca gagtttcgct 99300

tttgttatcc aggccggagt gcagtggtgt gatctcagct cactgcatcc tccacctccc 99360

aggttcaagc gattctccta cctcagcctc cctagtagct gggattacag gcacctgcca 99420 2020267230

ctatgcccgg ctaatttttt gtatttttag tagagacagg gtttcaccat gttggccagg 99480

ctggtctcga acgcctgacc tcaggtgatc cacctgcctc ggcctcccaa agtgctggga 99540

ttacaggcat gagccaccac tcccagcctg aatcctcact ttttatcaat gaagaaattg 99600

aggctgattc tgcagcatga taaaaaaaaa tacagaaaaa ggaaaaaaaa gaaagaaatc 99660

gagcctctga gagtttgctt gactgagtct aaccagctca ttttaaaccc gaggaaaatg 99720

cagtcacatg actactaagt ggcagctctc ggagcctctc tggccccaag tccagggttc 99780

catagaggca gccccagcat ggcatgtttt cagtccccaa atgagactct ggagacaaat 99840

gtctctggag acagagcagc agcctggata agtcacaatg ggtgacgtca ctcagggctc 99900

aacccctggg cagcttaact tgctagggac gttaggagtc tgctgcaaaa cctgagggtc 99960

ttagctgagc agtcacaggc tgggcccgtt gccctgggct cctgtgagta aaacccagtc 100020

aattttgagt acccagtaag gcatccattg agttattttg cagccaggag tgctattaag 100080

aacagtcgcg gctgggcgtg gtggctcatg cctgtaatcc cagcactttg ggaggccaag 100140

gtgggcggat cacctgaggt caggagttcg agaccagctt ggccaacatg gcaaaacccc 100200

gtctctaata aaaatacaaa ataattagct gggcgtggtg gcgggcgcct gtaatcccag 100260

cttctcagga gggtgaggaa ggagaatcac ttgaacccag gaggcagagg ttgcagtgag 100320

ctgagatcgc accattgcac tccagcctgg atgacaaaag tgagattcct tctcaaaaaa 100380

aaaaaaaaaa aaacagtcgt cctctttggg gattagggac agcctgcctg cctgcccgag 100440

cacttctctc ttccattgcc ccagtgaagt attccaggcc cctgggttta gactctgcac 100500

catgtagggg tgtctgacct gcacttgctc cttggtggca cgggcagcct atggcacttg 100560

ctgcgggctg tgaccaaagc ctggcctgga tcttggatct tggtgactct gcttctccct 100620

ggcctgaggg agctgcccag agcctgccca ccacctgctg cgtgtctttg cggtggcatt 100680

Page 65

BIOL0285WOSEQ_ST25 12 Nov 2020

tctcgcacac atgccgtgcg gtggcacccc caaggatggc cattcactaa ggcccattgt 100740

ttttgtcttt tcgcttcgtg ttttctggcc tggtgttttt ctcatataca tgtgatccag 100800

ggataattcc cagaattttg acaggatttt aagtagcgtt tggatcctgc tgtttttttt 100860

tcacttaaca tcgggccagt tgactcacac tctgtttttt gttgttgttt ttttgagacg 100920

gagtctcact gtgtcaccca ggctgaagtg cagtggcaca atcttggcat actgcaacct 100980 2020267230

ctgcttccca aattcaagca gttttcctgc ctcagcctcc tgagtagctg ggactacagg 101040

cacaggccac cacgccctgc taatttttgt atttttagta aagacagggt ttcaccattt 101100

tggccagcct agtctcgaac tcctgacctc aagtgatccg cccacctcgg cctcccaaag 101160

tgctgggatt acaggggact cacactttgt aacaacctga aacaacgtga tgcatttccc 101220

tttgggtctt acctgctctt cggtggctgc ctgcaggtgg agagaccctc ccccttgggc 101280

ccctcgacct tgtttcagaa tggggcccct gctgggccag ctgtgggtgc ctgccacgtg 101340

aaggactcat taaggccctg tttaagcctg atgataataa ggctttcgtg gatttttctc 101400

tttaagcgac taagcaagtc cagagaagac caccccctgc agggcccaga tctgagagag 101460

gtactcggga gcctacttcg ctgggagcag cctccctttg cgtgtgtggc cattcactgg 101520

cttgtgtttc tagagccggg aggacccttt tctgcaatgc agggttcaca cagggttcgc 101580

agcctgaaga tggagcagtc cgaattctct tccctgtgca gtttgcgcag ctgtgtttgt 101640

ctgatgggct ttctaatcct gtgtgctctc cttgacttca gggacaatgg cattacaggc 101700

atgagccacc atgcctggct gtctccctat gtttcagatg aagacatagg cttaaggagg 101760

tcaggtgact tgcccacgac cactctgtaa ataagaggca tgaaaagtat ttggagccac 101820

caccaccaag cccactggtc accctgggtc tctgaagtca gggaggcagg aggatgggag 101880

gtctgaggag gcagagaggc tgagcctgga ggccctggag gccgaggccc catctgttgt 101940

ttccttatgt ggaaaataag aggcttcatt tgtcctattg ccacagagcg tactacttca 102000

ggaacatcca agacatggaa atccgcaggg cacggtggct cacgtctata atcccggcac 102060

tttgggaggt tgaggtggga gaatcgcttg aggccagaag ttcaagacca gcctgagcaa 102120

catagtcaga ccccgtctct ataaaaaaca ttatttttaa aaaagacatg gaagtcaaat 102180

tctaaaaact ggtgctggct gggtgcggtg gctcatgcct ataatcccag cactttggga 102240

Page 66

BIOL0285WOSEQ_ST25 12 Nov 2020

ggccgaggcg ggtggatcac ctgaggtcag gagttcaaga ccagcctggc caacatggta 102300

aaacctctac taaagaaatc tttactgaaa atacaaaaat ccagtctcta ctaaaataag 102360

tctctactaa aaatacaaaa attagccagg cgtggtgctg cacacctgta atatcagcta 102420

ctcgggaggc tgaggcagga gactcgcttg atcccatgca gcggaggttg cagtgagccg 102480

agatcacgcc attgcactcc agcctgggca tcagaataag actccgtctc aaaaaaaaaa 102540 2020267230

ccacaaaaaa acaaaacaac aacaaaagaa aactagtgct tattcgtcac tggccaagct 102600

gcccattggc tacatgggtg cttcaaagag ctgcccttct ccaggtctgg ccagcaggta 102660

tgtgttacag caaatgcctg gggcagcggc aggggcattg ctgcgggaag cttctggact 102720

tgcaggaaag ctaagttctc agactgcagg ggagctaagc acacctcggc acagggtgag 102780

gcctgcggtt ctcagacttc agtctttgtg gagcttgaga aaaatgaggc tttgcaggtc 102840

ccacccctag agattctgct ctatccactc ttgaagggga tcgagaaatt tgcattttgc 102900

aactcccact ttcctccttg aaagctccgg agattctgac gcagggttcc gtgggccaca 102960

ctttggaaaa tacagaccca tgagatagaa taccagactg ttgaagtgta acgggggcct 103020

gggaagtgca gtaacagaag caagtttgag ggtaaaggac acccagagga gggagggaca 103080

gcatctgcat ggagaggaga agagaccccc cagcagcttc cagggtgttg gaagggtgcg 103140

ctagtaactg ctatgcatgg caggtgggga actgtacgtc agggcacagc agcatgaagc 103200

ggtatggctc gtgtggacag ctagggacag gcaggcgtgg agcaggcatc ctgttctgaa 103260

ggccaaatcc cacagaggag ccagggtgct ggcaggagcc ctgaactagc cgaacagctg 103320

aacagctgaa cattcaccct gtggggaaag ggtcagaagc gtccaggctt gagggcacag 103380

ctgggtctcg tcactgcatc acccttattt aggataaagg ccctgaagaa ttgtattaga 103440

ggttggcaaa gcatatctac cacctcctgg agccacgctg gccgcaggga ttataattat 103500

ttccattttc aaattaaggc ctctgagctc agagagggga agttacttgt ctgaggccac 103560

acagcttgtt ggagcccatc tcttgaccca aagactgtgg agccgagttg gccacctctc 103620

tgggagcggg tattggatgg tggttgatgg ttttccattg ctttcctggg aaaggggtgt 103680

ctctgtccct aagcaaaaag gcagggagga agagatgctt ccccagggca gccgtctgct 103740

gtagctgcgc ttccaacctg gcttccacct gcctaaccca gtggtgagcc tgggaatgga 103800

Page 67

BIOL0285WOSEQ_ST25 12 Nov 2020

cccacgggac aggcagcccc cagggccttt tctgacccca cccactcgag tcctggcttc 103860

actcccttcc ttccttccca ggtgaacctc caaaatcagg ggatcgcagc ggctacagca 103920

gccccggctc cccaggcact cccggcagcc gctcccgcac cccgtccctt ccaaccccac 103980

ccacccggga gcccaagaag gtggcagtgg tccgtactcc acccaagtcg ccgtcttccg 104040

ccaagagccg cctgcagaca gcccccgtgc ccatgccaga cctgaagaat gtcaagtcca 104100 2020267230

agatcggctc cactgagaac ctgaagcacc agccgggagg cgggaaggtg agagtggctg 104160

gctgcgcgtg gaggtgtggg gggctgcgcc tggaggggta gggctgtgcc tggaagggta 104220

gggctgcgcc tggaggtgcg cggttgagcg tggagtcgtg ggactgtgca tggaggtgtg 104280

gggctccccg cacctgagca cccccgcata acaccccagt cccctctgga ccctcttcaa 104340

ggaagttcag ttctttattg ggctctccac tacactgtga gtgccctcct caggcgagag 104400

aacgttctgg ctcttctctt gccccttcag cccctgttaa tcggacagag atggcagggc 104460

tgtgtctcca cggccggagg ctctcatagt cagggcaccc acagcggttc cccacctgcc 104520

ttctgggcag aatacactgc cacccatagg tcagcatctc cactcgtggg ccatctgctt 104580

aggttgggtt cctctggatt ctggggagat tgggggttct gttttgatca gctgattctt 104640

ctgggagcaa gtgggtgctc gcgagctctc cagcttccta aaggtggaga agcacagact 104700

tcgggggcct ggcctggatc cctttcccca ttcctgtccc tgtgcccctc gtctgggtgc 104760

gttagggctg acatacaaag caccacagtg aaagaacagc agtatgcctc ctcactagcc 104820

aggtgtgggc gggtgggttt cttccaaggc ctctctgtgg ccgtgggtag ccacctctgt 104880

cctgcaccgc tgcagtcttc cctctgtgtg tgctcctggt agctctgcgc atgctcatct 104940

tcttataaga acaccatggc agctgggcgt agtggctcac gcctataatc ccagcacttt 105000

gggaggctga ggcaggcaga tcacgaggtc aggagttcga gaccaacctg accaacaggg 105060

tgaaacctcg tctctactaa aaatacaaaa atacctgggc gtggtggtgg tgcgcgccta 105120

taatcccagc tactcaggag gctgaggcag gagaatcgct tgaacccagg aggcagaggt 105180

tgcagtgagc cgagatagtg ccactgcact ccagtttgag caacagagcg agactctgtc 105240

tcaaaacaaa ataaaacaaa ccaaaaaaac ccaccatggc ttagggccca gcctgatgac 105300

ctcatttttc acttagtcac ctctctaaag gccctgtctc caaatagagt cacattctaa 105360

Page 68

BIOL0285WOSEQ_ST25 12 Nov 2020

ggtacggggg tgttggggag gggggttagg gcttcaacat gtgaatttgc ggggaccaca 105420

attcagccca ggaccccgct cccgccaccc agcactgggg agctggggaa gggtgaagag 105480

gaggctgggg gtgagaagga ccacagctca ctctgaggct gcagatgtgc tgggccttct 105540

gggcactggg cctcggggag ctagggggct ttctggaacc ctgggcctgc gtgtcagctt 105600

gcctccccca cgcaggcgct ctccacacca ttgaagttct tatcacttgg gtctgagcct 105660 2020267230

ggggcatttg gacggagggt ggccaccagt gcacatgggc accttgcctc aaaccctgcc 105720

acctcccccc acccaggatc ccccctgccc ccgaacaagc ttgtgagtgc agtgtcacat 105780

cccatcggga tggaaatgga cggtcgggtt aaaagggacg catgtgtaga ccctgcctct 105840

gtgcatcagg cctcttttga gagtccctgc gtgccaggcg gtgcacagag gtggagaaga 105900

ctcggctgtg ccccagagca cctcctctca tcgaggaaag gacagacagt ggctcccctg 105960

tggctgtggg gacaagggca gagctccctg gaacacagga gggagggaag gaagagaaca 106020

tctcagaatc tccctcctga tggcaaacga tccgggttaa attaaggtcc ggccttttcc 106080

tgctcaggca tgtggagctt gtagtggaag aggctctctg gaccctcatc caccacagtg 106140

gcctggttag agaccttggg gaaataactc acaggtgacc cagggcctct gtcctgtacc 106200

gcagctgagg gaaactgtcc tgcgcttcca ctggggacaa tgcgctccct cgtctccaga 106260

ctttccagtc ctcattcggt tctcgaaagt cgcctccaga agccccatct tgggaccacc 106320

gtgactttca ttctccaggg tgcctggcct tggtgctgcc caagacccca gaggggccct 106380

cactggcctt tcctgccttt tctcccattg cccacccatg cacccccatc ctgctccagc 106440

acccagactg ccatccagga tctcctcaag tcacataaca agcagcaccc acaaggtgct 106500

cccttccccc tagcctgaat ctgctgctcc ccgtctgggg ttccccgccc atgcacctct 106560

gggggcccct gggttctgcc ataccctgcc ctgtgtccca tggtggggaa tgtccttctc 106620

tccttatctc ttcccttccc ttaaatccaa gttcagttgc catctcctcc aggaagtctt 106680

cctggattcc cctctctctt cttaaagccc ctgtaaactc tgaccacact gagcatgtgt 106740

ctgctgctcc ctagtctggg ccatgagtga gggtggaggc caagtctcat gcatttttgc 106800

agcccccaca agactgtgca ggtggccggc cctcattgaa tgcggggtta atttaactca 106860

gcctctgtgt gagtggatga ttcaggttgc cagagacaga accctcagct tagcatggga 106920

Page 69

BIOL0285WOSEQ_ST25 12 Nov 2020

agtagcttcc ctgttgaccc tgagttcatc tgaggttggc ttggaaggtg tgggcaccat 106980

ttggcccagt tcttacagct ctgaagagag cagcaggaat ggggctgagc agggaagaca 107040

actttccatt gaaggcccct ttcagggcca gaactgtccc tcccaccctg cagctgccct 107100

gcctctgccc atgaggggtg agagtcaggc gacctcatgc caagtgtaga aaggggcaga 107160

cgggagcccc aggttatgac gtcaccatgc tgggtggagg cagcacgtcc aaatctacta 107220 2020267230

aagggttaaa ggagaaaggg tgacttgact tttcttgaga tattttgggg gacgaagtgt 107280

ggaaaagtgg cagaggacac agtcacagcc tcccttaaat gccaggaaag cctagaaaaa 107340

ttgtctgaaa ctaaacctca gccataacaa agaccaacac atgaatctcc aggaaaaaag 107400

aaaaagaaaa atgtcataca gggtccatgc acaagagcct ttaaaatgac ccgctgaagg 107460

gtgtcaggcc tcctcctcct ggactggcct gaaggctcca cgagcttttg ctgagacctt 107520

tgggtccctg tggcctcatg tagtacccag tatgcagtaa gtgctcaata aatgtttggc 107580

tacaaaagag gcaaagctgg cggagtctga agaatccctc aaccgtgccg gaacagatgc 107640

taacaccaaa gggaaaagag caggagccaa gtcacgtttg ggaacctgca gaggctgaaa 107700

actgccgcag attgctgcaa atcattgggg gaaaaacgga aaacgtctgt tttccccttt 107760

gtgcttttct ctgttttctt ctttgtgctt ttctctgttt tcaggatttg ctacagtgaa 107820

catagattgc tttggggccc caaatggaat tattttgaaa ggaaaatgca gataatcagg 107880

tggccgcact ggagcaccag ctgggtaggg gtagagattg caggcaagga ggaggagctg 107940

ggtggggtgc caggcaggaa gagcccgtag gccccgccga tcttgtggga gtcgtgggtg 108000

gcagtgttcc ctccagactg taaaagggag cacctggcgg gaagagggaa ttcttttaaa 108060

catcattcca gtgcccgagc ctcctggacc tgttgtcatc ttgaggtggg cctcccctgg 108120

gtgactctag tgtgcagcct ggctgagact cagtggccct gggttcttac tgctgacacc 108180

taccctcaac ctcaaccact gcggcctcct gtgcaccctg atccagtggc tcattttcca 108240

ctttcagtcc cagctctatc cctatttgca gtttccaagt gcctggtcct cagtcagctc 108300

agacccagcc aggccagccc ctggttccca catccccttt gccaagctca tccccgccct 108360

gtttggcctg cgggagtggg agtgtgtcca gacacagaga caaaggacca gcttttaaaa 108420

cattttgttg gggccaggtg tggtggctca cacctaatcc caacacctgg ggaggccaag 108480

Page 70

BIOL0285WOSEQ_ST25 12 Nov 2020

gcagaaggat cacttgagtc caggagttca agaccagcct gggcaacata gggagaccct 108540

gtctctacaa tttttttttt aattagctgg gcctgttggc actctcctgt agttccagct 108600

actctagagg ctgaggtggg aggactgctt gagcctggga ggtcagggct gcaatgagcc 108660

atgttcacac cactgaacgc cagcctgggc gagaccctgt atcaaaaaag taaagtaaaa 108720

tgaatcctgt acgttatatt aaggtgcccc aaattgtact tagaaggatt tcatagtttt 108780 2020267230

aaatactttt gttatttaaa aaattaaatg actgcagcat ataaattagg ttcttaatgg 108840

aggggaaaaa gagtacaaga aaagaaataa gaatctagaa acaaagataa gagcagaaat 108900

aaaccagaaa acacaacctt gcactcctaa cttaaaaaaa aaaatgaaga aaacacaacc 108960

agtaaaacaa catataacag cattaagagc tggctcctgg ctgggcgcgg tggcgcatgc 109020

ctgtaatccc aacactttgg gaggccgatg ctggaggatc acttgagacc aggagttcaa 109080

ggttgcagtg agctatgatc ataccactac accctagcct gggcaacaca gtgagactga 109140

gactctatta aaaaaaaaat gctggttcct tccttatttc attcctttat tcattcattc 109200

agacaacatt tatggggcac ttctgagcac caggctctgt gctaagagct tttgccccca 109260

gggtccaggc caggggacag gggcaggtga gcagagaaac agggccagtc acagcagcag 109320

gaggaatgta ggatggagag cttggccagg caaggacatg cagggggagc agcctgcaca 109380

agtcagcaag ccagagaaga caggcagacc cttgtttggg acctgttcag tggcctttga 109440

aaggacagcc cccacccgga gtgctgggtg caggagctga aggaggatag tggaacactg 109500

caacgtggag ctcttcagag caaaagcaaa ataaacaact ggaggcagct ggggcagcag 109560

agggtgtgtg ttcagcacta aggggtgtga agcttgagcg ctaggagagt tcacactggc 109620

agaagagagg ttggggcagc tgcaagcctc tggacatcgc ccgacaggac agagggtggt 109680

ggacggtggc cctgaagaga ggctcagttc agctggcagt ggccgtggga gtgctgaagc 109740

aggcaggctg tcggcatctg ctggggacgg ttaagcaggg gtgagggccc agcctcagca 109800

gcccttcttg gggggtcgct gggaaacata gaggagaact gaagaagcag ggagtcccag 109860

ggtccatgca gggcgagaga gaagttgctc atgtggggcc caggctgcag gatcaggaga 109920

actggggacc ctgtgactgc cagcggggag aagggggtgt gcaggatcat gcccagggaa 109980

gggcccaggg gcccaagcat gggggggcct ggttggctct gagaagatgg agctaaagtc 110040

Page 71

BIOL0285WOSEQ_ST25 12 Nov 2020

actttctcgg aggatgtcca ggccaatagt tgggatgtga agacgtgaag cagcacagag 110100

cctggaagcc caggatggac agaaacctac ctgagcagtg gggctttgaa agccttgggg 110160

cggggggtgc aatattcaag atggccacaa gatggcaata gaatgctgta actttcttgg 110220

ttctgggccg cagcctgggt ggctgcttcc ttccctgtgt gtattgattt gtttctcttt 110280

tttgagacag agtcttgctg ggttgcccag gctggagtgc agtggtgcga tcatagctca 110340 2020267230

ctgcagcctt gaagtcctga gctcaagaga tccttccacc tcagcctcct gagtagttgg 110400

gaccacaggc ttgcaccaca gtgcccaact aatttcttat attttttgta gagatggggt 110460

ttcactgtgt cgcccaggat ggtcttgaac tcctgggctc aagtgatcct cctgcctcag 110520

cctcgcaaat tgctgggatt acaggtgtga gccaccatgc ccgaccttct ctttttaagg 110580

gcgtgtgtgt gtgtgtgtgt gtgtgggcgc actctcgtct tcaccttccc ccagccttgc 110640

tctgtctcta cccagtcacc tctgcccatc tctccgatct gtttctctct ccttttaccc 110700

ctctttcctc cctcctcata caccactgac cattatagag aactgagtat tctaaaaata 110760

cattttattt atttattttg agacagagtc tcactctgtc acccaggctg gagtgcagtg 110820

gtgcaatctc ggctcactgc aacctccgcc tcccaggttg aagcaactct cctgcctcag 110880

cctccctagt agctgggatt acaagcacac accaccatgc ctagcaaatt tttatatttt 110940

tagtagagga ggagtgtcac catgtttgcc aagctggtct caaactcctg gcctcaggtg 111000

atctgcctac cttggtctcc caaagtgctg ggattacagg tgtgagccac cacgcctgcc 111060

cttaaaaata cattatattt aatagcaaag ccccagttgt cactttaaaa agcatctatg 111120

tagaacattt atgtggaata aatacagtga atttgtacgt ggaatcgttt gcctctcctc 111180

aatcagggcc agggatgcag gtgagcttgg gctgagatgt cagaccccac agtaagtggg 111240

gggcagagcc aggctgggac cctcctctag gacagctctg taactctgag accctccagg 111300

catcttttcc tgtacctcag tgcttctgaa aaatctgtgt gaatcaaatc attttaaagg 111360

agcttgggtt catcactgtt taaaggacag tgtaaataat tctgaaggtg actctaccct 111420

gttatttgat ctcttctttg gccagctgac ttaacaggac atagacaggt tttcctgtgt 111480

cagttcctaa gctgatcacc ttggacttga agaggaggct tgtgtgggca tccagtgccc 111540

accccgggtt aaactcccag cagagtattg cactgggctt gctgagcctg gtgaggcaaa 111600

Page 72

BIOL0285WOSEQ_ST25 12 Nov 2020

gcacagcaca gcgagcacca ggcagtgctg gagacaggcc aagtctgggc cagcctggga 111660

gccaactgtg aggcacggac ggggctgtgg ggctgtgggg ctgcaggctt ggggccaggg 111720

agggagggct gggctctttg gaacagcctt gagagaactg aacccaaaca aaaccagatc 111780

aaggtctagt gagagcttag ggctgctttg ggtgctccag gaaattgatt aaaccaagtg 111840

gacacacacc cccagcccca cctcaccaca gcctctcctt cagggtcaaa ctctgaccac 111900 2020267230

agacatttct cccctgacta ggagttccct ggatcaaaat tgggagcttg caacacatcg 111960

ttctctccct tgatggtttt tgtcagtgtc tatccagagc tgaagtgtaa tatatatgtt 112020

actgtagctg agaaattaaa tttcaggatt ctgatttcat aatgacaacc attcctcttt 112080

tctctccctt ctgtaaatct aagattctat aaacggtgtt gacttaatgt gacaattggc 112140

agtagttcag gtctgctttg taaataccct tgtgtctatt gtaaaatctc acaaaggctt 112200

gttgcctttt ttgtggggtt agaacaagaa aaagccacat ggaaaaaaaa tttctttttt 112260

gtttttttgt ttgcttgttt ttttgagaca gagtttcact ctgtcgccca ggctggagtg 112320

cagtggtgcg atctccgccc actgcaagct ccacctcccg ggttcatgct attctcctgt 112380

ctcagcctcc caagtagctg ggactgcagg tgcccgccac cacacctggc taattttttt 112440

gtatttttag tagagacggg gtttcaccgt gttagccagg atggtctcaa tctcctgacc 112500

tcgtcatctg cctgcctcgg cctcccaaag tgctgagatt acaggcgtga gccaccgtgc 112560

ccggccagaa aaaaacattt ctaagtatgt ggcagatact gaattattgc ttaatgtcct 112620

ttgattcatt tgtttaattt ctttaatgga ttagtacaga aaacaaagtt ctcttccttg 112680

aaaaactggt aagttttctt tgtcagataa ggagagttaa ataacccatg acatttccct 112740

ttttgcctcg gcttccagga agctcaaagt taaatgtaat gatcactctt gtaattatca 112800

gtgttgatgc ccttcccttc ttctaatgtt actctttaca ttttcctgct ttattattgt 112860

gtgtgttttc taattctaag ctgttcccac tcctttctga aagcaggcaa atcttctaag 112920

ccttatccac tgaaaagtta tgaataaaaa atgatcgtca agcctacagg tgctgaggct 112980

actccagagg ctgaggccag aggaccactt gagcccagga atttgagacc tgggctgggc 113040

agcatagcaa gactctatct ccattaaaac tatttttttt tatttaaaaa ataatccgca 113100

aagaaggagt ttatgtggga ttccttaaaa tcggagggtg gcatgaattg attcaaagac 113160

Page 73

BIOL0285WOSEQ_ST25 12 Nov 2020

ttgtgcagag ggcgacagtg actccttgag aagcagtgtg agaaagcctg tcccacctcc 113220

ttccgcagct ccagcctggg ctgaggcact gtcacagtgt ctccttgctg gcaggagaga 113280

atttcaacat tcaccaaaaa gtagtattgt ttttattagg tttatgaggc tgtagccttg 113340

aggacagccc aggacaactt tgttgtcaca tagatagcct gtggctacaa actctgagat 113400

ctagattctt ctgcggctgc ttctgacctg agaaagttgc ggaacctcag cgagcctcac 113460 2020267230

atggcctcct tgtccttaac gtggggacgg tgggcaagaa aggtgatgtg gcactagaga 113520

tttatccatc tctaaaggag gagtggattg tacattgaaa caccagagaa ggaattacaa 113580

aggaagaatt tgagtatcta aaaatgtagg tcaggcgctc ctgtgttgat tgcagggcta 113640

ttcacaatag ccaagatttg gaagcaaccc aagtgtccat caacagacaa atggataaag 113700

aaaatgtggt gcatatacac aatggaatac tattcagcca tgaaaaagaa tgagaatctg 113760

tcatttgaaa caacatggat ggaactggag gacattatgt taagtgaaat aagccagaca 113820

gaaggacaga cttcacatgt tctcacacat ttgtgggagc taaaaattaa actcatggag 113880

atagagagta gaaggatggt taccagaggc tgaggagggt ggaggggagc agggagaaag 113940

tagggatggt taatgggtac aaaaacgtag ttagcatgca tagatctagt attggatagc 114000

acagcagggt gacgacagcc aacagtaatt tatagtacat ttaaaaacaa ctaaaagagt 114060

gtaactggac tggctaacat ggtgaaaccc cgtctctact aaaaatacaa aaattagctg 114120

ggcacggtgg ctcacgcctg taatcccagc actttgggag gccgaggcgg gccgatcacg 114180

aggtcaggag atcgagacca tcctagctaa catggtgaaa ccccgtctct actacaaata 114240

caaaaaaaag aaaaaattag ccgggcatgg tggtgggcgc ctgtagtccc agctactcgg 114300

gaggctgagg caggagaatg gcgtgaaccc gggaggcgga gcttgcagtg agccgagatc 114360

gcgccactgc actccagcct gggcgacaag gcaagattct atctcaaaaa aataaaaata 114420

aaataaaata aaataataaa ataaaataaa ataaaataaa ataaaataaa taaaataaaa 114480

tgtataattg gaatgtttat aacacaagaa atgataaatg cttgaggtga tagatacccc 114540

attcaccgtg atgtgattat tgcacaatgt atgtctgtat ctaaatatct catgtacccc 114600

acaagtatat acacctacta tgtacccata taaatttaaa attaaaaaat tataaaacaa 114660

aaataaataa gtaaattaaa atgtaggctg gacaccgtgg ttcacgcctg taatcccagt 114720

Page 74

BIOL0285WOSEQ_ST25 12 Nov 2020

gctttgtgag gctgaggtga gagaatcact tgagcccagg agtttgagac cggcctgggt 114780

gacatagcga gaccccatca tcacaaagaa tttttaaaaa ttagctgggc gtggtagcac 114840

ataccggtag ttccagctac ttgggagacc gaggcaggag gattgcttga gcccaggagt 114900

ttaaggctgc agtgagctac gatggcgcca ctgcattcca gcctgggtga cagagtgaga 114960

gcttgtctct attttaaaaa taataaaaag aataaataaa aataaattaa aatgtaaata 115020 2020267230

tgtgcatgtt agaaaaaata cacccatcag caaaaagggg gtaaaggagc gatttcagtc 115080

ataattggag agatgcagaa taagccagca atgcagtttc ttttattttg gtcaaaaaaa 115140

ataagcaaaa caatgttgta aacacccagt gctggcagca atgtggtgag gctggctctc 115200

tcaccagggc tcacagggaa aactcatgca acccttttag aaagccatgt ggagagttgt 115260

accgagaggt tttagaatat ttataacttt gacccagaaa ttctattcta ggactctgtg 115320

ttatgaaaat aacccatcat atggaaaaag ctcctttcag aaagaggttc atgggaggct 115380

gtttgtattt tttttttctt tgcatcaaat ccagctcctg caggactgtt tgtattattg 115440

aagtacaaag tggaatcaat acaaatgttg gatagcaggg gaacaatatt cacaaaatgg 115500

aatgggacat agtattaaac atagtgcttc tgatgaccgt agaccataga caatgcttag 115560

gatatgatat cacttctttt gttgtttttt gtattttgag acgaagtctc attctgtcac 115620

ccaggctgga gttcagtggc gccatctcag ctcactgcaa cctccatctc ccgggttcaa 115680

gctattctcc ttcctcaacc tcccgagtag ctgggttgcg caccaccatg cctggctaac 115740

ttttgtattt ttagtacaga cggggtttca ccacgttggc caggctgctc ttgaactcct 115800

gacgtcaggt gatccaccag ccttgacctc ccaaagtgct aggattacag gagccactgt 115860

acccagccta ggatatgata tcacttctta gagcaagata caaaattgca tgtgcacaat 115920

aattctacca agtataggta tacaggggta gttatatata aatgagactt caaggaaata 115980

caacaaaatg caatcgtgat tgtgttaggg tggtaagaaa acggtttttg ctttgatgag 116040

ctctgttttt taaaatcgtt atattttcta ataaaaatac atagtctttt gaaggaacat 116100

aaaagattat gaagaaatga gttagatatt gattcctatt gaagattcag acaagtaaaa 116160

ttaaggggaa aaaaaacggg atgaaccaga agtcaggctg gagttccaac cccagatccg 116220

acagcccagg ctgatggggc ctccagggca gtggtttcca cccagcattc tcaaaagagc 116280

Page 75

BIOL0285WOSEQ_ST25 12 Nov 2020

cactgaggtc tcagtgccat tttcaagatt tcggaagcgg cctgggcacg gctggtcctt 116340

cactgggatc accacttggc aattatttac acctgagacg aatgaaaacc agagtgctga 116400

gattacaggc atggtggctt acgcttgtaa tcggctttgg gaagccgagg tgggctgatt 116460

gcttgagccc aggagtttca aactatcctg gacaacatag catgacctcg tctctacaaa 116520

aaatacaaaa aatttgccag gtgtggtggc atgtgcctgt ggtcccagct acttgggagg 116580 2020267230

ctgaagtagg agaatcccct gagccctggg aagtcgaggc tgcactgagc cgtgatggtg 116640

tcactgcact ccagcctggg tgacaaagtg agaccctatc tcacaaagaa aaaaaacaaa 116700

acaaaaaacc caaagcacac tgtttccact gtttccagag ttcctgagag gaaaggtcac 116760

cgggtgagga agacgttctc actgatctgg cagagaaaat gtccagtttt tccaactccc 116820

taaaccatgg ttttctattt catagttctt aggcaaattg gtaaaaatca tttctcatca 116880

aaacgctgat attttcacac ctccctggtg tctgcagaaa gaaccttcca gaaatgcagt 116940

cgtgggagac ccatccaggc cacccctgct tatggaagag ctgagaaaaa gccccacggg 117000

agcatttgct cagcttccgt tacgcaccta gtggcattgt gggtgggaga gggctggtgg 117060

gtggatggaa ggagaaggca cagccccccc ttgcagggac agagccctcg tacagaaggg 117120

acaccccaca tttgtcttcc ccacaaagcg gcctgtgtcc tgcctacggg gtcagggctt 117180

ctcaaacctg gctgtgtgtc agaatcacca ggggaacttt tcaaaactag agagactgaa 117240

gccagactcc tagattctaa ttctaggtca gggctagggg ctgagattgt aaaaatccac 117300

aggtgattct gatgcccggc aggcttgaga acagccgcag ggagttctct gggaatgtgc 117360

cggtgggtct agccaggtgt gagtggagat gccggggaac ttcctattac tcactcgtca 117420

gtgtggccga acacattttt cacttgacct caggctggtg aacgctcccc tctggggttc 117480

aggcctcacg atgccatcct tttgtgaagt gaggacctgc aatcccagct tcgtaaagcc 117540

cgctggaaat cactcacact tctgggatgc cttcagagca gccctctatc ccttcagctc 117600

ccctgggatg tgactcgacc tcccgtcact ccccagactg cctctgccaa gtccgaaagt 117660

ggaggcatcc ttgcgagcaa gtaggcgggt ccagggtggc gcatgtcact catcgaaagt 117720

ggaggcgtcc ttgcgagcaa gcaggcgggt ccagggtggc gtgtcactca tccttttttc 117780

tggctaccaa aggtgcagat aattaataag aagctggatc ttagcaacgt ccagtccaag 117840

Page 76

BIOL0285WOSEQ_ST25 12 Nov 2020

tgtggctcaa aggataatat caaacacgtc ccgggaggcg gcagtgtgag taccttcaca 117900

cgtcccatgc gccgtgctgt ggcttgaatt attaggaagt ggtgtgagtg cgtacacttg 117960

cgagacactg catagaataa atccttcttg ggctctcagg atctggctgc gacctctggg 118020

tgaatgtagc ccggctcccc acattccccc acacggtcca ctgttcccag aagccccttc 118080

ctcatattct aggagggggt gtcccagcat ttctgggtcc cccagcctgc gcaggctgtg 118140 2020267230

tggacagaat agggcagatg acggaccctc tctccggacc ctgcctggga agctgagaat 118200

acccatcaaa gtctccttcc actcatgccc agccctgtcc ccaggagccc catagcccat 118260

tggaagttgg gctgaaggtg gtggcacctg agactgggct gccgcctcct cccccgacac 118320

ctgggcaggt tgacgttgag tggctccact gtggacaggt gacccgtttg ttctgatgag 118380

cggacaccaa ggtcttactg tcctgctcag ctgctgctcc tacacgttca aggcaggagc 118440

cgattcctaa gcctccagct tatgcttagc ctgcgccacc ctctggcaga gactccagat 118500

gcaaagagcc aaaccaaagt gcgacaggtc cctctgccca gcgttgaggt gtggcagaga 118560

aatgctgctt ttggcccttt tagatttggc tgcctcttgc caggagtggt ggctcgtgcc 118620

tgtaattcca gcactttggg agactaaggc gggaggttcg cttgagccca ggagttcaag 118680

accagcctgg gcaacaatga gacccctgtg tctacaaaaa gaattaaaat tagccaggtg 118740

tggtggcacg cacctgtagt cccagctact tgggaggctg aggtgggagg attgcctgag 118800

tccgggaggc ggaagttgca aggagccatg atcgcgccac tgcacttcaa cctaggcaac 118860

agagtgagac tttgtctcaa aaaacaatca tataataatt ttaaaataaa tagatttggc 118920

ttcctctaaa tgtccccggg gactccgtgc atcttctgtg gagtgtctcc gtgagattcg 118980

ggactcagat cctcaagtgc aactgaccca cccgataagc tgaggcttca tcatcccctg 119040

gccggtctat gtcgactggg cacccgaggc tcctctccca ccagctctct tggtcagctg 119100

aaagcaaact gttaacaccc tggggagctg gacgtatgag acccttgggg tgggaggcgt 119160

tgatttttga gagcaatcac ctggccctgg ctggcagtac cgggacactg ctgtggctcc 119220

ggggtgggct gtctccagaa aatgcctggc ctgaggcagc cacccgcatc cagcccagag 119280

ggtttattct tgcaatgtgc tgctgcttcc tgccctgagc acctggatcc cggcttctgc 119340

cctgaggccc cttgagtccc acaggtagca agcgcttgcc ctgcggctgc tgcatggggc 119400

Page 77

BIOL0285WOSEQ_ST25 12 Nov 2020

taactaacgc ttcctcacca gtgtctgcta agtgtctcct ctgtctccca cgccctgctc 119460

tcctgtcccc ccagtttgtc tgctgtgagg ggacagaaga ggtgtgtgcc gcccccaccc 119520

ctgcccgggc ccttgttcct gggattgctg ttttcagctg tttgagcttt gatcctggtt 119580

ctctggcttc ctcaaagtga gctcggccag aggaggaagg ccatgtgctt tctggttgaa 119640

gtcaagtctg gtgccctggt ggaggctgtg ctgctgaggc ggagctgggg agagagtgca 119700 2020267230

cacgggctgc gtggccaacc cctctgggta gctgatgccc aaagacgctg cagtgcccag 119760

gacatctggg acctccctgg ggcccgcccg tgtgtcccgc gctgtgttca tctgcgggct 119820

agcctgtgac ccgcgctgtg ctcgtctgcg ggctagcctg tgtcccgcgc tctgcttgtc 119880

tgcggtctag cctgtgacct ggcagagagc caccagatgt cccgggctga gcactgccct 119940

ctgagcacct tcacaggaag cccttctcct ggtgagaaga gatgccagcc cctggcatct 120000

gggggcactg gatccctggc ctgagcccta gcctctcccc agcctggggg ccccttccca 120060

gcaggctggc cctgctcctt ctctacctgg gacccttctg cctcctggct ggaccctgga 120120

agctctgcag ggcctgctgt ccccctccct gccctccagg tatcctgacc accggccctg 120180

gctcccactg ccatccactc ctctcctttc tggccgttcc ctggtccctg tcccagcccc 120240

cctccccctc tcacgagtta cctcacccag gccagaggga agagggaagg aggccctggt 120300

cataccagca cgtcctccca cctccctcgg ccctggtcca ccccctcagt gctggcctca 120360

gagcacagct ctctccaagc caggccgcgc gccatccatc ctccctgtcc cccaacgtcc 120420

ttgccacaga tcatgtccgc cctgacacac atgggtctca gccatctctg ccccagttaa 120480

ctccccatcc ataaagagca catgccagcc gacaccaaaa taattcggga tggttccagt 120540

ttagacctaa gtggaaggag aaaccaccac ctgccctgca ccttgttttt tggtgacctt 120600

gataaaccat cttcagccat gaagccagct gtctcccagg aagctccagg gcggtgcttc 120660

ctcgggagct gactgatagg tgggaggtgg ctgccccctt gcaccctcag gtgaccccac 120720

acaaggccac tgctggaggc cctggggact ccaggaatgt caatcagtga cctgcccccc 120780

aggccccaca cagccatggc tgcatagagg cctgcctcca agggacctgt ctgtctgcca 120840

ctgtggagtc cctacagcgt gccccccaca ggggagctgg ttctttgact gagatcagct 120900

ggcagctcag ggtcatcatt cccagaggga gcggtgccct ggaggccaca ggcctcctca 120960

Page 78

BIOL0285WOSEQ_ST25 12 Nov 2020

tgtgtgtctg cgtccgctcg agcttactga gacactaaat ctgttggttt ctgctgtgcc 121020

acctacccac cctgttggtg ttgctttgtt cctattgcta aagacaggaa tgtccaggac 121080

actgagtgtg caggtgcctg ctggttctca cgtccgagct gctgaactcc gctgggtcct 121140

gcttactgat ggtctttgct ctagtgcttt ccagggtccg tggaagcttt tcctggaata 121200

aagcccacgc atcgaccctc acagcgcctc ccctctttga ggcccagcag ataccccact 121260 2020267230

cctgcctttc cagcaagatt tttcagatgc tgtgcatact catcatattg atcacttttt 121320

tcttcatgcc tgattgtgat ctgtcaattt catgtcagga aagggagtga catttttaca 121380

cttaagcgtt tgctgagcaa atgtctgggt cttgcacaat gacaatgggt ccctgttttt 121440

cccagaggct cttttgttct gcagggattg aagacactcc agtcccacag tccccagctc 121500

ccctggggca gggttggcag aatttcgaca acacattttt ccaccctgac taggatgtgc 121560

tcctcatggc agctgggaac cactgtccaa taagggcctg ggcttacaca gctgcttctc 121620

attgagttac acccttaata aaataatccc attttatcct ttttgtctct ctgtcttcct 121680

ctctctctgc ctttcctctt ctctctcctc ctctctcatc tccaggtgca aatagtctac 121740

aaaccagttg acctgagcaa ggtgacctcc aagtgtggct cattaggcaa catccatcat 121800

aaaccaggta gccctgtgga aggtgagggt tgggacggga gggtgcaggg ggtggaggag 121860

tcctggtgag gctggaactg ctccagactt cagaaggggc tggaaaggat attttaggta 121920

gacctacatc aaggaaagtg ttgagtgtga aacttgcggg agcccaggag gcgtggtggc 121980

tccagctcgc tcctgcccag gccatgctgc ccaagacaag gtgaggcggg agtgaagtga 122040

aataaggcag gcacagaaag aaagcacata ttctcggccg ggcgctgtgg ctcacgcctg 122100

taattccagc actttgggag gccaaggtgg gtggatcatg aggtcaggag attgagacca 122160

tcctggctaa cacagtgaaa ccccgtctct actaaaaata caaaaaatta gccgggcgtg 122220

gtggtgggcg cctgtagtcc cagctactcc ggaggctgag gcaggaaaat ggcgtgaacc 122280

cggaaggcgg agcttgcagt gagcggagtg agcagagatc gcgccactgc actccagcct 122340

gggcgacaga gcgagactcc gtctcaaaaa aaaaaagcac atgttctcgc ttctttgtgg 122400

gatccaggag atagagaata gaaggatggt taccagaggc tgggaagggt agtgagggga 122460

tggtgggggg atggtcaatg ggtacaaaaa aaatagaata agacctagta tttgatagtg 122520

Page 79

BIOL0285WOSEQ_ST25 12 Nov 2020

caacagggtg actatagtca ataataattt aattgtacat ttaaaaataa ctaaaagata 122580

gccgggtgca gtggcttacg tctgtaatcc cagtactttg ggaggctgag gtgggcgttt 122640

gagaccagcc tggccaacat ggtgaaaccc catctctact aaaaatacaa aaattagcca 122700

ggcatggtgg cgggcgcctg taatcccagc tactcgggag gctgaggcag gagaatcact 122760

tgaacctggg aggcagaggt tgcagtgagc cgagatcttg ccactgcact ccagcctggg 122820 2020267230

tgacagtgaa actccgtctc aaaaataaaa ataaaaatac agctgggcac ggtggctcac 122880

gcctgtaatc ccagcacttt gggaggccga ggcgagcgga tcacaaggtc aggagatata 122940

gaccatcctg gctaacacgg tgaaacccgg tctctactaa aaatacaaaa aattagccag 123000

gcgtggtggc aggtgcctat agtcccagct actcacaagg ctgaggcagg agaatggcat 123060

gaacctggga ggcggagctt gcagtgagcc gagattgtgc cactgcactc cagcctgggc 123120

gagagagtga gactccgtct caaaacaaaa acaaaaacaa aaacaaaaac aaacacacaa 123180

caaaaaccta aaagaatata aatggattgt ttgtaacaca aaggacaaat gtttgagggg 123240

atggataccc cattttccat gatgtgatta ttatacattg tgtgtctgta tcaaaacatc 123300

tcatgagccc cataaatata tacacctaac tatgtaccca caaaaattaa aaaaatatat 123360

tttttaaggt gaagagggag gcgagatgct ggccttaacc cctaacccgt tgttctccct 123420

gcaagctgtc cacagggcct ctcagactcg aggttcagct atatggatgc atgagcttgg 123480

tccccagcca acatgggaga cacttcacca tcggcagcag ctacagcaca ggaaccctgg 123540

gtcactgcca tgtcccctct gtgactttgt ttaaacagaa aatgatgctc tgggccggct 123600

gtggtggccc acacctataa tcccagcacc ttgggaggcg ggggtgggca gattgcctga 123660

ggtcaggagt tggagatcag cctggccgac atggcgaaac cccatgtcta ctaaaaatac 123720

aaaaactagc caggcatggt ggcacatgcc tgtaatccca gctacttggg aggctgaagc 123780

aggagaatca cttgaaccca ggaggcagag gctgagtgag ccaagatcgt gccaatgcac 123840

tccagcttgg gtgagggagt gagactccgt ctcaaaaaaa aaaaaaaaga aagaaaaaga 123900

aaagaaagtg atcctactgg aaccatgctt actcccctcc ccacctcaca ctgtgtagaa 123960

attagtgctg tcggccaggc gcggtggctc atgcctgtaa tcgcagcact ttgggaggcc 124020

aaggcaggcg gatcacgagg tcaggagatc aagaccatcc tggctaacac agtgaaaccc 124080

Page 80

BIOL0285WOSEQ_ST25 12 Nov 2020

tgtctctact aaaaatacaa aaaattagcc gggcatggtg gcaggcacct gtagtcccaa 124140

ctacttggga ggctgaggca ggagaatggc atgaacctgg gaggcggagc ttgcagtgag 124200

ccaagatcgc gccactgcat accagcctag gtgacagagt gagactcagc aaaaaaagaa 124260

agaaagaaag aaagaaatca gtgctgtcta tacttctttc tgcagtgatg gaaatattct 124320

gtatctgtgc tgtccagtat agtagccact agctacatgt ggcacttgaa acatggctgg 124380 2020267230

tacagttgag gaagagtggc tgccatatcg gacgacacag ctatagattc tgtcacccca 124440

ccccgagagt ccagagcggg gacttctgcc ttaggcccta ttcagggctg atttttactt 124500

gaacccttac tgtgggaaga gaaggccatg agaagttcag tctagaatgt gactccttat 124560

tttctggctc ccttggacac tttgtgggat ttagtctccc tgtggaaagt attccacaag 124620

tggtgccact accccagctg tgagagcagc tgggagctgc ttttgtcatc tttccctgga 124680

aagtcctgtg ggctgtctct tcctcatgcc ttgtcccatg cttgggcatg gtgtcaagcg 124740

tcaggaggga gaaagggtcc ttatttattt atttagagag ggacccttct tctgttccca 124800

ggctggagtg cagtggtgcg atctcggctc actgcaacct ccgcctcctg ggttcaagtg 124860

attctcctgc ctcagcctcc tgagtagctg agattacagg cacatgccaa catgcccggc 124920

taattttttt tttttttttt tttttttttt tttttttttt tttgagatgg agttgtactc 124980

tcattgccca ggctggaatg taatggcaca atctcggctc actgcaacct ccacctcctg 125040

gattcaagca attctcctgt ctcagcttcc caagtagctg ggattacagg tgcccgccac 125100

catgctcaac taatttttgt attttttttt tagtagagac gaggtttcac catgttggtc 125160

agactggtct caaactcctg acctcaggtg atccacctgc ctcggcctcc caaagtgcta 125220

ggattacagg catgagccac cacgcccggc ctgaaagggt tcttatttag tgtgcatttt 125280

gacattcaat ttaattccaa ggtcttgtgg ggtcatggtt tacaggatgt tgatatagaa 125340

aagacttcac ttaatgggcc gggcgcagtg gctcatgcct gtaatcccag cactttggga 125400

ggccgaggca ggcagatcag gaggtcagga gattgagacc atcctggcta acacagtgaa 125460

accccatctc tactgaaaat acaaaaaatt agctgggcgt ggtggcaggc acctgtagtc 125520

ccagccactc ggttggctga ggcaggagaa tggcatgaac ccgggaggcg gagcttgcag 125580

tgagcagaga ccatgccact gcactccagc ctgggcgaca gagcaagact ctgtctcaag 125640

Page 81

BIOL0285WOSEQ_ST25 12 Nov 2020

aaaaaaaaaa aaaaacagac tttacttact ggaagccaac caatgtatat ttagagtaat 125700

ttttcctggg ctgagctgtc atttactttt gcagtatctc aagaagaaga gtttacagtg 125760

taaatatttg atgcacactt tgattatata gatgaagcaa actattttca agagctttgc 125820

aaggacttac ttgtatccaa acaccattct aaaaggagtc ttacctactt ctaaaggctg 125880

gtctctactt ggaaccactt gcttggccct ggttcaagtc ctgctgcaaa cctggaagtc 125940 2020267230

ctgtcattgt cttcttccct ccagagcagt ggcacccaat ctaatttttg ctgtgcccca 126000

gcagcccctg gcactttgcc ctgtagactg cagacctcat gtaatgtatg ttaagtccac 126060

agaaccacag aagatgatgg caagatgctc ttgtgtgtgt tgtgttctag gaggtggcca 126120

ggtggaagta aaatctgaga agcttgactt caaggacaga gtccagtcga agattgggtc 126180

cctggacaat atcacccacg tccctggcgg aggaaataaa aaggtaaagg gggtagggtg 126240

ggttggatgc tgcccttggg tatatgggca ttaatcaagt tgagtggaca aaggctggtc 126300

cagttcccag aggaggaaaa cagaggcttc tgtgttgact ggctggatgt gggccctcag 126360

cagcatccag tgggtctcca ctgcctgtct caatcacctg gagctttagc acgtttcaca 126420

cctgggcccc aacctggaga ggctgaccaa tgggtctcag gggcagctcg gttgctggag 126480

tttttgtttt tatttatttt tatgtattta aggcagggtc tctgtattag tccattctca 126540

cactgctaat aaagacatac ccaagactgg gtaatttata aaggaaagag gtttaatgga 126600

ctcacagttc cacatggctg gggaggcctc aaaatcatgg cggaaggcaa aggagaagca 126660

aaggcatttc ttacatggcg acaggcaaga gagcgtgtgc aggggaactc ccatttataa 126720

aaccatcaga cctcatgaga tttattcact atcatgagaa cagcatggga aagacccgcc 126780

cccatgattc agttacctcc cactgggtcc ctcccatgac acatggaatt atgggagcta 126840

caattcaaga tgagatttgg gtggggacac agccaaacca tatcagtctc cctctgtcat 126900

ccaggctgga gtgcactggc atgatctcgg ctcactgcag cctctacctc cctgggtcag 126960

gtgatcttcc cacctcagcc tcccaggtag ctggaactac aggtacctgc cactatgcct 127020

ggctaaatat tttgtatttc ctgtggagac gaggttttgc cacgttgccc aggctggtct 127080

tgaactcctg aggtcaagca atatgcccac ctcggcctcc caaggtgctg ggattacagg 127140

tgtgagccac agtgctcggc ctaagtcact gcagttttta aagctcccag gtgattcttc 127200

Page 82

BIOL0285WOSEQ_ST25 12 Nov 2020

agtgcagtca aaagtgagaa ctggctgggt gcggtggctc atgcctgtaa tcccagcacc 127260

ttgggaggcg aaggtgggca gatggcttga ggtcaggagt tcaagaccag cctggccaac 127320

atggtaaaac cccatctcta ctaaaaatac aaaagttagc tgggtgtggt ggtgcgtgcc 127380

tgtaatccca gctacttggg aggctgaggc atgagaattg cttgaaccca ggggacagag 127440

gttgtagtga gccgagatcg tgccactgca ctccagcctg ggcaacagag tgagattcca 127500 2020267230

tctcacaaaa aaaaaaaaaa gcgagaacca ctgtcctagg ccctgatgtt tgcaggcaac 127560

taaaaaagga agtggacatc cccagtcagc tgtggcgcac caagaacaag tcatgggaac 127620

ataacctaat tttctaaatg ggttactagg cacttagagc aaaacaatga tgccgaaatc 127680

ctgatttcag caaagcctct gcctgcctgt cttggaagta tccacatgag gctgctgggg 127740

ccttggtgtc cccagcagtt tctagtctct aggtcttgct gtgggtgtct gtgcagtgag 127800

ggtgtgtgtg gcgctgggtg agctctgtct aggcctggca caggatgcgg tctggtagct 127860

gctgcttctc ttctgcagaa gcgcagccaa gcaccctctg gggtttcagg cccacaccca 127920

gcctgaagtt ctgggagtgg ctcactttcc aaccttcagg gtctcccagc agctgactgg 127980

ggagtggtgg agggaaaagg gattgtatta gtccgttttc acgccgctga tgaagacata 128040

cccgatactg ggcagtctaa aagatagagg tctgatggac tcacagttcc acgtgactgg 128100

ggaggcctga caatcatggt ggaaggtgaa aggcttgtct cacacggtgg cagacaagag 128160

aaaagagctt gtgcagggga actccccttt ataaaaccat cagatctcgg gagacttatt 128220

cactatcatg agaacagcac gggaaagacc ctcctctatg attcaattac ctcccaccag 128280

gtccctccca caacatgtag gaattgtggg aactacaatt caagatgaca tttgggtggg 128340

gacacagcca aaccatatca gggcgtccca gaaagggtat agggtctgag acccaagtca 128400

gcatgagaaa gtatgcttct catggtggcc cagttgggtg gaagtggcag ccgggccgtc 128460

tttccaccag gccactcaag tagcagctga gagacccctg ccctggccag tccccgccct 128520

cccctcttgc cactgcctct ggttctgaac agatgggcac cctcatcttg tatttgtgat 128580

taatgtctaa caatgtagtt ttgtgagaag ggtttgctga tacagccttg ctgcagatgc 128640

tgcgaactgt ggcctggggc agaccttacc tccagacacg ccctgaggca ggggagggca 128700

ctggcccgta gctggccgag agctctcggg ttgcgcgaca gggatacttt tcagcggctg 128760

Page 83

BIOL0285WOSEQ_ST25 12 Nov 2020

ggtcgctatc caaagtgaga aaacgaggag ggaccaggag gctgtccgcc tcaagagatg 128820

tgggggccag gtccagttat ctggggaagc agtaagcttc tctgctgttt ctaaccccag 128880

gcctcccctg gtctaaggca gggcctccca gcctcggggc actttaaaga tatctgggcc 128940

tggccccatc cccacagtct gactgagtgg gtctggatag ggcctgagca ttggtgattt 129000

cctgggtgaa aggaggcccc tcacagtctc tggaagcttc tctgtgttag gaaaagctct 129060 2020267230

gggcttgact ctgctttgaa agtcaagatc cgcaaatcct ctcagcctca gtttctcctt 129120

cagcaagatg aaatggaaat gctgtaccta cgtcccgggg tggttgtgag acccaaaaaa 129180

gacaatgttc tggaaggttc ctggtgcgtt gcagtcctct aagaacctga gttagagcca 129240

cgctgagtct cagcttcttg gctccttctg tttcaaactc gtccatgtga tagctcagga 129300

agggtaggca gggccctgcc ccctactcag aaaacaccat cctggtcctg gggatccccg 129360

cagcattagt cccctgtttt cccagtgtat tgagaaaaat tgctaacaag cagtggggca 129420

caccaccagc ctcctgggtt cctttcagtt tggggatttt tggacattcc caggaatgtc 129480

ttaaaaaaca cttcaaaaaa cattaacata aatattttta tcaaagcctg tattaaatgg 129540

tctttcaaga aaatacagta acaggtcagg catggtggct catgcctgta accccagcac 129600

tttgggaggc caaggcaggc agatcacctg aaatcaggag ttcaagacca acctggccaa 129660

cacagccaaa tcccatctct acaaaaaata caaaaattag ctgggtgtgg tggcacacac 129720

ctgtagtccc agctacttgg gaggccgagg caggagaatt gcttgatccc ggaggcggag 129780

gttgcagtga gccgagatcg tgccactgca ctccagcgtg ggtgacaagg tgaatctttg 129840

tctcaaaaaa aaaaaaaaaa aaaagataaa atacagtata cagtaataga gaacaatcct 129900

tttttcaaag tagtgacccc aaatgaacaa aatatgcatc tagcttaaat gcgaacctgg 129960

ttttctctac gcccattcaa gcccctgcaa taggggccct tcaccccgca tccatggact 130020

cctaaaatta tatggaaaat ggctgtgtgt gagtgtggat ggacatgtgc acacatattt 130080

ttggctttac cagatgctca aagagcctag gacccaaaaa gggctgagaa tgaccgtgtc 130140

ggccacttca gggtcatcag gaattgctgt gcactgctca cttctccagt gaacactttc 130200

tgcttctgtg tttcctggta tcctttggga ctcctggcta ggtcatgtgt ttctctactt 130260

tcaaaagggc ttcagccagg cacgatggca tgagcctgta gtcccagttg ctctggaggt 130320

Page 84

BIOL0285WOSEQ_ST25 12 Nov 2020

taaggtggga agattgcttg agcccaggaa tttgaggcca gcctgggcaa gtagataggt 130380

agatgattga tagatagata gatagataaa tagatggata gataagtcgc tagacagtca 130440

tccatccacc catccacaca taaaaaggcc tttgtcatgt catgttttgt ggcccacctg 130500

ccagtgttgc ccacagttgc tgcccctcca aactcatcag tcactggcaa acaggaggaa 130560

tgtgtggctc atgtctgggc atcagtggct gtgggagaca tccttgatct tctccagctt 130620 2020267230

ctccttccac attttccttt gcaatctggc aatatctatt aaaataaaat gtgcatgcct 130680

tttgacctaa gagcttcact tctaggaccc acttacacgt gtgtgacatg atgttcatac 130740

gggtttattt atctgaggtt gttcatacac accattgcct gtaatcacta aaggcgggag 130800

cagcctacac atccatccac agaggagtag atgccttttg gtacatccgt ggcgacggaa 130860

tactaagcag cctgtgtatc tatacactca cacgtgtttg tttatgtgtg gaatatctct 130920

ggagggtaca caagaaactt aaaatgatca ctgtctctgg ggagggtacc tgggtgcctg 130980

ggaggcaggt cagggaagga gtgggcacag gtattaccaa ttggaagaca ataaaaacaa 131040

cagctcctgg ccaggcgcag tggctcacgc ctgtaatggc agcactctga gaggctgagg 131100

cgggcagatt gcttgcgtcc aggagttcaa gaccagcctg ggcaacatag caaaaccccg 131160

tttctattaa aaatacaaaa aattagccag gtgtggtggc atgcacctgt aatcccagct 131220

actcgggagg ctgaggtggg agaatcacct gagcctggga ggtcaaggct gcagtgaggt 131280

gagattgtgc caccgcactc tagcctgggc gatagagcaa gaccctgtct caaaaacaaa 131340

caaaaaacag tccctggcac tctgggccag gcctggcagg gcagttggca gggctggtct 131400

ttctctggca cttcatctca ccctccctcc cttcctcttc ttgcagattg aaacccacaa 131460

gctgaccttc cgcgagaacg ccaaagccaa gacagaccac ggggcggaga tcgtgtacaa 131520

gtcgccagtg gtgtctgggg acacgtctcc acggcatctc agcaatgtct cctccaccgg 131580

cagcatcgac atggtagact cgccccagct cgccacgcta gctgacgagg tgtctgcctc 131640

cctggccaag cagggtttgt gatcaggccc ctggggcggt caataattgt ggagaggaga 131700

gaatgagaga gtgtggaaaa aaaaagaata atgacccggc ccccgccctc tgcccccagc 131760

tgctcctcgc agttcggtta attggttaat cacttaacct gcttttgtca ctcggctttg 131820

gctcgggact tcaaaatcag tgatgggagt aagagcaaat ttcatctttc caaattgatg 131880

Page 85

BIOL0285WOSEQ_ST25 12 Nov 2020

ggtgggctag taataaaata tttaaaaaaa aacattcaaa aacatggcca catccaacat 131940

ttcctcaggc aattcctttt gattcttttt tcttccccct ccatgtagaa gagggagaag 132000

gagaggctct gaaagctgct tctgggggat ttcaagggac tgggggtgcc aaccacctct 132060

ggccctgttg tgggggtgtc acagaggcag tggcagcaac aaaggatttg aaacttggtg 132120

tgttcgtgga gccacaggca gacgatgtca accttgtgtg agtgtgacgg gggttggggt 132180 2020267230

ggggcgggag gccacggggg aggccgaggc aggggctggg cagaggggag aggaagcaca 132240

agaagtggga gtgggagagg aagccacgtg ctggagagta gacatccccc tccttgccgc 132300

tgggagagcc aaggcctatg ccacctgcag cgtctgagcg gccgcctgtc cttggtggcc 132360

gggggtgggg gcctgctgtg ggtcagtgtg ccaccctctg cagggcagcc tgtgggagaa 132420

gggacagcgg gtaaaaagag aaggcaagct ggcaggaggg tggcacttcg tggatgacct 132480

ccttagaaaa gactgacctt gatgtcttga gagcgctggc ctcttcctcc ctccctgcag 132540

ggtagggggc ctgagttgag gggcttccct ctgctccaca gaaaccctgt tttattgagt 132600

tctgaaggtt ggaactgctg ccatgatttt ggccactttg cagacctggg actttagggc 132660

taaccagttc tctttgtaag gacttgtgcc tcttgggaga cgtccacccg tttccaagcc 132720

tgggccactg gcatctctgg agtgtgtggg ggtctgggag gcaggtcccg agccccctgt 132780

ccttcccacg gccactgcag tcacccctgt ctgcgccgct gtgctgttgt ctgccgtgag 132840

agcccaatca ctgcctatac ccctcatcac acgtcacaat gtcccgaatt cccagcctca 132900

ccaccccttc tcagtaatga ccctggttgg ttgcaggagg tacctactcc atactgaggg 132960

tgaaattaag ggaaggcaaa gtccaggcac aagagtggga ccccagcctc tcactctcag 133020

ttccactcat ccaactggga ccctcaccac gaatctcatg atctgattcg gttccctgtc 133080

tcctcctccc gtcacagatg tgagccaggg cactgctcag ctgtgaccct aggtgtttct 133140

gccttgttga catggagaga gccctttccc ctgagaaggc ctggcccctt cctgtgctga 133200

gcccacagca gcaggctggg tgtcttggtt gtcagtggtg gcaccaggat ggaagggcaa 133260

ggcacccagg gcaggcccac agtcccgctg tcccccactt gcaccctagc ttgtagctgc 133320

caacctccca gacagcccag cccgctgctc agctccacat gcatagtatc agccctccac 133380

acccgacaaa ggggaacaca cccccttgga aatggttctt ttcccccagt cccagctgga 133440

Page 86

BIOL0285WOSEQ_ST25 12 Nov 2020

agccatgctg tctgttctgc tggagcagct gaacatatac atagatgttg ccctgccctc 133500

cccatctgca ccctgttgag ttgtagttgg atttgtctgt ttatgcttgg attcaccaga 133560

gtgactatga tagtgaaaag aaaaaaaaaa aaaaaaaagg acgcatgtat cttgaaatgc 133620

ttgtaaagag gtttctaacc caccctcacg aggtgtctct cacccccaca ctgggactcg 133680

tgtggcctgt gtggtgccac cctgctgggg cctcccaagt tttgaaaggc tttcctcagc 133740 2020267230

acctgggacc caacagagac cagcttctag cagctaagga ggccgttcag ctgtgacgaa 133800

ggcctgaagc acaggattag gactgaagcg atgatgtccc cttccctact tccccttggg 133860

gctccctgtg tcagggcaca gactaggtct tgtggctggt ctggcttgcg gcgcgaggat 133920

ggttctctct ggtcatagcc cgaagtctca tggcagtccc aaaggaggct tacaactcct 133980

gcatcacaag aaaaaggaag ccactgccag ctggggggat ctgcagctcc cagaagctcc 134040

gtgagcctca gccacccctc agactgggtt cctctccaag ctcgccctct ggaggggcag 134100

cgcagcctcc caccaagggc cctgcgacca cagcagggat tgggatgaat tgcctgtcct 134160

ggatctgctc tagaggccca agctgcctgc ctgaggaagg atgacttgac aagtcaggag 134220

acactgttcc caaagccttg accagagcac ctcagcccgc tgaccttgca caaactccat 134280

ctgctgccat gagaaaaggg aagccgcctt tgcaaaacat tgctgcctaa agaaactcag 134340

cagcctcagg cccaattctg ccacttctgg tttgggtaca gttaaaggca accctgaggg 134400

acttggcagt agaaatccag ggcctcccct ggggctggca gcttcgtgtg cagctagagc 134460

tttacctgaa aggaagtctc tgggcccaga actctccacc aagagcctcc ctgccgttcg 134520

ctgagtccca gcaattctcc taagttgaag ggatctgaga aggagaagga aatgtggggt 134580

agatttggtg gtggttagag atatgccccc ctcattactg ccaacagttt cggctgcatt 134640

tcttcacgca cctcggttcc tcttcctgaa gttcttgtgc cctgctcttc agcaccatgg 134700

gccttcttat acggaaggct ctgggatctc ccccttgtgg gggcaggctc ttggggccag 134760

cctaagatca tggtttaggg tgatcagtgc tggcagataa attgaaaagg cacgctggct 134820

tgtgatctta aatgaggaca atccccccag ggctgggcac tcctcccctc ccctcacttc 134880

tcccacctgc agagccagtg tccttgggtg ggctagatag gatatactgt atgccggctc 134940

cttcaagctg ctgactcact ttatcaatag ttccatttaa attgacttca gtggtgagac 135000

Page 87

BIOL0285WOSEQ_ST25 12 Nov 2020

tgtatcctgt ttgctattgc ttgttgtgct atggggggag gggggaggaa tgtgtaagat 135060

agttaacatg ggcaaaggga gatcttgggg tgcagcactt aaactgcctc gtaacccttt 135120

tcatgatttc aaccacattt gctagaggga gggagcagcc acggagttag aggcccttgg 135180

ggtttctctt ttccactgac aggctttccc aggcagctgg ctagttcatt ccctccccag 135240

ccaggtgcag gcgtaggaat atggacatct ggttgctttg gcctgctgcc ctctttcagg 135300 2020267230

ggtcctaagc ccacaatcat gcctccctaa gaccttggca tccttccctc taagccgttg 135360

gcacctctgt gccacctctc acactggctc cagacacaca gcctgtgctt ttggagctga 135420

gatcactcgc ttcaccctcc tcatctttgt tctccaagta aagccacgag gtcggggcga 135480

gggcagaggt gatcacctgc gtgtcccatc tacagacctg cggcttcata aaacttctga 135540

tttctcttca gctttgaaaa gggttaccct gggcactggc ctagagcctc acctcctaat 135600

agacttagcc ccatgagttt gccatgttga gcaggactat ttctggcact tgcaagtccc 135660

atgatttctt cggtaattct gagggtgggg ggagggacat gaaatcatct tagcttagct 135720

ttctgtctgt gaatgtctat atagtgtatt gtgtgtttta acaaatgatt tacactgact 135780

gttgctgtaa aagtgaattt ggaaataaag ttattactct gattaaataa ggtctccatt 135840

catggattcc aaggacaaga aagtcatata gaatgtctat tttttaagtt ctttcccacg 135900

cacccttaga taatttagct cagaacagga aatgatagta ttaataaaag ctggacatca 135960

ggattaacag ctctctctgg ggccctgaag gtgagagttc tcagacttgc tcatttgcag 136020

ttgcttcttt gtgatgctgg caaaccatcc tagtcccatt caaagggcaa tacaaagcct 136080

tgtggctgac ctcacgatgc agcactcagt ttgcaagacc ggcaccagtg tatgcaaacc 136140

tgagaaggtt ggggatgagg atatgggatc tttcatccct ggaaatttag tccagaggcc 136200

tggggctgga gcagaacacc aagccaatca gcttaatgaa tggcttagat tcctgctagg 136260

tttgcagagc tgccttcttt cctttggtac cttattatag attgaggagt atttctgcta 136320

aaccaagata gggataacca gatagcatct tcatagcaat gccacaaagg aaaacaaaaa 136380

caaaacagta atccatcata ttattcctta gtaactatgc caaggtcatg atactgaatc 136440

cttagattgt ttcaaaatac tacttttctt tgctcttcct gatgtgtttg ccaccgcagg 136500

cagatgttta agtaaaacag attttaactg cagctacaaa agcagcaaca ggccagcaaa 136560

Page 88

BIOL0285WOSEQ_ST25 12 Nov 2020

agagaagtgc tatctcagag agcatggctt tcagagccac aagagacagc ctcactggct 136620

gtttcagctt gactgccatg caaagaagag agcagaggga gaaccagccc cacccactta 136680

ttcatcttgt acaaaaaaaa agcacctacc agcctaggct acatagtgag acactatctc 136740

cacaaaaaac ccacgaaaac tagctgggta tggtggcaca tgcctacagt cccagctact 136800

ggtaaggctg tggtgggagg atctcttgag gccaggaagg agatccaggc tgcagtgagc 136860 2020267230

caagattgca ccactgcact ccagtctgga caatcgagca agatcccatc tcaaacaata 136920

aaaaaaaaaa gcgtgtaacc tcctcagaag aaagatgtta taatctcagg cagcaggcaa 136980

gaaccaatcc aggctctaag c 137001

<210> 2

<400> 2 000

<210> 3

<400> 3 000

<210> 4

<400> 4 000

<210> 5 <211> 21 <212> DNA <213> Artificial sequence

<220> <223> Primer

<400> 5 aagattgggt ccctggacaa t 21

<210> 6 <211> 26 <212> DNA <213> Artificial sequence

<220> <223> Primer

Page 89

BIOL0285WOSEQ_ST25 12 Nov 2020

<400> 6 agcttgtggg tttcaatctt tttatt 26

<210> 7 <211> 19 <212> DNA <213> Artificial sequence

<220> 2020267230

<223> Probe

<400> 7 cacccacgtc cctggcgga 19

<210> 8 <211> 18 <212> DNA <213> Artificial sequence

<220> <223> Synthetic oligonucleotide

<400> 8 ccgttttctt accaccct 18

<210> 9 <211> 23 <212> DNA <213> Artificial sequence

<220> <223> Primer

<400> 9 aggacagagt gcagtcgaag atc 23

<210> 10 <211> 21 <212> DNA <213> Artificial sequence

<220> <223> Primer

<400> 10 aggtcagctt gtgggtttca a 21

Page 90

BIOL0285WOSEQ_ST25 12 Nov 2020

<210> 11 <211> 21 <212> DNA <213> Artificial sequence

<220> <223> Probe

<400> 11 cacccatgtc cctggcggag g 21 2020267230

Page 91

Claims (30)

CLAIMS:

1. Amodified oligonucleotide according to the following fonmula-. NH 2

NNH NH 2 2 HO N'A0l_ '1 o4,j NH 2 0 0 HS1= 0. HSP- HSN0 o.) H NO NH1) H OS- 0H H I-N O-P-0

0 o 00. HO-P O0 L~

A NHHS- P0 NHNH 2

0 N4N NH 2 O\~NOHS-P=O

O 0"-) 0 0NH 2 0 HS-P-0 HS-P0O <

_N O IN N 0

HS-P=O NH 0

NH 2

HS-O NOP=

O 1 NH0NH HS-P0 HS-P=0 NHN0 0O N~O0 NN

0 H 0 0 0 </

O 0' HS-P=O H-=

(SEQ ID NO: 8).

2. An oligomeric compound comprising amodified oligonucleotide according to the following formula: mCes mCeo Ges Tes Tes Tdsds mCds s TdsAds mCdsmCdsAes mCeo mCes mCes Te; wherein, A =an adenine, mC =a 5-methylcytosine, G =a guanine, T =a thymine,

e = a 2'-MOE nucleoside, d = a 2'-deoxynucleoside, s = a phosphorothioate intemucleoside linkage, and o = a phosphodiester intemucleoside linkage.

3. The oligomeric compound of claim 2 comprising a conjugate group.

4. An oligomeric duplex comprising an oligomeric compound of claim 2 or claim 3.

5. An antisense compound comprising or consisting of a modified oligonucleotide according to claim 1, an oligomeric compound according to claim 2 or claim 3, or an oligomeric duplex according to claim 4.

6. A pharmaceutical composition comprising a modified oligonucleotide according to claim 1, an oligomeric compound according to claim 2 or claim 3, or an oligomeric duplex according to claim 4 or a salt thereof and a pharmaceutically acceptable carrier or diluent.

7. The composition of claim 6, wherein the salt is sodium.

8. A method comprising administering to an animal a pharmaceutical composition according to claim 6 or claim 7.

9. A method of treating a disease associated with Tau comprising administering to an individual having or at risk for developing a disease associated with Tau a therapeutically effective amount of a pharmaceutical composition according to claim 6 or claim 7; and thereby treating the disease associated with Tau.

10. The method of claim 9, wherein the disease associated with Tau is a neurodegenerative disease.

11. The method of claim 10, wherein the neurodegenerative disease is any of a tauopathy, Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, or Dravet's Syndrome.

12. The method of claim 10 or claim 11, wherein at least one symptom of the neurodegenerative disease is ameliorated.

13. The method of claim 12, wherein the symptom is any of loss of memory, loss of motor function, and increase in the number and/or volume of neurofibrillary inclusions.

14. A modified oligonucleotide according to the following formula: NH 2

ONH 2 NH 2 HOS-P=O NO

0O ONH N 2 HS-FO ~ N O H 0 HP NSNHI) NH O NH 2N HS-P

ONN2NO HO-P=O

0 0 HO-P=O NH OH 0N NSO NN ONH2 o 0 0 rO NH 2 ?- NHH NH2 OO NH 0 UIS-POL

HS-P0 HS-P=O HS NNO O NO N N 0 H- =O H-0 NH HS 00 HS-P=O O NO O O N NH2 OH0

HS HS-O HS-PH0 NS IA~. NH O) 01 6 0 0.1 NH 2 0 o'-) 0SP= 00

0 NH2 O, HS-F 0 I0 NH ~~ HS-P=O I N111 /IN

tN N 01- 0

or~~ aOSP= at href HS-P=OHSP

(SEQ ID NO: 8)

or asalt thereof

15. The modified oligonucleotide of claim 14, which is a sodium salt of the formula.

16. A compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is a gapmer consisting of a 5' wing segment, a central gap segment, and a 3' wing segment, wherein: the 5' wing segment consists of five 2'-MOE nucleosides, the central gap segment consists of eight 2'-deoxynucleosides, and the 3' wing segment consists of five 2'-MOE nucleosides; wherein the modified oligonucleotide has the nucleobase sequence 5'-CCGTITTCTTACCACCCT

3' (SEQ ID NO: 8), wherein each cytosine is a 5-methylcytosine; and wherein the intemucleoside linkages of the modified oligonucleotide are, from 5' to 3', sossssssssssssoss, wherein each s is a phosphorothioate linkage and each o is a phosphodiester linkage.

17. A modified oligonucleotide, wherein the modified oligonucleotide is a gapmer consisting of a 5' wing segment, a central gap segment, and a 3' wing segment, wherein: the 5' wing segment consists of five 2'-MOE nucleosides, the central gap segment consists of eight 2'-deoxynucleosides, and the 3' wing segment consists of five 2'-MOE nucleosides; wherein the modified oligonucleotide has the nucleobase sequence 5'-CCGTTTTCTTACCACCCT 3' (SEQ ID NO: 8), wherein each cytosine is a 5-methylcytosine; and wherein the intemucleoside linkages of the modified oligonucleotide are, from 5' to 3', sossssssssssssoss, wherein each s is a phosphorothioate linkage and each o is a phosphodiester linkage.

18. A chirally enriched population of modified oligonucleotides of any of claims 14, 15 or 17 wherein the population is enriched for modified oligonucleotides comprising at least one particular phorphorothioate intemucleoside linkage having a particular stereochemical configuration.

19. The chirally enriched population of claim 18, wherein the population is enriched for modified oligonucleotides comprising at least one particular phorphorothioate intemucleoside linkage having the (Sp) configuration.

20. The chirally enriched population of claim 18, wherein the population is enriched for modified oligonucleotides comprising at least one particular phorphorothioate intermucleoside linkage having the (Rp) configuration.

21. The chirally enriched population of claim 18, wherein the population is enriched for modified oligonucleotides having a particular, independently selected stereochemical configuration at each phosphorothioate intemucleoside linkage

22. The chirally enriched population of claim 21, wherein the population is enriched for modified oligonucleotides having the (Sp) configuration at each phosphorothioate intemucleoside linkage.

23. The chirally enriched population of claim 21, wherein the population is enriched for modified oligonucleotides having the (Rp) configuration at each phosphorothioate intemucleoside linkage.

24. The chirally enriched population of claim 21, wherein the population is enriched for modified oligonucleotides having the (Rp) configuration at one particular phosphorothioate intemucleoside linkage and the (Sp) configuration at each of the remaining phosphorothioate intemucleoside linkages.

25. The chirally enriched population of claim 18 or claim 21 wherein the population is enriched for modified oligonucleotides having at least 3 contiguous phosphorothioate intemucleoside linkages in the Sp, Sp, and Rp configurations, in the 5' to 3' direction.

26. A chirally enriched population of modified oligonucleotides of any of claims 1-17, wherein all of the phosphorothioate intemucleoside linkages of the modified oligonucleotide are stereorandom.

27. A pharmaceutical composition comprising the modified oligonucleotide of any of claims 14, 15, or 17 and a pharmaceutically acceptable diluent or carrier.

28. A pharmaceutical composition comprising the population of modified oligonucleotides of any of claims 18-26 and a pharmaceutically acceptable diluent or carrier.

29. The pharmaceutical composition of claim 27 or claim 28, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS) or artificial CSF (aCSF).

30. The pharmaceutical composition of claim 27 or claim 28, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and phosphate-buffered saline (PBS) or artificial CSF (aCSF).